Substituted oxoisoindoline compounds for treating cancer
By inhibiting the Helios protein with substituted oxoisoindoline compounds, the problems of Treg cell instability and anti-tumor immune response were solved, and effective treatment of cancer and viral infections was achieved.
Patent Information
- Application Number
- CN202180022533.8
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Priority Date
- 2020-03-23
- Filing Date
- 2021-03-22
- Publication Date
- 2024-11-01
- Estimated Expiration
- 2041-03-22
AI Technical Summary
The prior art is difficult to effectively inhibit Helios protein, resulting in increased instability of Treg cells and hindering the therapeutic effect of anti-tumor immune response and viral infection.
Substituted oxoisoindoline compounds are provided to reduce Helios protein content and activity and inhibit their expression by promoting the interaction of Helios protein with the Cullin4-Cereblon ubiquitin ligase complex to control Treg differentiation.
Effectively reduce Helios protein levels, stabilize Treg cells, enhance anti-tumor immune response and attenuate the therapeutic effect of viral infection, providing a pharmaceutical composition for the treatment of cancer and viral infection.
Smart Images

Figure CN115605466B_ABST
Abstract
Description
[0001] Cross-references
[0002] This application claims the rights of U.S. Provisional Application No. 62 / 993,144, filed on March 23, 2020, the entire contents of which are incorporated herein by reference. Technical Field
[0003] This invention generally relates to substituted oxoisoindoline compounds that inhibit the Helios protein. Substituted oxoisoindoline compounds, compositions comprising said compounds, and methods of using them are provided herein. The invention further relates to pharmaceutical compositions comprising at least one compound according to the invention, suitable for treating proliferative disorders (such as cancer) and viral infections. Background Technology
[0004] Regulatory T cells (Tregs) play a crucial role in controlling autotolerance and immune homeostasis by maintaining suppressive activity and anergy in the face of strong immune and inflammatory responses. By maintaining a stable, anergic, and suppressive phenotype, Tregs attenuate excessive immune responses and prevent or improve autoimmunity. The presence of Tregs in human tumor tissues has been documented in numerous reports. Studies have demonstrated a significant negative correlation between the number of Tregs and T cells infiltrating tumors and survival rates (Curiel et al. 2004, Nat. Med. 10:942-949; Viguier et al. 2004, J Immuno. 1173:1444-1453; Beyer et al. 2006, Blood 108:804-811; Zou et al. 2006, Nat. Rev. Immunol. 6:295-307), suggesting a potentially critical role for Tregs in preventing the development of effective antitumor immunity. Cumulative evidence indicates that Foxp3+CD25+CD4+ Tregs primarily infiltrate tumors and significantly impair immune responses to tumor cells in rodents and humans. Once activated by specific antigens, Tregs suppress reactive T cells in vitro in an antigen-nonspecific and bystander manner (Takahashi et al. 1998, Int Immunol. 10:1969-80; Thornton et al. 1998, J Exp. Med. 188:287-96). Foxp3+CD25+CD4+ Tregs significantly inhibit a broad spectrum of antitumor immune responses involving CD4+ helper T cells, CD8+ T cells, natural killer cells, and natural killer T cells (Tanaka et al. 2017, Cell Research 27:109-118). Intratumoral depletion of CD25+CD4+ Tregs has establishedly induced tumor regression, accompanied by changes in the tumor site cytokine environment (Yu et al. 2005, J Exp Med. 201:779-91). Furthermore, metastasis of Treg-depleted CD4+ T cells significantly enhances antitumor immune responses compared to metastasis of Treg-containing T cells (Antony et al. 2005, J Immunol 174:2591-601). Tumor-invasive Tregs activated by tumor-derived autoantigens or tumor-associated antigens can similarly suppress specific antitumor immune responses. Regulating the activity of key factors to control Treg differentiation may represent a potential therapeutic strategy for treating certain diseases, including cancer and viral infections.
[0005] FoxP3+CD4 Tregs are highly stable. Research is ongoing to understand the genetic mechanisms that ensure phenotypic stability after expansion during inflammation, infection, or autoimmunity. Transcription factors (TFs) responsible for maintaining a stable immunosuppressive phenotype of Tregs may contribute to this process. The Helios (IKZF2) gene (a member of the Ikaros family of TFs) is selectively expressed based on thymocytes undergoing negative selection, as well as regulatory lineages of CD4 and CD8 T cells, unlike other members of the Ikaros family. Helios is expressed by two regulatory T cell lineages, FoxP3+CD4+ and Ly49+CD8+ Tregs, which are essential for maintaining autotolerance (Kim et al. 2015, Science 350:334-339; Sebastian et al. 2016, J Immunol 196:144-155). Notably, recent studies have shown that although Helios is largely non-essential for homeostatic Treg activity, it is crucial for maintaining a stable phenotype and enhancing repressive function in inflammatory conditions by controlling the genetic programming of FoxP3+CD4 Tregs via Helios (Thornton et al. 2010, J Immunol. 184:3433-3441; Kim et al. 2015). Helios expression in Tregs has been shown to be essential for their ability to maintain a repressive and anapneic phenotype in the face of severe inflammatory responses. Activation of the IL-2Rα-STAT5 pathway has been shown to be a key contributing factor in ensuring Treg survival and stability (Kim et al. 2015). Helios plays an essential role in maintaining the phenotype of FoxP3+CD4 Tregs by exerting primary lymphocyte-intrinsic repression to prevent autoimmune diseases in the presence of highly activated autoreactive T cells from scurfy mice lacking the FoxP3 forkhead domain. Rapid autoimmunity is generated in bone marrow (BM) chimeras remodeled from Helios- / - / dandruff BM cells rather than Helios+ / + / dandruff BM cells (Kim et al. 2015). These observations indicate the important contribution of Helios to the selection, differentiation, and function of autoreactive T cells. Immunosuppression imposed by Tregs can impair antitumor immune responses. Selective deficiency of Helios in FoxP3+CD4 Tregs leads to increased Treg instability and the conversion of intratumoral CD4 Tregs into effector T cells (Teff). Intratumoral Treg instability can increase the number of intratumoral Teff cells due to the combined effects of Treg conversion and reduced Treg suppressive activity. In addition, a deficient IL-2 response was observed in Helios-deficient intratumoral Tregs, which reduced the number of activated Tregs and also promoted increased intratumoral Teff activity.The interaction between tumor cells and infiltrating immune cells leads to the secretion of inflammatory mediators, including TNF-α, IL-6, IL-17, IL-1 and TGF-β, and the formation of a local inflammatory environment (Kim et al. 2015).
[0006] Helios-deficient Treg lineage instability is also accompanied by decreased FoxP3 expression and the acquisition of effector phenotypes through the production of pro-inflammatory cytokines. Effector cell transformation in Helios-deficient Tregs within the tumor microenvironment is associated with increased expression of genes controlling the Teff phenotype (Yates et al. 2018, PNAS, 2018, 115:2162-2167). The acquisition of an unstable phenotype through Helios deficiency occurs only within the tumor microenvironment (TME), not in peripheral lymphoid organs (Nakagawa et al. 2016, PNAS 113:6248-6253). Within the chronic inflammatory TME, Helios deficiency in Tregs can significantly alleviate repressed gene programs associated with T helper cell differentiation by upregulating T helper cell-related TFs and effector cytokines. These genetic changes in Helios-deficient Tregs are most pronounced in Treg subsets with high affinity for autoantigens, as demonstrated by enhanced GITR / PD-1 expression and increased responsiveness to autoantigens. Their combined effects can promote the transformation of the Treg phenotype into Teff within the TME, with increased T cell receptor (TCR) binding and Treg co-stimulatory receptor expression, indicating that changes in gene expression, as a central feature of Treg transformation, are immune environment dependent (Yates et al. 2018).
[0007] Reduced Helios expression in FoxP3+CD4 Tregs enables memory Tregs to be converted into Teff cells expressing autoreactive T cell receptors specific to tumor antigens. This altered Treg labeling can be selectively induced within the chronic inflammatory symptom of tumor growth. Helios-deficient Tregs exhibit a TCR repertoire biased towards high affinity for autopeptides / MHC, which can promote stable activation within the tumor microenvironment (TME) (Yates et al. 2018). Given the increased autoreactivity of TCRs in CD4 Tregs compared to conventional T cells, Treg conversion can produce highly efficient effector CD4 T cells, accompanied by attenuated Treg-mediated repression within the TME. More effective strategies could be devised to selectively convert intratumoral Tregs into Teff cells without affecting the systemic Treg population. As a key player in maintaining Treg size and functional stability in response to various immune perturbations, pharmacological interventions of Helios could be relevant to strategies for enhancing current tumor immunotherapy. Because the conversion of Tregs to Teffs can be confined to the inflammatory tumor microenvironment, antibody- or small-molecule-based approaches targeting Helios can produce modified Treg-dependent cancer immunotherapies. Importantly, the conversion of Helios-deficient Tregs occurs only within the local inflammatory environment of the tumor. This approach does not induce autoimmune side effects associated with systemic Treg reduction. Therefore, strategies that specifically utilize the intratumoral Treg phenotype for Helios-dependent control represent an important prospect for improving cancer immunotherapy. Furthermore, the removal of Foxp3+ Tregs to enhance vaccine-induced anti-tumor T-cell responses has been reported (Nishikawa et al. 2010, Int. J. Cancer 127:759-767), indicating that reducing Helios levels may be beneficial in enhancing the efficacy of cancer vaccines.
[0008] In addition to antitumor immunotherapy, during viral infection, Treg cells can limit immunopathology resulting from excessive inflammation, but potentially suppress effective antiviral T cell responses and promote viral persistence (Schmitz et al. 2013, PLOS Pathogens 9:e1003362). Chronic but non-acute murine lymphocytic choriomeningitis virus infection induced significant amplification of Foxp3+ Tregs, suggesting a potential mechanism by which certain infectious agents can evade the host immune response by activating and amplifying Tregs (Punkosdy et al. 2011, PNAS 108:3677-3682). In cases associated with chronic viral infection, therapeutic benefits can be achieved by reducing the Helios content in activated Tregs.
[0009] Compounds suitable as inhibitors of Helios protein are needed. Summary of the Invention
[0010] The present invention provides substituted (I) oxoisoindoline compounds or salts thereof suitable for reducing the content of Helios protein in cells, decreasing the level of Helios activity in cells and / or inhibiting the expression of Helios in cells.
[0011] The present invention also provides pharmaceutical compositions comprising a compound of formula (I) and / or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable carrier.
[0012] The present invention also provides a method for treating a disease or condition by reducing the activity of Helios protein, the method comprising administering to a patient a compound of formula (I) and / or a pharmaceutically acceptable salt thereof.
[0013] The present invention also provides methods and intermediates for manufacturing compounds of formula (I) and / or their salts.
[0014] The present invention also provides a compound of formula (I) for use in therapy and / or a pharmaceutically acceptable salt thereof.
[0015] The present invention also provides the use of the compound of formula (I) and / or its pharmaceutically acceptable salt for the manufacture of agents for the treatment of certain diseases, including cancer and viral infections, by reducing the content of Helios protein in cells, decreasing the level of Helios activity in cells and / or inhibiting the expression of Helios in cells to control Treg differentiation.
[0016] Compounds of formula (I) and compositions comprising compounds of formula (I) can be used to treat, prevent, or cure viral infections and various proliferative conditions, such as cancer. Pharmaceutical compositions comprising these compounds can be used in multiple therapeutic areas to treat, prevent, or slow the progression of diseases or conditions, such as viral infections and cancer.
[0017] These and other features of the invention will be set forth in an expanded form as the invention continues. Detailed Implementation
[0018] The applicant has discovered substituted oxoisoindoline compounds that inhibit Helios protein by promoting the interaction between Helios protein and the corresponding E3 ubiquitin conjugase complex (Cullin4-Cereblon, CUL4-CRBN). These compounds reduce the amount of Helios protein in cells, decrease the level of Helios activity in cells, and / or inhibit the expression of Helios in cells to control Treg differentiation. These compounds are suitable for the treatment of certain diseases, including cancer and viral infections. The compounds are intended to be pharmaceutical products with the required stability, bioavailability, therapeutic index, and toxicity values that are important for their pharmaceutical usability.
[0019] The first aspect of the present invention provides at least one compound of formula (I):
[0020]
[0021] or a salt thereof, wherein:
[0022] Ring A is:
[0023]
[0024]
[0025] Each R1 is independently F, Cl, Br, -CN, -OH, -NO2, through zero to six R... 1a Replacement C 1-6 Alkyl, via zero to 6 R 1a Replacement C 1-3 Alkoxy, -CR x R x OCR x R x (phenyl), -NR y R y -NR x C(O)H, -NR x C(O)(C 1-2 alkyl), -NR x C(O)NR x R x , -C(O)H, -C(O)OH, -C(O)O(C 1-3 Alkyl), -C(O)NR x R x -C(O)NR x (C 3-6 Cycloalkyl), -OC(O)(C 1-3 alkyl), -SO2(C 1-3 alkyl), -NHN(C 1-2 Alkyl group 2, -CH2CH2Si(CH3)3 or selected from C 3-6 Cycloalkyl, phenyl, pyridyl, piperidinyl, piperazinyl, pyrrolidinyl, morpholinyl, and dioxothiomorpholinyl cycloalgides, wherein the cycloalgide is formed by zero to four R groups. 1b replace;
[0026] Each R 1a Independently, it can be F, Cl, -CN, -OH, or C. 1-2 Alkoxy, C 1-2 Fluoroalkoxy, -SO2(C 1-3 alkyl) or phenyl;
[0027] Each R 1b F, Cl, C independently1-2 Alkyl, C 1-2 fluoroalkyl, C 1-2 Alkoxy, C 1-2 Fluoroalkoxy, -C(O)(C 1-3 alkyl) or -SO2(C 1-3 alkyl);
[0028] Each R x Independently H or -CH3;
[0029] Each R y Independently H or C 1-6 Alkyl groups; and
[0030] n can be zero, 1, 2, 3, or 4.
[0031] One embodiment provides a compound of formula (I) or a salt thereof, wherein each R1 is independently F, Cl, Br, -CN, -OH, -NO2, or via zero to six R... 1a Replacement C 1-5 Alkyl, via zero to five R 1a Replacement C 1-2 Alkoxy, -CR x R x OCH2 (phenyl), -NR y R y -NR x C(O)CH3、-NR x C(O)NR x R x , -C(O)H, -C(O)OH, -C(O)O(C 1-2 Alkyl), -C(O)NR x R x -C(O)NR x (Cyclopropyl), -OC(O)(C 1-2 alkyl), -SO2(C 1-2 Alkyl group, -NHN(CH3)2, -CH2CH2Si(CH3)3 or selected from C 3-6 Cycloalkyl, phenyl, pyridyl, piperidinyl, piperazinyl, pyrrolidinyl, morpholinyl, and dioxothiomorpholinyl cycloalgides, wherein the cycloalgide is formed by zero to three R groups. 1b replace.
[0032] One embodiment provides a compound of formula (I) or a salt thereof, wherein each R1 is independently F, Cl, Br, -CN, -OH, -NO2, or via zero to six R... 1a Replacement C 1-5 Alkyl, via zero to five R 1a Replacement C 1-2 Alkoxy, -CR x Rx OCH2 (phenyl), -NR y R y -NR x C(O)CH3、-NR x C(O)NR x R x , -C(O)H, -C(O)OH, -C(O)O(C 1-2 Alkyl), -C(O)NR x R x -C(O)NR x (Cyclopropyl), -OC(O)(C 1-2 alkyl), -SO2(C 1-2 Alkyl group, -NHN(CH3)2, -CH2CH2Si(CH3)3 or selected from C 3-6 Cycloalkyl, phenyl, pyridyl, piperidinyl, piperazinyl, pyrrolidinyl, morpholinyl, and dioxothiomorpholinyl cycloalgides, wherein the cycloalgide is formed by zero to three R groups. 1b Replace; each R 1b Independent of F, Cl, C 1-2 Alkyl, -CH2F, -CHF2, -CF3, C 1-2 Alkoxy, -OCF3, -C(O)(C 1-2 alkyl) or -SO2(C 1-2 Alkyl); and n is zero, 1, 2 or 3.
[0033] One embodiment provides a compound of formula (I) or a salt thereof, wherein each R1 is independently F, Cl, Br, -CN, -OH, -NO2, -CH3, -CH2CH3, -CHCH2CH3, -CH(CH3)2, -CH2C(CH3)3, -CF3, -CH2Cl, -CH2CN, -CH2(phenyl), -CH2OH, -CH2OCH2(phenyl), -OCH3, -OCH2CH3, -OCH2(phenyl), -NH2, -NH(CH3), -NH(CH2CH3), -NH(C H(CH3)CH2CH3), -N(CH3)2, -N(CH2CH3)2, -NHC(O)CH3, -N(CH3)C(O)CH3, -C(O)H, -C(O)OCH3, -C(O)NH (cyclopropyl), -C(O)NH2, -C(O)N(CH3)2, -CH2CH2Si(CH3)3, -OC(O)CH3, -NHN(CH3)2, cyclopropyl, phenyl, pyridyl, (benzyl)morpholinyl, (methanesulfonyl)piperazinyl or acetylpiperazinyl; and n is zero, 1, 2 or 3.
[0034] One embodiment provides a compound of formula (I) or a salt thereof, wherein each R1 is independently F, Cl, Br, -CN, -OH, -NO2, -CH3, -CH2CH3, -CH(CH3)2, -CH2C(CH3)3, -CF3, -CH2Cl, -CH2CN, -CH2(phenyl), -CH2OH, -CH2OCH2(phenyl), -OCH3, -OCH2CH3, -OCH2(phenyl), -NH2, -NH(CH3), -NH(CH2CH3). -NH(CH(CH3)CH2CH3), -N(CH3)2, -N(CH2CH3)2, -NHC(O)CH3, -N(CH3)C(O)CH3, -C(O)H, -C(O)OCH3, -C(O)NH(cyclopropyl), -C(O)NH2, -C(O)N(CH3)2, -CH2CH2Si(CH3)3, -OC(O)CH3, -NHN(CH3)2, cyclopropyl, phenyl, pyridyl or acetylpiperazinyl; and n is zero, 1, 2 or 3.
[0035] One embodiment provides a compound of formula (I) or a salt thereof, wherein:
[0036] Ring A is:
[0037]
[0038] One embodiment provides a compound of formula (I) or a salt thereof, wherein:
[0039] Ring A is: One embodiment provides a compound of formula (I) or a salt thereof, wherein:
[0040] Ring A is: One embodiment provides a compound of formula (I) or a salt thereof, wherein:
[0041] Ring A is: One embodiment provides a compound of formula (I) or a salt thereof, wherein:
[0042] Ring A is:
[0043]
[0044] One embodiment provides a compound of formula (I) or a salt thereof, wherein ring A is:
[0045] One embodiment provides a compound of formula (I) or a salt thereof, wherein ring A is:
[0046]
[0047] One embodiment provides a compound of formula (I) or a salt thereof, wherein ring A is:
[0048]
[0049] One embodiment provides a compound of formula (I) or a salt thereof, wherein ring A is:
[0050]
[0051] One embodiment provides a compound of formula (I) or a salt thereof, wherein ring A is:
[0052]
[0053] One embodiment provides a compound of formula (I) or a salt thereof, wherein ring A is:
[0054]
[0055] One embodiment provides a compound of formula (I) or a salt thereof, wherein ring A is:
[0056] One embodiment provides a compound of formula (I) or a salt thereof, wherein ring A is:
[0057]
[0058] One embodiment provides a compound of formula (I) or a salt thereof, wherein ring A is:
[0059] One embodiment provides a compound of formula (I) or a salt thereof, wherein each R1 is independently F, Cl, Br, -CN, -OH, -NO2, or via zero to six R... 1a Replacement C 1-6 Alkyl, via zero to 6 R 1a Replacement C 1-3 Alkoxy, -CR x R x OCR x R x (phenyl), -NR y R y -NR x C(O)H, -NR x C(O)(C 1-2 alkyl), -NR x C(O)NR x R x , -C(O)H, -C(O)OH, -C(O)O(C 1-3 Alkyl), -C(O)NR x R x -C(O)NRx (C 3-6 Cycloalkyl), -OC(O)(C 1-3 alkyl), -SO2(C 1-3 alkyl) or -NHN(C 1-2 Alkyl)2. This embodiment includes compounds wherein each R1 is independently F, Cl, Br, -CN, -OH, -NO2, or via zero to six R... 1a Replacement C 1-5 Alkyl, via zero to five R 1a Replacement C 1-2 Alkoxy, -CR x R x OCH2 (phenyl), -NR y R y -NR x C(O)CH3、-NR x C(O)NR x R x , -C(O)H, -C(O)OH, -C(O)O(C 1-2 Alkyl), -C(O)NR x R x -C(O)NR x (Cyclopropyl), -OC(O)(C 1-2 alkyl), -SO2(C 1-2 Alkyl) or -NHN(CH3)2. This embodiment also includes compounds wherein each R1 is independently F, Cl, Br, -CN, -OH, -NO2, -CH3, -CH2CH3, -CH(CH3)2, -CH2C(CH3)3, -CF3, -CH2Cl, -CH2CN, -CH2(phenyl), -CH2OH, -CH2OCH2(phenyl), -OCH3, -OCH2CH3, -OCH2(phenyl), -NH2, -NH(CH3), -NH(CH2CH3), -NH(CH(CH3)CH2CH3), -N(CH3)2, -N(CH2CH3)2, -NHC(O)CH3, -N(CH3)C (O)CH3, -C(O)H, -C(O)OCH3, -C(O)NH(cyclopropyl), -C(O)NH2, -C(O)N(CH3)2, -OC(O)CH3 or -NHN(CH3)2.
[0060] One embodiment provides a compound of formula (I) or a salt thereof, wherein each R1 is independently selected from C 3-6 Cycloalkyl, phenyl, pyridyl, piperidinyl, piperazinyl, pyrrolidinyl, morpholinyl, and dioxothiomorpholinyl cycloalgides, wherein the cycloalgide is formed by zero to four R groups. 1bSubstitution. This embodiment includes compounds wherein each R1 is independently selected from C 3-6 Cycloalkyl, phenyl, pyridyl, piperidinyl, piperazinyl, pyrrolidinyl, morpholinyl, and dioxothiomorpholinyl cycloalgides, wherein the cycloalgide is formed by zero to three R groups. 1b Substitution. This embodiment also includes compounds wherein each R1 is independently cyclopropyl, phenyl, pyridyl or acetylpiperazinyl.
[0061] One embodiment provides a compound of formula (I) or a salt thereof, wherein n is zero, 1, 2, or 3. This embodiment includes compounds wherein n is zero, 1, or 2. Alternatively, this embodiment includes compounds wherein n is 1 or 2.
[0062] One embodiment provides a compound of formula (I) or a salt thereof, wherein ring A is Each R1 is independently F, Cl, -CN, -OH, -CH3, -OCH3, -OCH2(phenyl), -NH2, -N(CH3)2, -CH2CH3, -CH(CH3)2, -CH2C(CH3)3, -CF3, -CH2Cl, -CH2CN, -CH2(phenyl), -CH2OH, -CH2OCH2(phenyl), -OCH2CH3, -NH(CH3), -NH(CH2CH3) or -NHC(O)CH3; and n is zero, 1 or 2.
[0063] One embodiment provides a compound of formula (I) or a salt thereof, wherein ring A is Each R1 is independently Cl, -CN, -CH3, -OCH3, -OCH2CH3, -NH2, -NH(CH3), -N(CH3)2, -NHC(O)CH3, -N(CH3)C(O)CH3, -C(O)NH2, -C(O)N(CH3)2 or cyclopropyl; and n is zero, 1 or 2.
[0064] One embodiment provides a compound of formula (I) or a salt thereof, wherein ring A is Each R1 is independently F, Cl, -OH, -CH3, -OCH3, -NH2, -C(O)OCH3, -C(O)NH (cyclopropyl) or phenyl; and n is zero, 1 or 2.
[0065] One embodiment provides a compound of formula (I) or a salt thereof, wherein ring A is: Each R1 is independently F, Cl, -NH2, -OCH3, -N(CH2CH3)2 or -C(O)OCH3; and n is zero, 1, 2 or 3.
[0066] One embodiment provides a compound of formula (I) or a salt thereof, wherein ring A is: Each R1 is independently Cl, -OH, -CH(CH3)2, -OCH3, -NH2, -NH(CH2CH3), -C(O)OCH3, cyclopropyl, or
[0067] One embodiment provides a compound of formula (I) or a salt thereof, wherein ring A is: Each R1 is independently F, Cl, Br, -CN, -OH, -NO2, -CH3, -OCH3, -NH2, -NH(CH3), -NH(CH2CH3), -NHC(O)CH3, -NHN(CH3)2, cyclopropyl, phenyl, (benzyl)morpholino, (methanesulfonyl)piperazinyl or acetylpiperazinyl; and n is zero, 1, 2 or 3.
[0068] One embodiment provides a compound of formula (I) or a salt thereof, wherein ring A is: Each R1 is independently -CN, -NH2, -C(O)NH2, phenyl, or pyridyl; and n is zero, 1, or 2.
[0069] One embodiment provides a compound of formula (I) or a salt thereof, wherein the compound is: 3-[1-oxo-5-(quinolin-2-yl)-2,3-dihydro-1H-isoindol-2-yl]piperidine-2,6-dione (1); 3-[5-(4-aminoisoquinolin-3-yl)-1-oxo-2,3-dihydro-1H-isoindol-2-yl]piperidine-2,6-dione (2); 3-(5-{8-oxa-3,5-diazatricyclo[7.4.0.0] 2,7] 13-1(9),2,4,6,10,12-hexen-6-yl}-1-oxo-2,3-dihydro-1H-isoindol-2-yl)piperidine-2,6-dione(3); 3-[5-(1-aminoisoquinoline-3-yl)-1-oxo-2,3-dihydro-1H-isoindol-2-yl]piperidine-2,6-dione(4); 3-[5-(3-aminoquinoxolin-2-yl)-1-oxo-2,3-dihydro-1H-isoindol-2-yl]piperidine-2,6-dione(5); 3-(1-oxo-5-{7H-pyrrolo[2,3-c]pyridazin-3-yl}-2,3-dihydro-1H-isoindol-2-yl)piperidine-2,6-dione(6); 3-[1-oxo-5-(quinoxolin-2-yl)-2,3-dihydro-1H-isoindol-2-yl]piperidin-2,6-dione (7); 3-[5-(4-aminoquinoxolin-2-yl)-1-oxo-2,3-dihydro-1H-isoindol-2-yl]piperidin-2,6-dione (8); 3-[1-oxo-5-(quinoxolin-2-yl)-2,3-dihydro-1H-isoindol-2-yl]piperidin-2,6-dione (9); 3-(5-{2-[(but-2-yl)amino]-[1,3]thiazo[5,4-b]pyridin-5-yl}-1-oxo-2,3-dihydro-1H-isoindol-2-yl)piperidin-2,6-dione (10); 3-(5 -{7-fluoro-1H-pyrrolo[3,2-c]pyridin-4-yl}-1-oxo-2,3-dihydro-1H-isoindol-2-yl)piperidin-2,6-dione (11); 3-[5-(4-methoxyquinoline-2-yl)-1-oxo-2,3-dihydro-1H-isoindol-2-yl]piperidin-2,6-dione (12); 3-[1-oxo-5-(4-phenylquinoline-2-yl)-2,3-dihydro-1H-isoindol-2-yl]piperidin-2,6-dione (13); N-cyclopropyl-2-[2-(2,6-dioxopiperidin-3-yl)-1-oxo-2,3-dihydro-1H-isoindol-5-yl]quinoline-4-carboxamide (14); 3- {5-[6-chloro-4-(diethylamino)quinazolin-2-yl]-1-oxo-2,3-dihydro-1H-isoindol-2-yl]piperidin-2,6-dione (15); 3-[5-(4-amino-6,7-dimethoxyquinazolin-2-yl)-1-oxo-2,3-dihydro-1H-isoindol-2-yl]piperidin-2,6-dione (16); 3-[5-(6-methoxyisoquinolin-1-yl)-1-oxo-2,3-dihydro-1H-isoindol-2-yl]piperidin-2,6-dione (17); 3-[5-(6-chloroquinoxolin-2-yl)-1-oxo-2,3-dihydro-1H-isoindol-2-yl]piperidin-2,6-dione (18);3-[5-(7-fluoroisoquinoline-1-yl)-1-oxo-2,3-dihydro-1H-isoindol-2-yl]piperidin-2,6-dione (19); 3-[5-(5-fluoroisoquinoline-1-yl)-1-oxo-2,3-dihydro-1H-isoindol-2-yl]piperidin-2,6-dione (20); 3-[5-(1,5-naphthidine-2-yl]piperidin-2,6-dione 3-[5-(4-aminoquinoline-2-yl)-1-oxo-2,3-dihydro-1H-isoindol-2-yl]piperidin-2,6-dione (21); 3-[5-(4-aminoquinoline-2-yl)-1-oxo-2,3-dihydro-1H-isoindol-2-yl]piperidin-2,6-dione (22); 3-[5-(6-methylisoquinoline-1-yl)-1-oxo-2,3-dihydro-1H-isoindol-2-yl]piperidin-2,6-dione (23); 3-[5-(4-methylquinoline-2-yl)-1-oxo-2,3-dihydro-1H-isoindol-2-yl]piperidin-2,6-dione (24); 3-[5-(3-aminoisoquinoline-1-yl)-1-oxo-2,3-dihydro-1H-isoindol-2-yl] Piperidine-2,6-dione (25); 3-[5-(6-fluoroquinoxalo-2-yl)-1-oxo-2,3-dihydro-1H-isoindol-2-yl]piperidine-2,6-dione (26); 3-[5-(6-chloroquino-2-yl)-1-oxo-2,3-dihydro-1H-isoindol-2-yl]piperidine-2,6-dione (27); 3- [5-(7-chloroquinoline-2-yl)-1-oxo-2,3-dihydro-1H-isoindol-2-yl]piperidine-2,6-dione (28); 3-[5-(6-methoxyquinoline-2-yl)-1-oxo-2,3-dihydro-1H-isoindol-2-yl]piperidine-2,6-dione (29); 3-[2-(2,6-dioxopiperidine- 3-(2,6-dioxopiridin-3-yl)-1-oxo-2,3-dihydro-1H-isoindol-5-yl]quinoxaline-2-carboxylic acid ethyl ester (30); 2-(2,6-dioxopiridin-3-yl)-1-oxo-2,3-dihydro-1H-isoindol-5-yl]quinoxaline-6-carboxylic acid methyl ester (31); 3-(5-(3-methylquinoxaline-2-yl)-1-oxo-2 3-[5-(8-methoxyquinoline-2-yl)-1-oxo-2,3-dihydro-1H-isoindol-2-yl]piperidin-2,6-dione (32); 3-[5-(8-methoxyquinoline-2-yl)-1-oxo-2,3-dihydro-1H-isoindol-2-yl]piperidin-2,6-dione (33); 3-[5-(8-chloroquinoline-2-yl)-1-oxo-2,3-dihydro-1H-isoindol-2-yl]piperidin-2,6-dione
[34] 3-[5-(6-fluoroquinazolin-2-yl)-1-oxo-2,3-dihydro-1H-isoindol-2-yl]piperidine-2,6-dione; 35-[5-(3-chloroquinolin-2-yl)-1-oxo-2,3-dihydro-1H-isoindol-2-yl]piperidine-2,6-dione;3-[5-(4-hydroxyquinoline-2-yl)-1-oxo-2,3-dihydro-1H-isoindol-2-yl]piperidin-2,6-dione (37); 3-[5-(6-fluoroquinoline-2-yl)-1-oxo-2,3-dihydro-1H-isoindol-2-yl]piperidin-2,6-dione (38); 3-[5-(6-methylquinoline-2-yl)-1-oxo-2,3-dihydro-1H-isoindol-2-yl]piperidin-2,6-dione (39); 3-[5-(6-hydroxyquinoline-2-yl)-1-oxo-2,3-dihydro-1H-isoindol-2-yl]piperidin-2,6-dione (40); 2-[2-(2,6-dioxopiperidin-3-yl)-1- [Oxo-2,3-dihydro-1H-isoindol-5-yl]quinazolin-7-carboxylate (41); 3-(5-{5-amino-3-[2-(trimethylsilyl)ethyl]-3H-[1,2,3]triazolo[4,5-d]pyrimidin-7-yl}-1-oxo-2,3-dihydro-1H-isoindol-2-yl)piperidin-2,6-dione (42); 3-[5-(2-amino-9H-purin-6-yl)-1-oxo-2,3-dihydro-1H-isoindol-2-yl]piperidin-2,6-dione (43); 3-[5-(6-amino-7H-purin-2-yl)-1-oxo-2,3-dihydro-1H-isoindol-2-yl]piperidin-2,6-dione (44); 3-(5-{6-amino-1-ethyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl}-1-oxo-2,3-dihydro-1H-isoindol-2-yl)piperidin-2,6-dione (45); 3-{5-[5-amino-1-(2,2-dimethylpropyl)-4-oxo-1,4-dihydro-1,6-naphthidin-7-yl]-1-oxo-2,3-dihydro-1H-isoindol-2-yl}piperidin-2,6-dione (46); 3-[5-(5-amino-4-oxo-1,4-dihydro-1,6-naphthidin-7-yl)-1-oxo-2,3-dihydro-1H-isoindol-2-yl]piperidin-2,6-dione (47); N-{3- [2-(2,6-dioxopiperidin-3-yl)-1-oxo-2,3-dihydro-1H-isoindol-5-yl]isoquinoline-1-yl}acetamide (48); 3-{5-[1-(dimethylamino)isoquinoline-3-yl]-1-oxo-2,3-dihydro-1H-isoindol-2-yl}piperidin-2,6-dione (49); 3-{5-[1-(methylamino)isoquinoline-3-yl]-1-oxo-2,3-dihydro-1H-isoindol-2-yl}piperidin-2,6-dione (50); 3-{5-[5-(methylamino)-1,6-naphthidin-7-yl]-1-oxo-2,3-dihydro-1H-isoindol-2-yl}piperidin-2,6-dione (51);N-{3-[2-(2,6-dioxopiperidin-3-yl)-1-oxo-2,3-dihydro-1H-isoindol-5-yl]isoquinoline-1-yl}-N-methylacetamide (52); 3-[5-(6-amino-1,7-naphthidin-8-yl)-1-oxo-2,3-dihydro-1H-isoindol-2-yl]piperidin-2,6-dione (53); 3-[5-(3-amino-5-methoxyisoquinoline-1-yl)-1-oxo-2,3-dihydro-1H-isoindol-2-yl]piperidin-2,6-dione (54); 3-(5-(4-(4-acetylpiperazin-1-yl)pyrido[2,3-d]pyrimidin-2-yl)-1-oxoisoindololine-2-yl] 3-(5-{4-bromo-1H-pyrrolo[2,3-c]pyridin-7-yl}-1-oxo-2,3-dihydro-1H-isoindol-2-yl)piperidin-2,6-dione (56); 3-[5-(5-amino-1,6-naphthidin-7-yl)-1-oxo-2,3-dihydro-1H-isoindol-2-yl]piperidin-2,6-dione (57); 3-[5-(3,6-dimethoxyisoquinoline-1-yl)-1-oxo-2,3-dihydro-1H-isoindol-2-yl]piperidin-2,6-dione (58); 1-[2-(2,6-dioxopiperidin-3-yl)-1-oxo-2,3-dihydro-1H- -isoindol-5-yl]isoquinoline-3-carboxylon (59); 4-[2-(2,6-dioxopiperidin-3-yl)-1-oxo-2,3-dihydro-1H-isoindol-5-yl]thieno[3,2-c]pyridine-2-carboxaldehyde (60); 3-{5-[1-methyl-4-(methylamino)-1H-imidazo[4,5-c]pyridin-6-yl]-1-oxo-2,3-dihydro-1H-isoindol-2-yl}piperidin-2,6-dione (61); 3-(5-{2-methyl-4-oxo-4H-pyrano[2,3-b]pyridin-7-yl}-1-oxo-2,3-dihydro-1H-isoindol-2-yl)piperidin-2,6-dione (62); 3-{5-[5,7-dichloro-3-(dimethylamino)isoquinoline-1-yl]-1-oxo-2,3-dihydro-1H-isoindol-2-yl}piperidin-2,6-dione (63); 3-[5-(1,7-naphthidin-8-yl)-1-oxo-2,3-dihydro-1H-isoindol-2-yl]piperidin-2,6-dione (64); 3-(5-{2-aminoimidazo[1,2-b]pyridazin-6-yl}-1-oxo-2,3-dihydro-1H-isoindol-2-yl)piperidin-2,6-dione (65); 3-[5-(isoquinoline-1-yl)-1-oxo-2,3-dihydro-1H-isoindol-2-yl]piperidin-2,6-dione (66);3-[5-(isoquinolin-3-yl)-1-oxo-2,3-dihydro-1H-isoindol-2-yl]piperidin-2,6-dione (67); 3-(5-(2-amino-6-methoxypyrimidin-4-yl)-1-oxoisoindolin-2-yl)piperidin-2,6-dione (68); 3-(5-(6-aminopyridin-2-yl)-1-oxoisoindolin-2-yl)piperidin-2,6-dione (69); 3-(5-(2-aminopyrimidin-4-yl)-1-oxoisoindolin-2-yl)piperidin-2,6-dione (70); 3-(1-oxo-5-(4-phenylpyrimidin-2-yl)isoindolin-2-yl)piperidin-2,6-dione (71); 3-(1- oxo-5-(4-(pyridin-3-yl)pyrimidin-2-yl)isoindoline-2-yl)piperidin-2,6-dione (72); 3-(5-(4-amino-6-phenyl-1,3,5-triazin-2-yl)-1-oxoisoindoline-2-yl)piperidin-2,6-dione (73); 3-(1-oxo-5-(4-phenylpyridin-2-yl)isoindoline-2-yl)piperidin-2,6-dione (74); 3-(1-oxo-5-(4-(pyridin-2-yl)pyrimidin-2-yl)isoindoline-2-yl)piperidin-2,6-dione (75); 3-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindoline-5-yl)pyridazine-4-carboxylonitrile (76) ); 6-[2-(2,6-dioxopiperidin-3-yl)-1-oxo-2,3-dihydro-1H-isoindol-5-yl]pyridazine-3-carboxylonitrile (77); 6-[2-(2,6-dioxopiperidin-3-yl)-1-oxo-2,3-dihydro-1H-isoindol-5-yl]pyridazine-3-carboxamide (78); 3-[5-(6-amino-3-nitropyridin-2-yl)-1-oxo-2,3-dihydro-1H-isoindol-2-yl]piperidin-2,6-dione (79); 4-amino-2-[2-(2,6-dioxopiperidin-3-yl)-1-oxo-2,3-dihydro-1H-isoindol-5-yl]pyrimidine-5-carboxylonitrile (80); 4-amino-2- [2-(2,6-dioxopiperidin-3-yl)-1-oxo-2,3-dihydro-1H-isoindole-5-yl]pyrimidin-5-carboxamide (81); (3S)-3-[5-(1-aminoisoquinoline-3-yl)-1-oxo-2,3-dihydro-1H-isoindole-2-yl]piperidin-2,6-dione (82); (3R)-3-[5-(1-aminoisoquinoline-3-yl)-1-oxo-2,3-dihydro-1H-isoindole-2-yl]piperidin-2,6-dione (83); (3S)-3-[5-(1-amino-4-ethoxyisoquinoline-3-yl)-1-oxo-2,3-dihydro-1H-isoindole-2-yl]piperidin-2,6-dione (84);3-(5-(4-ethoxyisoquinoline-3-yl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione (85); 3-(5-(1-chloro-4-ethoxyisoquinoline-3-yl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione (86); 3-(5-(2,3-dihydro-1H-pyrido[3,4-b][1,4]oxazin-7-yl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione (87); 3-(5-(1-methylisoquinoline-3-yl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione (88); 3-(5-(1-cyclopropylisoquinoline-3-yl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione 2,6-dione (89); -(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindoline-5-yl)isoquinoline-4-carboxynitrile (90); 3-(1-oxo-5-(quinazolin-4-yl)isoindoline-2-yl)piperidin-2,6-dione (91); 3-(5-(6-methyl-5-oxo-5,6,7,8-tetrahydro-1,6-naphthidin-2-yl)-1-oxoisoindoline-2-yl)piperidin-2,6-dione (92); 3-(5-(3-chloroquinoxolin-2-yl)-1-oxoisoindoline-2-yl)piperidin-2,6-dione (93); 3-(5-(3-methoxyquinoxolin-2-yl)-1-oxoisoindoline-2-yl)piperidin-2-dione Piperidine-2,6-dione (94); 3-(5-(3-(ethylamino)quinoxalin-2-yl)-1-oxoisoindoline-2-yl)piperidine-2,6-dione (95); 3-(5-(3-hydroxyquinoxalin-2-yl)-1-oxoisoindoline-2-yl)piperidine-2,6-dione (96); 3-(5-(3-cyclopropylquinoxalin-2-yl)-1-oxoisoindoline-2-yl)piperidine-2,6-dione (97); 3-(5-(3-isopropylquinoxalin-2-yl)-1-oxoisoindoline-2-yl)piperidine-2,6-dione (98); 3-(1-oxo-5-(3-phenylquinoxalin-2-yl)isoindoline-2-yl)piperidine-2,6- Dione (99); 3-(5-(1,6-naphthid-5-yl)-1-oxoisoindoline-2-yl)piperidine-2,6-dione (100); 3-(5-(6-amino-3-bromopyridin-2-yl)-1-oxoisoindoline-2-yl)piperidine-2,6-dione (101); 3-(5-(6-aminoisoquinoline-3-yl)-1-oxoisoindoline-2-yl)piperidine-2,6-dione (102); 3-(5-(4-methoxyisoquinoline-1-yl)-1-oxoisoindoline-2-yl)piperidine-2,6-dione (103); 3-(5-(3-methoxypyridin-2-yl)-1-oxoisoindoline-2-yl)piperidine-2,6-dione (104);3-(5-(4-(benzyloxy)isoquinolin-1-yl)-1-oxoisoindololin-2-yl)piperidin-2,6-dione (105); 3-(5-(6-amino-3-methoxypyridin-2-yl)-1-oxoisoindololin-2-yl)piperidin-2,6-dione (106); 3-(5-(3-(hydroxymethyl)pyridin-2-yl)-1-oxoisoindololin-2-yl)piperidin-2,6-dione (107); 3-(5-(4-(hydroxymethyl)pyridin-2-yl)-1-oxoisoindololin-2-yl)piperidin-2,6-dione (108); 3-(1-oxo-5-(pyridin-2-yl)isoindololin-2-yl)piperidin-2,6-dione (109); 2-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindoline-5-yl)isonicotinonitrile (110); 2-(2-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindoline-5-yl)pyridin-4-yl)acetonitrile (111); 3-(5-(6-amino-4-(hydroxymethyl)pyridin-2-yl)-1-oxoisoindoline-2-yl)piperidin-2,6-dione (112); 3-(5-(2,3-dihydro-1H-pyrrolo[2,3-c]pyridin-5-yl)-1-oxoisoindoline-2-yl)piperidin-2,6-dione (113); 3-(1-oxo-5-(2-oxo-2,3-di)pyridin-5-yl)pyridin-5-yl)piperidin-2,6-dione 1H-pyrrolo[2,3-b]pyridin-6-yl)isoindoline-2-yl)piperidin-2,6-dione (114); 3-(1-oxo-5-(5,6,7,8-tetrahydroisoquinoline-3-yl)isoindoline-2-yl)piperidin-2,6-dione (115); 3-(5-(6-amino-5-methylpyridin-2-yl)-1-oxoisoindoline-2-yl)piperidin-2,6-dione (116); 3-(5-(5,6-diaminopyridin-2-yl)-1-oxoisoindoline-2-yl)piperidin-2,6-dione (117); 3-(1-oxo-5-(1,2,3,4-tetrahydropyrido[2,3-b]pyrazin-6-yl)isoindoline (118) 3-(5-(5-amino-4,6-dimethylpyridin-2-yl)-1-oxoisoindolin-2-yl)piperidin-2,6-dione (119) 3-(5-(6-amino-4-(trifluoromethyl)pyridin-2-yl)-1-oxoisoindolin-2-yl)piperidin-2,6-dione (120) 3-(5-(4,5-dimethylpyridin-2-yl)-1-oxoisoindolin-2-yl)piperidin-2,6-dione (121) (3S)-3-[5-(1,8-naphthidin-2-yl)-1-oxo-2,3-dihydro-1H-isoindolin-2-yl]piperidin-2,6-dione (122)(S)-3-(5-(3-aminoisoquinolin-1-yl)-1-oxoisoindololin-2-yl)piperidine-2,6-dione (123); (S)-N-(1-(2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindololin-5-yl)isoquinolin-3-yl)acetamide (124); 3-{2-[(3S)-2,6-dioxopiperidine-3-yl]-1-oxo-2,3-dihydro-1H-isoindololin-5-yl}isoquinolin-1-carboxynitrile (125); 3-{2-[(3S)-2,6-dioxopiperidine-3-yl]-1-oxo-2,3-dihydro-1H-isoindololin-5-yl}isoquinolin-1-carboxamide (126) ); (4S)-Acetic acid 7-{2-[(3S)-2,6-dioxopiperidin-3-yl]-1-oxo-2,3-dihydro-1H-isoindole-5-yl}-2H,3H,4H-pyrano[2,3-b]pyridin-4-yl ester (127); (4R)-Acetic acid 7-{2-[(3S)-2,6-dioxopiperidin-3-yl]-1-oxo-2,3-dihydro-1H-isoindole-5-yl}-2H,3H,4H-pyrano[2,3-b]pyridin-4-yl ester (128); 3-{5-[7-chloro-4-(dimethylamino)isoquinoline-1-yl]-1-oxo-2,3-dihydro-1H-isoindole-2-yl}piperidin-2 ,6-Diketone (129); 1-Amino-3-[2-(2,6-dioxopiridin-3-yl)-1-oxo-2,3-dihydro-1H-isoindol-5-yl]-N,N-dimethylisoquinoline-4-carboxamide (130); 3-[5-(1-amino-4-methylisoquinoline-3-yl)-1-oxo-2,3-dihydro-1H-isoindol-2-yl]piperidin-2,6-diketone (131); 3-[5-(6-amino-3-cyclopropylpyridin-2-yl)-1-oxo-2,3-dihydro-1H-isoindol-2-yl]piperidin-2,6-diketone (132); 3-[5-(6-amino-isoquinoline-1-yl)-1-oxo-2,3- Dihydro-1H-isoindol-2-yl]piperidin-2,6-dione (133); N-{1-[2-(2,6-dioxopiperidin-3-yl)-1-oxo-2,3-dihydro-1H-isoindol-5-yl]isoquinoline-6-yl}acetamide (134); 3-{5-[6-amino-4-(chloromethyl)pyridin-2-yl]-1-oxo-2,3-dihydro-1H-isoindol-2-yl}piperidin-2,6-dione (135); 3-(1-oxo-5-{5H,6H,7H,8H,9H-pyrido[2,3-b]azaphen-2-yl}-2,3-dihydro-1H-isoindol-2-yl)piperidin-2,6-dione (136);3-[1-oxo-5-(5,6,7,8-tetrahydro-1,8-naphthidin-2-yl)-2,3-dihydro-1H-isoindol-2-yl]piperidin-2,6-dione (137); 3-{5-[6-(2,2-dimethylhydrazine-1-yl)pyridin-2-yl]-1-oxo-2,3-dihydro-1H-isoindol-2-yl}piperidin-2,6-dione (138); 3-(5-(1H-imidazo[4,5-b]pyridin-5-yl)-1-oxoisoindololin-2-yl)piperidin-2,6-dione (139); 3-(5-(6-amino-4-methylpyridin-2-yl)-1-oxoisoindololin-2-yl)piperidin-2,6-dione (140); 3-(5- (3,4-Dihydro-2H-pyrido[3,2-b][1,4]oxazin-6-yl)-1-oxoisoindololin-2-yl)piperidine-2,6-dione (141); 3-(5-(6-aminopyrazin-2-yl)-1-oxoisoindololin-2-yl)piperidine-2,6-dione (142); 3-(5-(2-amino-6-methylpyrimidin-4-yl)-1-oxoisoindololin-2-yl)piperidine-2,6-dione (143); 3-(5-(4,6-dimethylpyridin-2-yl)-1-oxoisoindololin-2-yl)piperidine-2,6-dione (144); 3-(5-(5-chloro-3-hydroxyisoquinolin-1-yl)-1-oxoisoindololin-2-yl)piperidine -2,6-dione (145); 3-(5-(6-methoxy-4-methylpyridin-2-yl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione (146); 3-(5-(6-hydroxy-4-methylpyridin-2-yl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione (147); 2-amino-6-(2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindolin-5-yl)-4-methylnicotinonitrile (148); 2-amino-6-(2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindolin-5-yl)isonicotinonitrile (149); 3-(5-(1-amino-5,6,7,8-tetrahydroisoquinoline-3-yl) 3-(5-(6-amino-4,5-dimethylpyridin-2-yl)-1-oxoisoindoline-2-yl)piperidine-2,6-dione (151); 6-(2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindoline-5-yl)-4-methylnicotinonitrile (152); 3-(5-(6-amino-5-methoxy-4-methylpyridin-2-yl)-1-oxoisoindoline-2-yl)piperidine-2,6-dione (153); 3-(5-(6-amino-5-methoxy-4-methylpyridin-2-yl)-1-oxoisoindoline-2-yl)piperidine-2,6-dione (154);3-[5-(6-methoxypyridin-2-yl)-1-oxo-2,3-dihydro-1H-isoindol-2-yl]piperidin-2,6-dione (155); 3-[5-(1-methoxyisoquinoline-3-yl)-1-oxo-2,3-dihydro-1H-isoindol-2-yl]piperidin-2,6-dione (156); 3-[1-oxo-5-(1-oxo-1,2-dihydroisoquinoline-3-yl)-2,3-dihydro-1H-isoindol-2-yl]piperidin-2,6-dione (157); 3-(5-{1-benzyl-1H-pyrrolo[3,2-c]pyridin-6-yl}-1-oxo-2,3-dihydro-1H-isoindol-2-yl)piperidin-2,6-dione (158) ); 3-(1-oxo-5-(1H-pyrrolo[3,2-c]pyridin-6-yl)isoindoline-2-yl)piperidin-2,6-dione (159); 3-(1-oxo-5-(1H-pyrrolo[3,2-c]pyridin-4-yl)isoindoline-2-yl)piperidin-2,6-dione (160); 3-(5-(1-benzyl- 1H-pyrrolo[3,2-c]pyridin-4-yl)-1-oxoisoindolin-2-yl)piperidin-2,6-dione (161); 6-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)2-cyanopyridine (162); 3-(5-(6-amino-4-(trifluoromethyl)pyridin-2-yl)-1-oxo 3-(5-(6-amino-4-methoxypyridin-2-yl)-1-oxoisoindoline-2-yl)piperidine-2,6-dione (164); 3-(5-(6-amino-4-chloropyridin-2-yl)-1-oxoisoindoline-2-yl)piperidine-2,6-dione (165); 2-amino-6-(2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindoline-5-yl)nicotinonitrile (166); 2-amino-6-(2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindoline-5-yl)pyridin-3,5-dicarboxylonitrile (168); 2-amino-6-(2-(2,6-dioxopiperidine-3-yl)-1-oxoisoindoline-5-yl)pyridin-3,5-dicarboxylonitrile Piperidin-3-yl)-1-oxoisoindoline-5-yl)-5-fluoronicotinonitrile (169); 3-(5-(6-amino-4-phenylpyridin-2-yl)-1-oxoisoindoline-2-yl)piperidin-2,6-dione (170); 6-amino-2-(2-(2,6-dioxoperidin-3-yl)-1-oxoisoindoline-5-yl)-4-(trifluoromethyl)nicotinonitrile (171); 2-amino-6-(2-(2,6-dioxoperidin-3-yl)-1-oxoisoindoline-5-yl)-4-propylnicotinonitrile (172); 6-amino-2-(2-(2,6-dioxoperidin-3-yl)-1-oxoisoindoline-5-yl)-4-propylnicotinonitrile (173);6-Amino-4-(difluoromethyl)-2-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindoline-5-yl)nicotinonitrile (174); 2-Amino-6-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindoline-5-yl)-5-(trifluoromethyl)nicotinonitrile (175); 2-Amino-4-(difluoromethyl)-6-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindoline-5-yl)nicotinonitrile (176); 2-Amino-6-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindoline-5-yl)-4-(trifluoromethyl)nicotinonitrile (17) 7); 2-amino-6-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindoline-5-yl)-4-isopropylnicotinonitrile (178); 6-amino-2-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindoline-5-yl)-4-isopropylnicotinonitrile (179); 6-amino-2-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindoline-5-yl)-5-methylnicotinonitrile (180); 2-amino-6-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindoline-5-yl)-5-methoxynicotinonitrile (181); 6-amino-5-cyclopropyl -2-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindoline-5-yl)nicotinonitrile (182); 2-amino-5-cyclopropyl-6-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindoline-5-yl)nicotinonitrile (183); 3-(5-(6-amino-4-(4-benzylpiperazin-1-yl)pyridin-2-yl)-1-oxoisoindoline-2-yl)piperidin-2,6-dione (184); 3-(5-(6-amino-4-(4-(methanesulfonyl)piperazin-1-yl)pyridin-2-yl)-1-oxoisoindoline-2-yl)piperidin-2,6-dione (185); 3-( 5-(4-(4-acetylpiperazin-1-yl)-6-aminopyridin-2-yl)-1-oxoisoindoline-2-yl)piperidine-2,6-dione (186); 3-(5-(4-methyl-6-(methylamino)pyridin-2-yl)-1-oxoisoindoline-2-yl)piperidine-2,6-dione (187); 3-(5-(6-(ethylamino)-4-methylpyridin-2-yl)-1-oxoisoindoline-2-yl)piperidine-2,6-dione (188); or 3-(5-(4,5-dimethyl-6-(methylamino)pyridin-2-yl)-1-oxoisoindoline-2-yl)piperidine-2,6-dione (189);
[0070] This invention may be practiced in other specific forms without departing from its spirit or essential attributes. This invention encompasses all combinations of the aspects and / or embodiments of the invention as set forth herein. It should be understood that any and all embodiments of the invention may be combined with any other one or more embodiments to describe additional embodiments. It should also be understood that individual elements of an embodiment are intended to be combined with any and all other elements from any embodiment to describe additional embodiments.
[0071] Those skilled in the art will more readily understand the features and advantages of the present invention after reading the following embodiments. It should be understood that, in individual embodiments, certain features of the invention described above and below may also be combined to form a single embodiment for clarity. Conversely, various features of the invention described in the context of a single embodiment for brevity may also be combined to form sub-combinations thereof. The embodiments identified herein as illustrative or preferred are intended to be explanatory rather than restrictive.
[0072] Unless otherwise specified herein, the singular form may also refer to the plural form. For example, “a / an” may refer to one (kind) or one or more (kinds).
[0073] As used herein, the phrase “compound and / or its salt” means at least one compound, at least one salt of a compound, or a combination thereof. For example, a compound of formula (I) and / or its salt includes a compound of formula (I); two compounds of formula (I); a salt of a compound of formula (I); a compound of formula (I) and one or more salts of a compound of formula (I); and two or more salts of a compound of formula (I).
[0074] Unless otherwise specified, any atom with an unsaturated valence is assumed to have enough hydrogen atoms to saturate the valence.
[0075] The definitions set forth herein take precedence over those set forth in any patent, patent application and / or patent application publication incorporated herein by reference.
[0076] The following lists definitions of various terms used to describe the invention. These definitions apply to the terms as they are used individually throughout the specification or as part of a larger group (unless otherwise limited in specific circumstances).
[0077] Throughout this specification, those skilled in the art can select groups and their substituents to obtain stable moieties and compounds.
[0078] According to the specifications used in this field
[0079]
[0080] In the structural formula of this paper, the bonds are used to describe the connection points between the parts or substituents and the core or main chain structure.
[0081] As used in this article, the terms “halogen” and “halogen” refer to F, Cl, Br and I.
[0082] The term "cyano" refers to the -CN group.
[0083] The term "amino" refers to the -NH2 group.
[0084] The term "oxo" refers to the =O group.
[0085] As used herein, the term "alkyl" refers to a branched or straight-chain saturated aliphatic hydrocarbon group containing, for example, 1 to 12 carbon atoms, 1 to 6 carbon atoms, and 1 to 4 carbon atoms. Examples of alkyl groups include, but are not limited to, methyl (Me), ethyl (Et), propyl (e.g., n-propyl and isopropyl), butyl (e.g., n-butyl, isobutyl, sec-butyl, and tert-butyl), and pentyl (e.g., n-pentyl, isopentyl, and neopentyl), n-hexyl, 2-methylpentyl, 2-ethylbutyl, 3-methylpentyl, and 4-methylpentyl. When a number appears in subscript form after the symbol "C", the subscript more specifically defines the number of carbon atoms that a particular group may contain. For example, "C..." 1-4 "Alkyl" refers to straight-chain and branched alkyl groups having one to four carbon atoms.
[0086] As used herein, the term "fluoroalkyl" is intended to include branched and straight-chain saturated aliphatic hydrocarbon groups substituted with one or more fluorine atoms. For example, "C 1-4 "Fluoroalkyl" is intended to include C1, C2, C3, and C4 alkyl groups substituted with one or more fluorine atoms. Representative examples of fluoroalkyl groups include, but are not limited to, -CF3 and -CH2CF3.
[0087] As used herein, the term "alkoxy" refers to an alkyl group, such as a methoxy group (-OCH3), that is attached to the parent molecule via an oxygen atom. For example, "C 1-3 "Alkoxy" refers to an alkoxy group having one to three carbon atoms.
[0088] The terms "fluoroalkoxy" and "-O (fluoroalkyl)" refer to fluoroalkyl groups as defined above, linked via an oxygen bond (-O-). For example, "C 1-4 "Fluoroalkoxy" is intended to include C1, C2, C3, and C4 fluoroalkoxy groups.
[0089] As used herein, the term "cycloalkyl" refers to a group derived from a non-aromatic monocyclic or polycyclic hydrocarbon molecule by removing a hydrogen atom from a self-saturated ring carbon atom. Representative examples of cycloalkyl groups include, but are not limited to, cyclopropyl, cyclopentyl, and cyclohexyl. When a number appears in subscript form after the symbol "C," the subscript more specifically defines the number of carbon atoms that a particular cycloalkyl group may contain. For example, "C3-C6 cycloalkyl" indicates a cycloalkyl group having three to six carbon atoms.
[0090] The compounds of this invention comprise all isotopes of the atoms present in the compounds of this invention. Isotopes include those atoms with the same number of atoms but different mass numbers. As a general example, but not limitingly, isotopes of hydrogen include deuterium (D) and tritium (T). Isotopes of carbon include... 13 C and 14 C. The isotopically labeled compounds of the present invention can generally be prepared by conventional techniques known to those skilled in the art or by methods similar to those described herein, using appropriately isotopically labeled reagents instead of the originally used unlabeled reagents.
[0091] The phrase “pharmaceutically acceptable” is used in this article to refer to compounds, materials, compositions, and / or dosage forms that, within the scope of reasonable medical judgment, are suitable for contact with human and animal tissues without excessive toxicity, irritation, allergic reactions, or other problems or complications, and in proportion to a reasonable benefit / risk ratio.
[0092] Compounds of formula (I) can form salts that also fall within the scope of this invention. Unless otherwise indicated, reference to compounds of this invention should be understood to include reference to one or more of their salts. The term "(one or more) salt" means an acidic and / or basic salt formed from inorganic and / or organic acids and bases. Additionally, the term "(one or more) salt" can include zwitterions (internal salts), for example when a compound of formula (I) contains a basic moiety (such as an amine or pyridine or imidazole ring) and an acidic moiety (such as a carboxylic acid). Pharmaceutically acceptable (i.e., non-toxic and physiologically acceptable) salts are preferably such as acceptable metal and amine salts, wherein the cation does not significantly promote the toxicity or biological activity of the salt. However, other salts may be suitable for, for example, separation or purification steps used during preparation, and are therefore considered within the scope of this invention. Salts of compounds of formula (I) can be formed, for example, by reacting a compound of formula (I) with a certain amount (such as an equal amount) of an acid or base in a medium (such as a medium for precipitating the salt) or in an aqueous medium, followed by lyophilization.
[0093] Exemplary acid addition salts include acetates (such as those formed with acetic acid or trihaloacetic acid (e.g., trifluoroacetic acid), adipates, alginates, ascorbic acid salts, aspartates, benzoates, benzenesulfonates, hydrogen sulfates, borates, butates, citrates, camphorates, camphorsulfonates, cyclopentanepropionates, disaccharides, dodecyl sulfates, ethanesulfonates, fumarates, gluconate-heptate, glycerophosphates, hemisulfates, heptanoates, hexanoates, hydrochlorides (formed with hydrochloric acid), and hydrobromides (formed with hydrogen bromide). Hydroiodide, maleate (formed with maleic acid), 2-hydroxyethane sulfonate, lactate, methanesulfonate (formed with methanesulfonic acid), 2-naphthalene sulfonate, nicotinate, nitrate, oxalate, pectate, persulfate, 3-phenylpropionate, phosphate, picrate, pentanoate, propionate, salicylate, succinate, sulfate (such as those formed with sulfuric acid), sulfonate (such as those mentioned herein), tartrate, thiocyanate, toluene sulfonate (such as methanesulfonate), undecanoate and similar salts.
[0094] Exemplary basic salts include ammonium salts; alkali metal salts, such as sodium, lithium, and potassium salts; alkaline earth metal salts, such as calcium and magnesium salts; barium, zinc, and aluminum salts; salts formed with organic bases (e.g., organic amines), such as trialkylamines (e.g., triethylamine), procaine, diphenylmethylamine, N-phenylmethyl-β-phenylethylamine, 1-aminophen, N,N'-diphenylmethylethylenediamine, dehydroabietylamine, N-ethylpiperidine, benzylamine, dicyclohexylamine, or similar pharmaceutically acceptable amines; and salts formed with amino acids (e.g., arginine, lysine, and their analogues). Basic nitrogen-containing groups can be quaternized with reagents such as: low-carbon alkyl halides (e.g., methyl, ethyl, propyl, and butyl chlorides, bromides, and iodides), dialkyl sulfates (e.g., dimethyl sulfate, diethyl sulfate, dibutyl sulfate, and dipentyl sulfate), long-chain halides (e.g., decyl, lauryl, myristyl, and stearyl chlorides, bromides, and iodides), aralkyl halides (e.g., benzyl and phenethyl bromides), and other substances. Preferred salts include monohydrochlorides, hydrogen sulfates, methanesulfonates, phosphates, or nitrates.
[0095] Compounds of formula (I) may be provided in amorphous or crystalline solid form. Lyophilization may be used to obtain compounds of formula (I) in solid form.
[0096] It should be further understood that solvates (e.g., hydrates) of compounds of formula (I) are also within the scope of this invention. The term "solvate" means the physical association of a compound of formula (I) with one or more solvent molecules (organic or inorganic). This physical association includes hydrogen bonding. In some cases, the solvate will be separable, for example when one or more solvent molecules are incorporated into the lattice of a crystalline solid. "Solvate" encompasses both the solution phase and the separable solvate. Exemplary solvates include hydrates, ethanol compounds, methanol compounds, isopropanol compounds, acetonitrile solvates, and ethyl acetate solvates. Solventing methods are known in the art.
[0097] Various forms of prodrugs are well known in the art and described in Rautio, J. et al., Nature Review Drug Discovery, 17, 559-587 (2018).
[0098] Additionally, the compound of formula (I) can be isolated and purified after its preparation to obtain a composition containing 99% or more by weight of the compound of formula (I) (“substantially pure”), which is then used or formulated as described herein. The “substantially pure” compound of formula (I) is also contemplated herein as part of the invention.
[0099] "Stable compound" and "stable structure" mean a compound that is sufficiently robust to withstand separation from the reaction mixture to a suitable purity and formulation into an effective therapeutic agent. This invention is intended to include stable compounds.
[0100] The term "Helios inhibitor" refers to drugs that can reduce the content of Helios protein in cells, decrease the level of Helios activity in cells, and / or inhibit the expression of Helios in cells to control Treg differentiation. Helios inhibitors can be reversible or irreversible inhibitors.
[0101] As used herein, "Helios" protein refers to a protein that is a member of the Ikaros family of zinc finger proteins. In humans, Helios is encoded by the IKZF2 gene. Helios is also known as IKAROS family zinc finger 2, ANF1A2, ZNF1A2, ZNFN1A2, zinc finger protein subfamily 1A,2, and Ikaros family zinc finger protein 2. Members of this protein family include Ikaros, Helios, Aiolos, Eos, and Pegasus. As used herein, Helios protein includes various isoforms, including isoforms 1 through 5 listed below.
[0102] Type 1 (UniProt Q9UKS7-1)
[0103]
[0104] Type 2 (UniProt Q9UKS7-2)
[0105]
[0106] Type 4 (UniProt Q9UKS7-4)
[0107]
[0108] Type 6 (UniProt Q9UKS7-6)
[0109]
[0110] Type 7 (UniProt Q9UKS7-7)
[0111]
[0112] The Helios isotypes 1, 2, 4, 6, and 7 listed above include the degradation determinant FHCNQCGASFTQKGNLLRHIKLH (SEQ ID NO: 6) (bold and underlined). Degradation determinants are parts of proteins that play a role in regulating the rate of protein degradation.
[0113] As used in this article, the “Eos” protein is encoded by the IKZF4 gene and is also known as IKAROS family zinc finger 4, ZNFN1A4, zinc finger protein subfamily 1A,4, Ikaros family zinc finger protein 4, and KIAA1782. The “Eos” protein includes isotypes encoded by the following two human isotypes: 1 (Q9H2S9-1) and 2 (Q9H2S9-2).
[0114] Type 1 (UniProt Q9H2S9-1)
[0115]
[0116] Type 2 (UniProt Q9H2S9-2)
[0117]
[0118] The “Eos” protein isotypes 1 and 2 listed above include the degradation determinant FHCNQCGASFTQKGNLLRHIKLH (SEQ ID NO:6) (bold and underlined), which is the same as the degradation determinant of the “Helios” protein.
[0119] As used in this article, the “Ikaros” protein is encoded by the IKZF1 gene. Ikaros is also known as IKAROS family zinc finger 1, ZNFN1A1, zinc finger protein subfamily 1A,1, Ikaros family zinc finger protein 1, IK1, lymphocyte transcription factor LyF-1, Hs.54452, PPP1R92, protein phosphatase 1, regulatory subunit 92, PRO0758, CVID13, and CLL-associated antigen KW-6. Ikaros proteins include isotypes encoded by amino acid sequences Q13422-1, Q13422-2, Q13422-3, Q13422-4, Q13422-7, and Q13422-8. Ikaros proteins also include isotypes encoded by amino acid sequences Q13422-5 and Q13422-6.
[0120] As used in this article, the “Aiolos” protein is encoded by the IKZF3 gene. Aiolos proteins are also known as IKAROS family zinc finger 3, ZNFN1A3, zinc finger protein subfamily 1A,3, Ikaros family zinc finger protein 3, and AIO. Aiolos proteins include isotypes encoded by the amino acid sequences Q9UKT9-1, Q9UKT9-3, Q9UKT9-4, Q9UKT9-6, Q9UKT9-7, Q9UKT9-8, Q9UKT9-9, and Q9UKT9-14. Aiolos proteins also include isotypes encoded by the amino acid sequences Q9UKT9-2, Q9UKT9-5, Q9UKT9-10, Q9UKT9-11, Q9UKT9-12, Q9UKT9-13, Q9UKT9-15, and Q9UKT9-16.
[0121] As used in this article, the “Pegasus” protein is also known as IKAROS family zinc finger 5, ZNFN1A5, zinc finger protein subfamily 1A,5, and Ikaros family zinc finger protein 5. Pegasus is encoded by the IKZF5 gene.
[0122] As used herein, the term “contact” means bringing the indicated portion into an in vitro or in vivo system. For example, “contacting” the Helios protein with a compound of formula (I) includes administering the compound of the invention to an individual or patient (such as a human) having the Helios protein, and, for example, introducing the compound of formula (I) into a sample containing cells or a purified formulation containing the Helios protein.
[0123] As used herein, the terms “treat,” “treating,” and “treatment” refer to any type of intervention or method applied to an individual, or the administration of an active agent to an individual, with the aim of reversing, alleviating, improving, suppressing, or slowing the progression, development, severity, or recurrence of symptoms, complications, symptom, or biochemical markers associated with the disease. In contrast, “prophylaxis” or “prevention” refers to the administration of medication to an individual who does not have the disease to prevent the onset of the disease. “Treatment,” “treating,” and “treatment” do not encompass prophylaxis or prevention.
[0124] "Therapeutic effective amount" is intended to include the amount of a single compound of the invention, or a combination of the claimed compounds, or the amount of the compound of the invention in combination with other active ingredients, that can effectively reduce the content of Helios protein in cells, decrease the level of Helios activity in cells and / or inhibit the expression of Helios in cells, or that can effectively treat or prevent viral infections and proliferative diseases (such as cancer).
[0125] As used herein, the term "cell" means a cell in vitro, outside the body, or in vivo. In some embodiments, the cell in vitro may be part of a tissue sample excised from an organism, such as a mammal. In some embodiments, the cell in vitro may be a cell in a cell culture. In some embodiments, the cell line in vivo is a cell line that survives in an organism, such as a mammal.
[0126] The term "patient" includes human and other mammalian individuals who receive therapeutic or preventative treatment.
[0127] The term "individual" includes any human or non-human animal. For example, the methods and compositions disclosed herein can be used to treat an individual suffering from cancer. Non-human animals include all vertebrates, such as mammals and non-mammals, including non-human primates, sheep, dogs, cattle, chickens, amphibians, reptiles, etc. In one embodiment, the individual is a human individual.
[0128] As used herein, the phrase "pharmaceutically acceptable carrier" refers to a pharmaceutically acceptable material, composition, or carrier for transporting or carrying the compounds of the present invention from one organ or part of the body to another organ or part of the body, such as liquid or solid fillers, diluents, excipients, manufacturing aids (e.g., lubricants, talc, magnesium stearate, calcium stearate, or zinc stearate, or stearic acid), or solvent encapsulation materials. Each carrier must be "acceptable" in terms of compatibility with other components in the formulation, including, i.e., adjuvants, excipients, or mediators, such as diluents, preservatives, fillers, flow conditioners, disintegrants, humectants, emulsifiers, suspending agents, sweeteners, flavorings, aromatizers, antibacterial agents, antifungal agents, lubricants, and dispersants, depending on the mode of administration and the nature of the dosage form; and must be harmless to the patient.
[0129] The term "pharmaceutical composition" means a composition comprising a combination of the compounds of the present invention with at least one additional pharmaceutically acceptable carrier.
[0130] utility
[0131] Compound (I) is suitable for treating cancer.
[0132] In one embodiment, the present invention provides a combination formulation of a compound of formula (I) and / or a pharmaceutically acceptable salt thereof, its stereoisomers or tautomers thereof, and one or more additional therapeutic agents, which may be used simultaneously, separately or sequentially for the treatment and / or prevention of a variety of diseases or conditions associated with the activity of Helios protein. The combination formulation may be used to reduce the content of Helios protein in cells, the level of Helios activity, and / or the expression level of Helios to control Treg differentiation.
[0133] Compounds of Formula (I) and pharmaceutical compositions comprising at least one compound of Formula (I) are suitable for the treatment or prevention of any disease or condition associated with Helios protein activity. These diseases or conditions include viral infections and other infections (e.g., skin infections, GI infections, urinary tract infections, genitourinary infections, systemic infections) and proliferative diseases (e.g., cancer). Compounds of Formula (I) and pharmaceutical compositions comprising at least one compound of Formula (I) may be administered to animals, preferably mammals (e.g., domesticated animals, cats, dogs, mice, rats), and more preferably to humans. Any method of administration may be used to deliver the compound or pharmaceutical composition to a patient. In some embodiments, the compound of Formula (I) or the pharmaceutical composition comprising at least one compound of Formula (I) is administered orally. In other embodiments, the pharmaceutical composition of Formula (I) or the pharmaceutical composition comprising at least one compound of Formula (I) is administered non-enterally.
[0134] Compound (I) can selectively reduce the content of Helios protein in cells, decrease the level of Helios activity in cells, and / or inhibit the expression of Helios in cells to control Treg differentiation. For example, compound (I) can be used to selectively reduce the level of Helios activity in cells or individuals in which a reduction of Helios protein content, a decrease in the level of Helios activity, and / or inhibition of Helios expression are required to control Treg differentiation by administering an inhibitory amount of compound (I) or a salt thereof.
[0135] In one aspect, one or more compounds of formula (I) are administered sequentially prior to the administration of an immuno-oncology agent. In another aspect, one or more compounds of formula (I) are administered simultaneously with an immuno-oncology agent. In yet another aspect, one or more compounds of formula (I) are administered sequentially after the administration of an immuno-oncology agent.
[0136] In another respect, compounds of formula (I) can be co-formulated with immuno-oncology agents.
[0137] Immuno-oncology agents include, for example, small molecule drugs, antibodies, or other biological agents or small molecules. Examples of biological immuno-oncology agents include, but are not limited to, cancer vaccines, antibodies, and cytokines. In one aspect, the antibody is a monoclonal antibody. In another aspect, the monoclonal antibody is a humanized antibody or human antibody.
[0138] In one aspect, immuno-oncology agents are agonists of (i) stimulating (including co-stimulating) receptors on T cells or antagonists of inhibitory (including co-inhibitory) signals, both of which amplify antigen-specific T cell responses (commonly referred to as immune checkpoint modulators).
[0139] Some stimulatory and inhibitory molecules are members of the immunoglobulin superfamily (IgSF). An important family of membrane-bound ligands that bind to co-stimulatory or co-inhibitory receptors is the B7 family, which includes B7-1, B7-2, B7-H1 (PD-L1), B7-DC (PD-L2), B7-H2 (ICOS-L), B7-H3, B7-H4, B7-H5 (VISTA), and B7-H6. Another family of membrane-bound ligands that bind to co-stimulatory or co-inhibitory receptors is the TNF family, which binds to molecules that are members of the homologous TNF receptor family, including CD40 and CD40L, OX-40, OX-40L, CD70, CD27L, CD30, CD30L, 4-1BBL, CD137 (4-1BB), TRAIL / Apo2-L, TRAILR1 / DR4, TRAILR2 / DR5, TRAILR3, TRAILR4, OPG, RANK, and RANKL. , TWEAKR / Fn14, TWEAK, BAFFR, EDAR, XEDAR, TACI, APRIL, BCMA, LTβR, LIGHT, DcR3, HVEM, VEGI / TL1A, TRAMP / DR3 , EDAR, EDA1, XEDAR, EDA2, TNFR1, lymphotoxin α / TNFβ, TNFR2, TNFα, LTβR, lymphotoxin α1β2, FAS, FASL, RELT, DR6, TROY, NGFR.
[0140] In one aspect, T cell responses can be stimulated by a compound of formula (I) in combination with one or more of the following: (i) antagonists of proteins that inhibit T cell activation (e.g., immune checkpoint inhibitors), such as CTLA-4, PD-1, PD-L1, PD-L2, LAG-3, TIM-3, galactoglobulin 9, CEACAM-1, BTLA, CD69, galactoglobulin-1, TIGIT, CD113, GPR56, VISTA, 2B4, CD48, GARP, PD1H, LAIR1, TIM-1, and TIM-4; and (ii) agonists of proteins that stimulate T cell activation, such as B7-1, B7-2, CD28, 4-1BB (CD137), 4-1BBL, ICOS, ICOS-L, OX40, OX40L, GITR, GITRL, CD70, CD27, CD40, DR3, and CD28H.
[0141] Other agents that can be combined with compounds of formula (I) to treat cancer include antagonists of inhibitory receptors on NK cells or agonists of activating receptors on NK cells. For example, compounds of formula (I) can be combined with KIR antagonists such as lirilumab.
[0142] Other agents used in combination therapy include agents that inhibit or deplete macrophages or monocytes, including but not limited to: CSF-1R antagonists, such as CSF-1R antagonist antibodies, including RG7155 (WO11 / 70024, WO11 / 107553, WO11 / 131407, WO13 / 87699, WO13 / 119716, WO13 / 132044) or FPA-008 (WO11 / 140249, WO13169264, WO14 / 036357).
[0143] In another aspect, the compound of formula (I) may be used in conjunction with one or more of the following: an agonist that binds to a positive co-stimulatory receptor, an inhibitor that attenuates signal transduction via an inhibitory receptor, an antagonist, and one or more agents that systemically increase the frequency of anti-tumor T cells, agents that overcome different immunosuppressive pathways within the tumor microenvironment (e.g., blocking inhibitory receptor binding (e.g., PD-L1 / PD-1 interaction), depleting or inhibiting Tregs (e.g., using anti-CD25 monoclonal antibodies (e.g., daclizumab) or depleting them via in vitro anti-CD25 beads), inhibiting metabolic enzymes (such as IDO), or reversing / preventing T cell anergy or depletion), and agents that trigger innate immune activation and / or inflammation at the tumor site.
[0144] In one aspect, immuno-oncology agents are CTLA-4 antagonists, such as antagonistic CTLA-4 antibodies. Suitable CTLA-4 antibodies include, for example, YERVOY (ipilimumab) or tremelimumab.
[0145] On the other hand, immuno-oncology agents are PD-1 antagonists, such as antagonistic PD-1 antibodies. Suitable PD-1 antibodies include, for example, OPDIVO (nivolumab), KEYTRUDA (pembrolizumab), or MEDI-0680 (AMP-514; WO2012 / 145493). Immuno-oncology agents may also include pidilizumab (CT-011), although its specificity for PD-1 binding is questionable. Another approach to targeting the PD-1 receptor is a recombinant protein called AMP-224, consisting of the extracellular domain of PD-L2 (B7-DC) fused to the Fc region of IgG1.
[0146] On the other hand, immuno-oncology agents are PD-L1 antagonists, such as antagonistic PD-L1 antibodies. Suitable PD-L1 antibodies include, for example, MPDL3280A (RG7446; WO2010 / 077634), durvalumab (MEDI4736), BMS-936559 (WO207 / 005874), and MSB0010718C (WO2013 / 79174).
[0147] On the other hand, immuno-oncology agents are LAG-3 antagonists, such as antagonistic LAG-3 antibodies. Suitable LAG3 antibodies include, for example, BMS-986016 (WO10 / 19570, WO14 / 08218) or IMP-731 or IMP-321 (WO08 / 132601, WO09 / 44273).
[0148] On the other hand, immuno-oncology agents are CD137 (4-1BB) agonists, such as agonist CD137 antibodies. Suitable CD137 antibodies include, for example, urelumab and PF-05082566 (WO12 / 32433).
[0149] On the other hand, immuno-oncology agents are GITR agonists, such as agonist GITR antibodies. Suitable GITR antibodies include, for example, BMS-986153, BMS-986156, TRX-518 (WO06 / 105021, WO09 / 009116) and MK-4166 (WO11 / 028683).
[0150] In the other hand, immuno-oncology agents are IDO antagonists. Suitable IDO antagonists include, for example, INCB-024360 (WO206 / 122150, WO07 / 75598, WO08 / 36653, WO08 / 36642), indoximod, or NLG-919 (WO09 / 73620, WO09 / 1156652, WO11 / 56652, WO12 / 142237).
[0151] On the other hand, immuno-oncology agents are OX40 agonists, such as agonist OX40 antibodies. Suitable OX40 antibodies include, for example, MEDI-6383 or MEDI-6469.
[0152] On the other hand, immuno-oncology agents are OX40L antagonists, such as antagonistic OX40 antibodies. Suitable OX40L antagonists include, for example, RG-7888 (WO06 / 029879).
[0153] In another embodiment, the immuno-oncology agent is a CD40 agonist, such as a stimulating CD40 antibody. In yet another embodiment, the immuno-oncology agent is a CD40 antagonist, such as an antagonistic CD40 antibody. Suitable CD40 antibodies include, for example, lucarumumab or dacetuzumab.
[0154] On the other hand, immuno-oncology agents are CD27 agonists, such as agonist CD27 antibodies. Suitable CD27 antibodies include, for example, varlilumab.
[0155] On the other hand, the immuno-oncology agent is MGA271 (targeting B7H3) (WO11 / 109400).
[0156] Combination therapy is intended to encompass the sequential administration of therapeutic agents, i.e., the administration of individual therapeutic agents at different times, and the administration of therapeutic agents or at least two therapeutic agents in a substantially simultaneous manner. Substantially simultaneous administration can be achieved, for example, by administering to an individual a single dosage form of each therapeutic agent in a fixed ratio, or multiple single dosage forms targeting each of the therapeutic agents. Sequential or substantially simultaneous administration of the therapeutic agents can be achieved via any suitable route, including but not limited to oral, intravenous, intramuscular, and direct absorption via mucosal tissue. The therapeutic agents can be administered via the same route or via different routes. For example, the first therapeutic agent in a selected combination may be administered intravenously, while the other therapeutic agents in the combination may be administered orally. Alternatively, for example, all therapeutic agents may be administered orally or all therapeutic agents may be administered intravenously. Combination therapy may also encompass the administration of the therapeutic agents as described above in further combination with other bioactive ingredients and non-pharmacological therapies (e.g., surgical or radiation therapy). Where the combination therapy further includes non-pharmacological treatment, the non-pharmacological treatment may be administered at any suitable time, provided that the synergistic effect of the combination of the therapeutic agents and the non-pharmacological treatment achieves a beneficial effect. For example, in appropriate circumstances, beneficial effects can still be achieved when non-pharmacological treatments are temporarily removed from the administration of therapeutic agents (possibly after several days or even weeks).
[0157] The types of cancers that can be treated with compounds of formula (I) include, but are not limited to, brain cancer, skin cancer, bladder cancer, ovarian cancer, breast cancer, stomach cancer, pancreatic cancer, prostate cancer, colon cancer, blood cancer, lung cancer, and bone cancer. Examples of the cancer types mentioned include neuroblastoma, colorectal cancer (such as rectal cancer, colon cancer, familial adenomatous polyposis, and hereditary nonpolyposis colorectal cancer), esophageal cancer, lip cancer, laryngeal cancer, hypopharyngeal cancer, tongue cancer, salivary gland cancer, stomach cancer, adenocarcinoma, medullary thyroid carcinoma, papillary thyroid carcinoma, kidney cancer, renal parenchymal carcinoma, ovarian cancer, cervical cancer, uterine cancer, endometrial cancer, choriocarcinoma, pancreatic cancer, prostate cancer, testicular cancer, breast cancer, urinary tract cancer, melanoma, brain tumors (such as glioblastoma, astrocytoma, meningioma, neurotubercula, and peripheral neuroectodermal tumors), Hodgkin lymphoma, non-Hodgkin lymphoma, and Burkitt lymphoma. Lymphoma, acute lymphoblastic leukemia (ALL), chronic lymphoblastic leukemia (CLL), acute myeloid leukemia (AML), chronic myeloid leukemia (CML), adult T-cell leukemia lymphoma, diffuse large B-cell lymphoma (DLBCL), hepatocellular carcinoma, gallbladder cancer, bronchial carcinoma, small cell lung cancer, non-small cell lung cancer, multiple myeloma, basal carcinoma, teratoma, retinoblastoma, choroidal melanoma, seminoma, rhabdomyosarcoma, craniopharyngioma, osteosarcoma, chondrosarcoma, myoma, liposarcoma, fibrosarcoma, Ewing sarcoma, and plasmacytoma.
[0158] One or more additional pharmaceutical agents or treatments, such as antiviral agents, chemotherapy agents or other anticancer agents, immune enhancers, immunosuppressants, radiation, antitumor and antiviral vaccines, cytokine therapies (e.g., IL2 and GM-CSF), and / or tyrosine kinase inhibitors, may optionally be used in combination with the compounds of formula (I) to treat Helios protein-related diseases, conditions, or symptoms. The pharmaceutical agents may be combined with the compounds of the present invention in a single dosage form, or the pharmaceutical agents may be administered simultaneously or sequentially in a single dosage form.
[0159] Suitable chemotherapeutic agents or other anticancer agents include, for example, alkylating agents (including but not limited to nitrogen mustard, ethyleneimine derivatives, alkyl sulfonates, nitrosoureas, and triazines), such as uracil mustard, dichloroethyl methylamine, and cyclophosphamide. Ifosfamide, melphalan, chlorambucil chlorbutyric acid, pipebroman, triethylene melamine, triethylene thiophosphoric acid, busulfan, carmustine, lomustine, streptozocin, dacarbazine, and temozolomide.
[0160] In the treatment of melanoma, agents suitable for combination with compounds of formula (I) include: dacarbazine (DTIC), optionally with other chemotherapy drugs such as carmustine (BCNU) and cisplatin; the "Dartmouth regimen," which consists of DTIC, BCNU, cisplatin, and tamoxifen; cisplatin, vinblastine, and DTIC, temozolomide, or YERVOY. TM The combination of compounds of formula (I) can also be combined with immunotherapeutic drugs (including cytokines such as interferon-α, interleukin-2 and tumor necrosis factor (TNF)) for the treatment of melanoma.
[0161] Compounds of formula (I) can also be used in combination with vaccine therapy to treat melanoma. Anti-melanoma vaccines are similar in some respects to antiviral vaccines used to prevent viral diseases such as polio, measles, and mumps. Attenuated melanoma cells, or a portion of melanoma cells called antigens, can be injected into a patient to stimulate the body's immune system to destroy the melanoma cells.
[0162] Melanoma confined to the arm or leg can also be treated using hyperthermia-isolated limb perfusion techniques, employing a combination of agents comprising one or more compounds of formula (I). This treatment regimen temporarily isolates the circulation of the affected limb from the rest of the body and injects a high dose of chemotherapy into the artery supplying the limb, thus delivering a high dose to the tumor area without exposing internal organs to these doses that could otherwise cause serious side effects. Typically, the fluid is heated to 38.9°C to 40°C. Melphalan is the most commonly used drug in this chemotherapy procedure. It may be administered in combination with another agent called tumor necrosis factor (TNF).
[0163] Suitable chemotherapy agents or other anticancer agents include, for example, antimetabolites (including but not limited to folic acid antagonists, pyrimidine analogs, purine analogs and adenosine deaminase inhibitors), such as methotrexate, 5-fluorouracil, fluorouridine, cytarabine, 6-mercaptopurine, 6-thioguanine, fludarabine phosphate, pentostatin and gemcitabine.
[0164] Suitable chemotherapeutic agents or other anticancer agents further include, for example, certain natural products and their derivatives (e.g., vinca alkaloids, antitumor antibiotics, enzymes, lymphotropic agents, and epipodophyllotoxin), such as vincristine, vindesine, bleomycin, dactinomycin D, daunorubicin, doxorubicin, epirubicin, idarubicin, ara-C, paclitaxel (Taxol), mithramycin, deoxyco-formycin, mitomycin-C, L-asparaginase, interferon (especially IFN-α), etoposide, and teniposide.
[0165] Other cytotoxic agents include navelbene, CPT-11, anastrozole, letrazole, capecitabine, reloxafine, and droloxafine.
[0166] The following cytotoxic agents are also suitable: epidophyllotoxin; anti-saprophyte enzymes; topoisomerase inhibitors; procarbazine; mitoxantrone; platinum coordination complexes, such as cisplatin and carboplatin; biological response modifiers; growth inhibitors; anti-hormonal therapy agents; leucovorin; tegafur; and hematopoietic growth factors.
[0167] One or more other anticancer agents include antibody therapies, such as trastuzumab. Antibodies against co-stimulatory molecules (such as CTLA-4, 4-1BB, and PD-1) or against cytokines (IL-1O or TGF-β).
[0168] Other anticancer agents also include those that block the migration of immune cells, such as antagonists of chemokine receptors (including CCR2 and CCR4).
[0169] Other anticancer agents also include those that enhance the immune system, such as adjuvants or recipient T-cell transfer.
[0170] Cancer vaccines include dendritic cell vaccines, synthetic peptide vaccines, DNA vaccines, and recombinant viruses.
[0171] The pharmaceutical compositions of the present invention may optionally include at least one signal transduction inhibitor (STI). A “signal transduction inhibitor” is an agent that selectively inhibits one or more important steps in the signal transduction pathways of normal cancer cell function, thereby inducing apoptosis. Suitable STIs include, but are not limited to: (i) bcr / abl kinase inhibitors, such as STI 571. (ii) Epidermal growth factor (EGF) receptor inhibitors, such as kinase inhibitors ( SSI-774) and antibodies (Imclone: C225 [Goldstein et al., Clin. Cancer Res., 1:1311-1318 (1995)] and Abgenix: ABX-EGF); (iii) her-2 / neu receptor inhibitors, such as farnesyltransferase inhibitors (FTIs), such as L-744,832 (Kohl et al., Nat. Med., 1(8):792-797 (1995)); (iv) Akt family kinases or Akt pathway inhibitors, such as rapamycin (see, for example, Sekulic et al., Cancer Res., 1:1311-1318 (1995)). (v) Cell cycle kinase inhibitors, such as flavopiridol and UCN-O1 (see, for example, Sausville, Curr. Med. Chem. Anti-Canc. Agents, 3:47-56 (203)); and (vi) Phosphatidylinositol kinase inhibitors, such as LY294002 (see, for example, Vlahos et al., J. Biol. Chem., 269:5241-5248 (1994)). Alternatively, at least one STI and at least one compound of formula (I) may be present in separate pharmaceutical compositions. In a particular embodiment of the invention, at least one compound of formula (I) and at least one STI may be administered to a patient simultaneously or sequentially. In other words, at least one compound of formula (I) may be administered first, at least one STI may be administered first, or at least one compound of formula (I) and at least one STI may be administered simultaneously. In addition, when using more than one compound of formula (I) and / or STI, the compounds may be applied in any order.
[0172] The present invention further provides a pharmaceutical composition for treating chronic viral infections in patients, wherein the pharmaceutically acceptable carrier comprises at least one compound of formula (I), optionally at least one chemotherapeutic agent, and optionally at least one antiviral agent.
[0173] A method for treating a patient’s chronic viral infection is also provided, which is carried out by administering an effective amount of the above-described pharmaceutical composition.
[0174] In one and certain embodiments of the invention, at least one compound of formula (I) is administered to the patient simultaneously or sequentially with at least one chemotherapeutic agent. In other words, at least one compound of formula (I) may be administered first, at least one chemotherapeutic agent may be administered first, or at least one compound of formula (I) and at least one STI may be administered simultaneously. Additionally, when more than one compound of formula (I) and / or chemotherapeutic agent is used, the compounds may be administered in any order. Similarly, any antiviral agent or STI may be administered at any point in time relative to the administration of the compound of formula (I).
[0175] Chronic viral infections that can be treated using the combination therapy of the present invention include, but are not limited to, diseases caused by: hepatitis C virus (HCV), human papillomavirus (HPV), cytomegalovirus (CMV), herpes simplex virus (HSV), Epstein-Barr virus (EBV), varicella-zoster virus, coxsackie virus, and human immunodeficiency virus (HIV).
[0176] Suitable antiviral agents for use in combination with compounds of formula (I) may include nucleoside and nucleotide reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs), protease inhibitors, and other antiviral drugs.
[0177] Suitable examples of NRTIs include zidovudine (AZT); didanosine (ddl); zalcitabine (ddC); stavudine (d4T); lamivudine (3TC); abacavir (1592U89); adefovir dipivoxil [bis(P] [OM)-PMEA]; lobucavir (BMS-180194); BCH-I0652; emitricitabine [(-)-FTC]; β-L-FD4 (also known as β-L-D4C and named β-L-2',3'-dideoxy-5-fluoro-cytosine nucleoside); DAPD ((-)-β-D-2,6-diamine-purine dioxane); and lodenosine (FddA). Typical suitable NNRTIs include nevirapine (BI-RG-587); delaviradine (BHAP, U-90152); efavirenz (DMP-266); PNU-142721; AG-1549; MKC-442 (1-(ethoxy-methyl)-5-(1-methylethyl)-6-(phenylmethyl)-(2,4(1H,3H)-pyrimidinidone); and (+)-tetracyclic coumarin A (calanolide A) (NSC-675451) and tetracyclic coumarin B. Typical suitable protease inhibitors include saquinavir (Ro... 31-8959); ritonavir (ABT-538); indinavir (MK-639); nelfnavir (AG-1343); amprenavir (141W94); lasinavir (BMS-234475); DMP-450; BMS-2322623; ABT-378; and AG-1549. Other antiviral agents include hydroxyurea, ribavirin, IL-2, IL-12, pentafuside, and Yissum Project No. 11607.
[0178] Combination therapy is intended to encompass the sequential administration of therapeutic agents, i.e., the administration of individual therapeutic agents at different times, and the administration of therapeutic agents or at least two therapeutic agents in a substantially simultaneous manner. Substantially simultaneous administration can be achieved, for example, by administering to an individual a single dosage form of each therapeutic agent in a fixed ratio, or multiple single dosage forms targeting each of the therapeutic agents. Sequential or substantially simultaneous administration of the therapeutic agents can be achieved via any suitable route, including but not limited to oral, intravenous, intramuscular, and direct absorption via mucosal tissue. The therapeutic agents can be administered via the same route or via different routes. For example, the first therapeutic agent in a selected combination may be administered intravenously, while the other therapeutic agents in the combination may be administered orally. Alternatively, for example, all therapeutic agents may be administered orally or all therapeutic agents may be administered intravenously. Combination therapy may also encompass the administration of the therapeutic agents as described above in further combination with other bioactive ingredients and non-pharmacological therapies (e.g., surgical or radiation therapy). Where the combination therapy further includes non-pharmacological treatment, the non-pharmacological treatment may be administered at any suitable time, provided that the synergistic effect of the combination of the therapeutic agents and the non-pharmacological treatment achieves a beneficial effect. For example, in appropriate circumstances, beneficial effects can still be achieved when non-pharmacological treatments are temporarily removed from the administration of therapeutic agents (possibly after several days or even weeks).
[0179] Pharmaceutical Composition
[0180] The present invention also provides pharmaceutical compositions comprising a therapeutically effective amount of one or more compounds of formula (I) formulated with one or more pharmaceutically acceptable carriers (additives) and / or diluents, and optionally comprising one or more additional therapeutic agents as described above.
[0181] The compounds of formula (I) may be administered via any suitable route, preferably in the form of a pharmaceutical composition suitable for said route and at a dose effective for the intended treatment. The compounds and compositions of the compounds of formula (I) may be administered by any suitable means for any of the uses described herein, such as orally, such as tablets, capsules (each of which includes sustained-release or timed-release formulations), pills, powders, granules, elixirs, tinctures, suspensions (including nanosuspensions, microsuspensions, spray-dried dispersions), syrups, and emulsions; sublingually; buccally; non-enterically, such as by subcutaneous, intravenous, intramuscular, or intrasternal injection, or by infusion techniques (e.g., sterile injectable aqueous or non-aqueous solutions or suspensions); nasally, including administration to a nasal membrane, such as by inhalation spray; topically, such as in the form of creams or ointments; or rectally, such as in the form of suppositories. They may be administered alone, but are usually administered in combination with a drug carrier selected based on the chosen route of administration and standard pharmaceutical practice.
[0182] For oral administration, the pharmaceutical composition may be in the form of, for example, tablets, capsules, liquid capsules, suspensions, or liquids. The pharmaceutical composition is preferably prepared in a dosage unit containing a specific amount of the active ingredient. For example, the pharmaceutical composition may be provided in tablet or capsule form containing an amount of the active ingredient ranging from about 0.1 to 1000 mg, preferably from about 0.25 to 250 mg, and more preferably from about 0.5 to 100 mg. The appropriate daily dose for human or other mammals can vary widely depending on the patient's condition and other factors, but can be determined using conventional methods.
[0183] Any pharmaceutical composition considered herein may be delivered orally, for example, via any acceptable and suitable oral formulation. Exemplary oral formulations include, but are not limited to, tablets, sugar-coated tablets, lozenges, aqueous and oily suspensions, dispersible powders or granules, emulsions, hard and soft capsules, liquid capsules, syrups, and elixirs. Pharmaceutical compositions intended for oral administration may be prepared according to any method known in the art for manufacturing pharmaceutical compositions intended for oral administration. To provide a pharmaceutically palatable formulation, pharmaceutical compositions according to the invention may contain at least one agent selected from sweeteners, flavoring agents, coloring agents, modifiers, antioxidants, and preservatives.
[0184] Tablets can be prepared, for example, by incorporating at least one compound of formula (I) and / or at least one pharmaceutically acceptable salt thereof with at least one non-toxic, pharmaceutically acceptable excipient suitable for the manufacture of tablets. Exemplary excipients include, but are not limited to, inert diluents such as calcium carbonate, sodium carbonate, lactose, calcium phosphate, and sodium phosphate; granulating agents and disintegrants such as microcrystalline cellulose, croscarmellose sodium, corn starch, and alginic acid; binders such as starch, gelatin, polyvinylpyrrolidone, and gum arabic; and lubricants such as magnesium stearate, stearic acid, and talc. Additionally, tablets may be uncoated or coated using known techniques to mask unpleasant tastes of the drug or to delay the disintegration and absorption of the active ingredient in the gastrointestinal tract, thereby prolonging the action of the active ingredient. Exemplary water-soluble taste-masking materials include, but are not limited to, hydroxypropyl-methylcellulose and hydroxypropyl-cellulose. Exemplary time-delaying materials include, but are not limited to, ethylcellulose and cellulose acetate butyrate.
[0185] Hard gelatin capsules can be prepared, for example, by mixing at least one compound of formula (I) and / or at least one salt thereof with at least one inert solid diluent (such as calcium carbonate; calcium phosphate; and kaolin).
[0186] Soft gelatin capsules can be prepared, for example, by mixing at least one compound of formula (I) and / or at least one pharmaceutically acceptable salt thereof with at least one water-soluble carrier (such as polyethylene glycol); and at least one oil medium (such as peanut oil, liquid paraffin and olive oil).
[0187] Aqueous suspensions can be prepared, for example, by incorporating at least one compound of formula (I) and / or at least one pharmaceutically acceptable salt thereof with at least one excipient suitable for the manufacture of aqueous suspensions. Excipients suitable for the manufacture of aqueous suspensions include, but are not limited to, suspending agents such as sodium carboxymethyl cellulose, methyl cellulose, hydroxypropyl methyl cellulose, sodium alginate, alginic acid, polyvinylpyrrolidone, tragacanth gum, and gum arabic; dispersants or wetting agents such as naturally occurring phospholipids, such as lecithin; condensation products of alkyl epoxides and fatty acids, such as polyoxyethylene stearate; condensation products of ethylene oxides and long-chain aliphatic alcohols, such as heptadecanethoxyhexadecyl alcohol; condensation products of ethylene oxides and esters derived from fatty acids and hexitols, such as polyoxyethylene sorbitan monooleate; and condensation products of ethylene oxides and esters derived from fatty acids and hexitol anhydrides, such as polyvinyl sorbitan monooleate. The aqueous suspension may also contain at least one preservative, such as ethylparaben and n-propylparaben; at least one colorant; at least one flavoring agent; and / or at least one sweetener, including but not limited to, sucrose, saccharin and aspartame.
[0188] The oily suspension may be prepared, for example, by suspending at least one compound of formula (I) and / or at least one pharmaceutically acceptable salt thereof in a vegetable oil (such as peanut oil; olive oil; sesame oil; and coconut oil); or a mineral oil (such as liquid paraffin). The oily suspension may also contain at least one thickener, such as beeswax; hard paraffin; and cetyl alcohol. To provide a palatable oily suspension, at least one of the sweeteners described above and / or at least one flavoring agent may be added to the oily suspension. The oily suspension may further contain at least one preservative, including but not limited to, antioxidants such as butylated hydroxyanisole and α-tocopherol.
[0189] Dispersible powders and granules can be prepared, for example, by incorporating at least one compound of formula (I) and / or at least one pharmaceutically acceptable salt thereof with at least one dispersant and / or wetting agent, at least one suspending agent and / or at least one preservative. Suitable dispersants, wetting agents and suspending agents have been described above. Exemplary preservatives include, but are not limited to, antioxidants such as ascorbic acid. In addition, dispersible powders and granules may also contain at least one excipient, including but not limited to, sweeteners, flavoring agents and coloring agents.
[0190] An emulsion of at least one compound of formula (I) and / or at least one pharmaceutically acceptable salt thereof may be prepared, for example, in the form of an oil-in-water emulsion. The oil phase of an emulsion containing a compound of formula (I) may be composed of known ingredients in a known manner. The oil phase may be provided, but is not limited to, vegetable oils such as olive oil and peanut oil; mineral oils such as liquid paraffin; and mixtures thereof. Although the phase may contain only an emulsifier, it may also contain at least one emulsifier with a fat or oil or a mixture of fat and oil. Suitable emulsifiers include, but are not limited to, naturally occurring phospholipids such as soybean lecithin; esters or metaesters derived from fatty acids and hexadiol anhydrides, such as sorbitan monooleate; and condensation products of metaesters and ethylene oxide, such as polyoxyethylene sorbitan monooleate. Preferably, hydrophilic emulsifiers and lipophilic emulsifiers acting as stabilizers are included. Both oils and fats are also preferred. In summary, with or without one or more stabilizers, one or more emulsifiers constitute a so-called emulsified wax, which, together with oils and fats, constitutes a so-called emulsified ointment matrix, forming the oily dispersed phase of the ointment formulation. The emulsion may also contain sweeteners, flavoring agents, preservatives, and / or antioxidants. Suitable emulsifiers and emulsion stabilizers for use in the formulations of this invention include Tween 60, Span 80, cetearyl alcohol, myristyl alcohol, glyceryl monostearate, sodium lauryl sulfate, glyceryl distearate alone or containing wax, or other materials well known in the art.
[0191] Compounds of formula (I) and / or at least one pharmaceutically acceptable salt thereof may also be delivered, for example, intravenously, subcutaneously, and / or intramuscularly, via any pharmaceutically acceptable and suitable injectable form. Exemplary injectable forms include, but are not limited to, sterile aqueous solutions containing, for example, acceptable mediators and solvents such as water, Ringer's solution, and isotonic sodium chloride solution; sterile oil-in-water microemulsions; and aqueous or oil suspensions.
[0192] Formulations intended for non-enteral administration may be in the form of aqueous or non-aqueous isotonic sterile injectable solutions or suspensions. These solutions and suspensions may be prepared from sterile powders or granules, using one or more of the carriers or diluents mentioned for oral administration, or by using other suitable dispersants or wetting agents and suspending agents. The compounds may be soluble in water, polyethylene glycol, propylene glycol, ethanol, corn oil, cottonseed oil, peanut oil, sesame oil, benzyl alcohol, sodium chloride, tragacanth gum, and / or various buffers. Other adjuvants and modes of administration are well-known and widely recognized in pharmaceutical technology. The active ingredient may also be administered by injection in the form of a composition having a suitable carrier (including physiological saline, dextran, or water) or having cyclodextrin (i.e., Captisol), co-solvent solubilization (i.e., propylene glycol), or micellar solubilization (i.e., Tween 80).
[0193] Sterile injectable formulations can also be sterile injectable solutions or suspensions in non-toxic, non-enteric acceptable diluents or solvents, such as solutions in 1,3-butanediol. Water, Ringer's solution, and isotonic sodium chloride solution can be used among acceptable mediators and solvents. Furthermore, sterile non-volatile oils are routinely used as solvents or suspension media. For this purpose, any mild non-volatile oil can be used, including synthetic monoglycerides or diglycerides. Additionally, fatty acids such as oleic acid can be used in the preparation of injectable formulations.
[0194] Sterile injectable oil-in-water microemulsions can be prepared, for example, by: 1) dissolving at least one compound of formula (I) in an oil phase, such as a mixture of soybean oil and lecithin; 2) combining the oil-containing compound of formula (I) with a mixture of water and glycerol; and 3) processing the combination to form a microemulsion.
[0195] Sterile aqueous or oily suspensions can be prepared according to methods known in the art. For example, sterile aqueous solutions or suspensions can be prepared using non-enteric acceptable non-toxic diluents or solvents (such as 1,3-butanediol); and sterile oily suspensions can be prepared using acceptable sterile, non-toxic solvents or suspension media (such as sterile non-volatile oils (e.g., synthetic monoglycerides or diglycerides); and fatty acids (such as oleic acid)).
[0196] Pharmaceutically acceptable carriers are formulated based on several factors known to those skilled in the art. These factors include, but are not limited to: the type and nature of the active agent being formulated; the individual to whom the composition containing the reagent is to be administered; the intended route of administration of the composition; and the targeted therapeutic indication. Pharmaceutically acceptable carriers include aqueous and non-aqueous liquid media, as well as a variety of solid and semi-solid dosage forms. In addition to the active agent, the carrier may also include a variety of different components and additives, which are included in the formulation for a variety of reasons well known to those skilled in the art (e.g., stabilization of the active agent, binder, etc.). Descriptions of suitable pharmaceutically acceptable carriers and the factors involved in their selection can be found in a variety of readily available sources, such as Allen, LV Jr. et al., Remington: The Science and Practice of Pharmacy (Vol. 2), 22nd ed. (2012), Pharmaceutical Press.
[0197] Pharmaceutically acceptable carriers, adjuvants, and mediators that can be used in the pharmaceutical compositions of the present invention include, but are not limited to, ion exchangers; alumina; aluminum stearate; lecithin; self-emulsifying drug delivery systems (SEDDS), such as d-α-tocopherol polyethylene glycol 1000 succinate; surfactants for pharmaceutical dosage forms, such as Tween, polyethoxylated castor oil (such as CREMOPHOR surfactant (BASF)) or other similar polymeric delivery matrices; serum proteins, such as human serum albumin; buffering substances, such as phosphates; glycine; sorbic acid; potassium sorbate; mixtures of saturated vegetable fatty acid metaglycerides; water; salts or electrolytes, such as protamine sulfate; disodium hydrogen phosphate; potassium hydrogen phosphate; sodium chloride; zinc salts; colloidal silica; magnesium trisilicate; polyvinylpyrrolidone; cellulose-based substances; polyethylene glycol; sodium carboxymethyl cellulose; polyacrylates; waxes; polyethylene-polyoxypropylene block polymers; polyethylene glycol and lanolin. Cyclodextrins (such as α-cyclodextrin, β-cyclodextrin and γ-cyclodextrin) or chemically modified derivatives (such as hydroxyalkyl cyclodextrins, including 2-hydroxypropyl-cyclodextrin and 3-hydroxypropyl-cyclodextrin) or other dissolved derivatives may also be advantageously used to enhance the delivery of compounds of the formulas described herein.
[0198] The pharmaceutically active compounds of the present invention can be processed according to conventional pharmaceutical methods to produce pharmaceutical preparations for administration to patients, including humans and other mammals. The pharmaceutical compositions may undergo conventional pharmaceutical processes such as sterilization and / or may contain conventional adjuvants, such as preservatives, stabilizers, humectants, emulsifiers, buffers, etc. Tablets and pills may be additionally prepared using enteric coating. The compositions may also contain adjuvants such as humectants, sweeteners, flavoring agents, and aromatizers.
[0199] For therapeutic purposes, the active compounds of the present invention are typically combined with one or more adjuvants suitable for the specified route of administration. For oral administration, the compounds may be blended with lactose, sucrose, starch powder, cellulose esters of alkyl cellulose, talc, stearic acid, magnesium stearate, magnesium oxide, sodium and calcium salts of phosphoric acid and sulfuric acid, gelatin, gum arabic, sodium alginate, polyvinylpyrrolidone, and / or polyvinyl alcohol, and subsequently tableted or encapsulated for convenient administration. The capsules or tablets may contain a controlled-release formulation, such as a dispersion of the active compound in hydroxypropyl methylcellulose.
[0200] The amount of compound applied and the dosing regimen for treating disease symptoms with the compounds and / or compositions of the present invention depend on a variety of factors, including an individual's lifespan, weight, sex, medical condition; disease type; disease severity; route and frequency of administration; and the specific compound used. Therefore, dosing regimens can vary widely, but can be routinely determined using standard methods. A daily dose of about 0.001 to 100 mg / kg body weight, preferably between about 0.0025 and about 50 mg / kg body weight, and most preferably between about 0.005 and 10 mg / kg body weight, may be appropriate. The daily dose can be administered one to four times daily. Other dosing schedules include cycles of weekly and every two days.
[0201] The pharmaceutical compositions of the present invention comprise at least one compound of formula (I) and / or at least one pharmaceutically acceptable salt thereof, and optionally another agent selected from any pharmaceutically acceptable carrier, adjuvant, and mediator. Alternative compositions of the present invention comprise a compound of formula (I) as described herein, or a prodrug thereof, and a pharmaceutically acceptable carrier, adjuvant, or mediator.
[0202] This invention also includes pharmaceutical kits suitable for, for example, treating or preventing Helios protein-related diseases or conditions and other diseases mentioned herein, comprising one or more containers containing a pharmaceutical composition comprising a therapeutically effective amount of a compound of formula (I). As will be readily apparent to those skilled in the art, the kit may further include, where necessary, one or more of various conventional pharmaceutical kit components, such as containers having one or more pharmaceutically acceptable carriers, or additional containers. The kit may also include instructions in insert or label form indicating the amount of the component to be administered, administration guidelines, and / or guidelines for mixing the components.
[0203] The dosing regimen of the compounds of this invention will naturally vary depending on known factors, such as the pharmacodynamic characteristics of the particular agent and its mode of administration and route of administration; the species, age, sex, health status, medical condition and weight of the recipient; the nature and severity of symptoms; the types of concurrent treatments; the frequency of treatment; the route of administration; the patient's renal and hepatic function; and the desired effect.
[0204] Using general guidelines, the daily oral dose of each active ingredient for its designated action will be between about 0.001 to about 5000 mg per day, preferably between about 0.01 to about 1000 mg per day, and most preferably between about 0.1 to about 250 mg per day. When administered intravenously, the optimal dose during a constant-rate infusion will be between about 0.01 to about 10 mg / kg per minute. Compounds of formula (I) may be administered as a single daily dose, or the total daily dose may be divided into two, three, or four daily doses.
[0205] Compounds are typically administered in combination with a suitable drug diluent, excipient, or carrier (collectively referred to herein as a drug carrier) that is appropriately selected for the intended form of administration (e.g., oral tablets, capsules, elixirs, and syrups) and consistent with routine pharmaceutical practice.
[0206] Suitable dosage forms (pharmaceutical compositions) may contain about 1 mg to about 200 mg of active ingredient per dose unit. In these pharmaceutical compositions, the active ingredient will typically be present in an amount of about 0.1-95% by weight, based on the total weight of the composition.
[0207] Typical capsules for oral administration contain at least one of the following: compound (I) (250 mg), lactose (75 mg), and magnesium stearate (15 mg). The mixture is passed through a 60-mesh sieve and filled into No. 1 gelatin capsules.
[0208] A typical injectable formulation is manufactured by aseptically placing at least one compound of formula (I) (250 mg) into a vial, aseptically freeze-drying and sealing it. For use, the contents of the vial are mixed with 2 mL of physiological saline to produce the injectable formulation.
[0209] This invention includes pharmaceutical compositions comprising at least one of a compound of formula (I), alone or in combination with a drug carrier, as an active ingredient. Optionally, the compound of formula (I) may be used alone, in combination with other compounds of formula (I), or in combination with one or more other therapeutic agents (e.g., anticancer agents or other pharmaceutically active materials).
[0210] Regardless of the chosen route of administration, the compound of formula (I) and / or the pharmaceutical composition of the present invention, in a suitable hydrated form, are formulated into a pharmaceutically acceptable dosage form by conventional methods known to those skilled in the art.
[0211] The actual dosage level of the active ingredient in the pharmaceutical composition of the present invention can be changed to obtain a certain amount of active ingredient that effectively achieves a therapeutic response for a specific patient, composition and administration mode, without being toxic to the patient.
[0212] The selected dose level will depend on a number of factors, including the activity of the specific formula (I) compound or its ester, salt or amide, the route of administration, the time of administration, the rate of excretion or metabolism of the specific compound, the rate and extent of absorption, the duration of treatment, other drugs, compounds and / or materials used in combination with the specific compound, the age, sex, weight, condition, general health and prior medical history of the patient being treated, and similar factors known in medical technology.
[0213] A physician or veterinarian with ordinary technical knowledge in the art can easily determine and prescribe the effective amount of the required pharmaceutical composition. For example, a physician or veterinarian may start with a dose of the compound of formula (I) used in the pharmaceutical composition below the level required to achieve the therapeutic effect, and gradually increase the dose until the effect is achieved.
[0214] Generally, the appropriate daily dose of a compound of formula (I) will be the lowest amount of compound that will effectively produce a therapeutic effect. The effective dose will generally depend on the factors described above. Generally, the oral, intravenous, intraventricular, and subcutaneous doses of a compound of formula (I) for a patient will range from approximately 0.01 to approximately 50 mg per kilogram of body weight per day.
[0215] If necessary, the effective daily dose of the active compound may be administered in two, three, four, five, six, or more sub-dose doses, optionally administered alone in unit dosage form at appropriate time intervals throughout the day. In some aspects of the invention, administration is once daily.
[0216] Although compounds of formula (I) can be administered alone, it is preferred to administer them as pharmaceutical formulations (compositions).
[0217] When used in combination with compounds of formula (I), the other therapeutic agents described above may be used in amounts, for example, as indicated in the Physicians' Desk Reference (PDR) or otherwise determined by those skilled in the art. In the methods of the present invention, the one or more other therapeutic agents may be administered before, simultaneously with, or after the application of the compounds of the present invention.
[0218] Preparation method
[0219] The compounds of this invention can be prepared in a variety of ways well known to those skilled in the art of organic synthesis. The compounds of this invention can be synthesized using the methods described below, as well as synthetic methods known in the field of organic synthetic chemistry, or variations thereof as understood by those skilled in the art. Preferred methods include, but are not limited to, those described below. All references cited herein are incorporated herein by reference in their entirety.
[0220] The compounds of this invention can be prepared using the reactions and techniques described in this section. Reactions are carried out in solvents suitable for the reagents and materials used and conducive to achieving the transformation. Furthermore, in the description of the synthetic methods below, it should be understood that all proposed reaction conditions (including solvent selection, reaction atmosphere, reaction temperature, experimental duration, and processing procedures) are chosen as standard conditions for the reaction that should be readily identifiable to those skilled in the art. Those skilled in the art of organic synthesis should understand that the functional groups present on various parts of the molecule must be compatible with the proposed reagents and reactions. The aforementioned limitations on substituents compatible with the reaction conditions will be readily apparent to those skilled in the art, and thus alternative methods must be used. Sometimes it is necessary to make judgments to modify the order of synthetic steps or to choose a particular methodological flow over another to obtain the compounds of this invention. It will also be recognized that another major consideration in the planning of any synthetic route in the art is the careful selection of protecting groups used to protect the reactive functional groups present in the compounds of this invention. Authoritative descriptions of many alternatives to trained practitioners are provided by Greene and Wuts (Protective Groups in Organic Synthesis, 4th Edition, Wiley and Sons, 207).
[0221] Compounds of formula (I) can be prepared by referring to the method described in the following procedure. As shown therein, the final product is a compound with the same structural formula as that of formula (I). It should be understood that any compound of formula (I) can be prepared by the described procedure, by appropriately selecting reagents with suitable substitutions. Solvents, temperatures, pressures, and other reaction conditions can be readily selected by those skilled in the art. Starting materials are commercially available or readily prepared by those skilled in the art. The components of the compound are as defined herein or elsewhere in the specification.
[0222] The general pathway for preparing the compounds described in this invention is illustrated in procedures 1-5, wherein the substituents R1 and A are as previously defined herein or are functional groups convertible into the final substituent. Substituent L is a leaving group, such as a halide ion (preferably I, Br, or Cl) or a trifluoromethanesulfonate ion. Substituent M is a suitable coupling complex, such as boric acid, borate ester, or stanane. Substituent R is a carboxylic acid protecting group, such as tert-butyl, methyl, ethyl, or benzyl. As shown in procedure 1, the general procedure for preparing the compounds of this invention involves starting with a suitably substituted isoindolinone 1. The leaving group L of 1 is converted into a suitable coupling complex M using conditions well known to those skilled in the art or methods described herein, yielding intermediate 2. When M is boric acid or a borate ester, 2 can be combined with a suitably substituted heterocycle 3 in the presence of a suitable base (e.g., cesium carbonate, potassium phosphate, or sodium bicarbonate) using a suitable palladium catalyst (e.g., Pd(PPh3)4 or 1,1'-bis(diphenylphosphine)ferrocene]dichloropalladium(II)) in a Suzuki-Miyaura coupling reaction to give 4. When M is tinane, 2 can be combined with a suitably substituted heterocycle 3 in a Stille coupling reaction using a suitable catalyst system (e.g., Pd(PPh3)4 or bis(triphenylphosphine)dichloropalladium(II) / CuI) to give 4. Intermediate 4 can be converted to 5 by treatment with a protic acid such as benzenesulfonic acid. Alternatively, in some cases, 4 can be converted to 5 by treatment with a base (e.g., K2CO3, K3PO4, or LiHMDS). In some cases, intermediate 4 can spontaneously cyclize into 5 under the Suzuki-Miyaura coupling or Stieler coupling conditions used to prepare it.
[0223] Process 1
[0224]
[0225] In some cases, it is advantageous to couple heterocycle A earlier in the synthetic sequence. In such cases, the leaving group L of 6 can be converted to a suitable coupling complex M using conditions well known to those skilled in the art or by methods described herein, to give intermediate 7. If M is boric acid or a borate ester, 7 can be coupled with the suitably substituted heterocycle 3 in the Suzuki-Miyaura coupling reaction using a suitable palladium catalyst (e.g., Pd(PPh3)4 or 1,1'-bis(diphenylphosphine)ferrocene]palladium(II) in the presence of a suitable base (e.g., cesium carbonate, potassium phosphate, or sodium bicarbonate) to give 8. If M is tinane, 7 can be coupled with the suitably substituted heterocycle 3 in the Stieler coupling reaction using a suitable catalyst system (e.g., Pd(PPh3)4 or bis(triphenylphosphine)palladium(II) / CuI) to give 8. The benzylmethyl group can be brominated via NBS in the presence of a radical initiator such as light or AIBN to give bromide 9. Bromide 9 can be condensed with 3-aminopiperidine-2,6-dione (10) in the presence of a base (e.g., diisopropylethylamine or triethylamine) to give 5.
[0226] Process 2
[0227]
[0228] Alternatively, bromide 9 can be condensed with 11 (where R = tert-butyl, methyl, ethyl, or benzyl) in the presence of a base (e.g., diisopropylethylamine or triethylamine) to give intermediate 12, as shown in process 3. In the case of R = tert-butyl, intermediate 12 can be further processed into compound 5 by the method described in process 1.
[0229] Process 3
[0230]
[0231] Depending on the specific choice of the acid protecting group R in intermediate 12, different conditions may be required to convert it to compound 5 (process 4). For example, in the case of R = methyl, ethyl, or benzyl, for the direct conversion of 12 to 5, base-induced cyclization of 12 using a suitable base (e.g., LiHMDS) in a suitable solvent (e.g., tetrahydrofuran) may be preferred. In the case of R = tert-butyl, for the direct conversion of 12 to 5, acid-induced cyclization of 12 using a suitable acid (e.g., benzenesulfonic acid) in a suitable solvent (e.g., acetonitrile) may be preferred. In some cases, a two-step procedure may be preferred, first using conditions suitable for the specific acid protecting group R to release the free carboxylic acid 13. These methods are well known to those skilled in the art of organic synthesis. For example, in the case of R = tert-butyl, acid hydrolysis using a suitable acid (e.g., trifluoroacetic acid or hydrochloric acid) may be preferred. In the case of R = methyl, ethyl, or benzyl, alkaline hydrolysis using a suitable base (e.g., LiOH) may be preferred. In other cases, where R = benzyl, the protecting group can be advantageously removed via palladium-catalyzed hydrogenolysis. Once released, the 13 carboxylic acid can be activated by intramolecular attack on the attached primary amide via thionyl chloride / dimethylformamide or carbonyl diimidazole / dimethylaminopyridine, yielding 5.
[0232] Process 4
[0233]
[0234] As shown in the preceding process, isoindolinones substituted with a suitable leaving group L are suitable intermediates in the synthesis of compounds of formula (I). They can be prepared as outlined in process 5, where L is a leaving group such as a halide ion. First, the benzyl methyl group of intermediate 6 can be brominated via NBS in the presence of a free radical initiator such as light or AIBN to give bromide 14. Bromide 14 can be condensed with 3-aminopiperidine-2,6-dione (10) in the presence of a base (e.g., diisopropylethylamine or triethylamine) to give 15. In some cases, it is possible to convert intermediate 15 to 5 by a method similar to the transformations in processes 1 to 4 (process 1). In other cases, it is preferable to condense bromide 14 with intermediate 11 to give 16. Intermediate 16 can be converted to 5 by a method similar to that described in processes 1 and 4.
[0235] Process 5
[0236]
[0237] Example
[0238] The following examples illustrate specific embodiments of the invention and do not limit the scope of the invention. Unless otherwise specified, chemical abbreviations and symbols, as well as scientific abbreviations and symbols, have their common and conventional meanings. Examples in this application and other abbreviations used elsewhere are as defined above. Common intermediates are generally applicable to the preparation of more than one example. Compounds of examples are identified by the example and steps in which they are prepared (e.g., "1-A" indicates step A of Example 1), or simply by the example identifier that the compound is the title compound of the example (e.g., "1" indicates the title compound of Example 1). In some cases, alternative preparations of intermediates or examples are described. Typically, chemists in the synthetic field can design alternative preparations that may be desirable based on one or more considerations, such as shorter reaction times, less expensive starting materials, ease of handling or separation, increased yields, ease of catalysis, avoidance of toxic reagents, accessibility to specialized equipment, and reduction of the number of linear steps. The purpose of describing alternative preparations is to further realize the preparation of the embodiments of the invention. In some cases, some functional groups in the examples and claims may be replaced by well-known bioisosteric substitutions, such as partial substitution of carboxylic acid groups with tetrazolium or phosphate esters.
[0239] abbreviation
[0240] AcOH acetic acid
[0241] ACN Acetonitrile
[0242] AIBN 2,2-azobisisobutyronitrile
[0243] BuLi n-Butyllithium
[0244] DCE dichloroethane
[0245] DCM dichloromethane
[0246] DIEA N,N-Diisopropylethylamine
[0247] DMF dimethylformamide
[0248] DMPU N,N'-Dimethylacrylurea
[0249] DMSO (dimethyl sulfoxide)
[0250] dppf bis(diphenylphosphine)ferrocene
[0251] EtOH
[0252] EtOAc (ethyl acetate)
[0253] Hexane
[0254] HPLC (High Performance Liquid Chromatography)
[0255] Hunig's base: N,N-diisopropylethylamine
[0256] LDA Lithium diisopropylamine
[0257] LiHMDS bis(trimethoxy)amide lithium
[0258] m-CPBA 3-chloroperbenzoic acid
[0259] MeCN Acetonitrile
[0260] min minutes
[0261] mL
[0262] NaBH(OAc)3 sodium triacetoxyborohydride
[0263] NBS N-bromosuccinimide
[0264] PdCl2(dppf)2[1,1'-bis(diphenylphosphino)ferrocene]palladium(II) dichloro
[0265] PdCl2(dtbpf) [1,1'-bis(di-tert-butylphosphino)ferrocene]palladium(II) dichloro
[0266] Pd2(dba)3 tris-(diphenylmethyleneacetone)dipalladium
[0267] Pd(PPh3)4 tetratetra(triphenylphosphine)palladium
[0268] PhSO3H benzenesulfonic acid
[0269] TEA triethylamine
[0270] THF Tetrahydrofuran
[0271] TPGS D-α-tocopherol polyethylene glycol succinate
[0272] XantPhos 4,5-bis(diphenylphosphino)-9,9-dimethyldibenzopyran
[0273] XPhos Pd G2 Chlorine(2-dicyclohexylphosphino-2',4',6'-triisopropyl-1,1'-biphenyl)[2-(2'-amino-1,1'-biphenyl)]palladium(II)
[0274] HPLC conditions:
[0275] Analytical HPLC Method 1: Waters XBridge C18, 2.1 mm × 50 mm, 1.7 μm particles; Mobile phase A: 5:95 acetonitrile:water + 0.1% trifluoroacetic acid; Mobile phase B: 95:5 acetonitrile:water + 0.1% trifluoroacetic acid; Temperature: 50 °C; Gradient: 0% B to 100% B over 3 min, followed by a hold at 100% B for 0.50 min; Flow rate: 1 mL / min; Detection: MS and UV (220 nm).
[0276] Analytical HPLC Method 2: Column: Waters XBridge C18, 2.1 mm × 50 mm, 1.7 μm particles; Mobile phase A: 5:95 acetonitrile:water + 10 mM ammonium acetate; Mobile phase B: 95:5 acetonitrile:water + 10 mM ammonium acetate; Temperature: 50 °C; Gradient: 0% B to 100% B for 3 min, followed by a hold at 100% B for 0.50 min; Flow rate: 1 mL / min; Detection: MS and UV (220 nm).
[0277] Preparative HPLC Method 1: XBridge C18, 200 mm × 19 mm, 5 μm particles; Mobile phase A: 5:95 acetonitrile:water + 10 mM ammonium acetate; Mobile phase B: 95:5 acetonitrile:water + 10 mM ammonium acetate; Gradient: 0 min at 15% B, 25 min at 15-50% B, followed by 6 min at 100% B; Flow rate: 20 mL / min; Column temperature: 25 °C. Elution was collected by MS signal trigger.
[0278] Preparative HPLC Method 2: XBridge C18, 200 mm × 19 mm, 5 μm particles; Mobile phase A: 5:95 acetonitrile:water + 0.1% trifluoroacetic acid; Mobile phase B: 95:5 acetonitrile:water + 0.1% trifluoroacetic acid; Gradient: 0 min at 0% B, 24 min at 0-40% B, followed by 4 min at 100% B; Flow rate: 20 mL / min; Column temperature: 25 °C. Elution was triggered by MS signal collection.
[0279] Preparative HPLC method 3: XBridge C18, 200 mm × 19 mm, 5 μm particles; Mobile phase A: 5:95 acetonitrile:water + 0.1% trifluoroacetic acid; Mobile phase B: 95:5 acetonitrile:water + 0.1% trifluoroacetic acid; Gradient: hold at 0% B for 5 min, 0-25% B for 28 min, followed by hold at 100% B for 4 min; Flow rate: 20 mL / min; Column temperature: 25 °C. Elution was collected by MS signal trigger.
[0280] Preparative HPLC Method 4: XBridge C18, 200 mm × 19 mm, 5 μm particles; Mobile phase A: 5:95 acetonitrile:water + 0.1% trifluoroacetic acid; Mobile phase B: 95:5 acetonitrile:water + 0.1% trifluoroacetic acid; Gradient: hold at 0% B for 3 min, 0-35% B for 30 min, followed by hold at 100% B for 6 min; Flow rate: 20 mL / min; Column temperature: 25 °C. Elution was collected by MS signal trigger. The eluates containing product were combined and evaporated to dryness by centrifugation.
[0281] The material was further purified by preparative LC / MS under the following conditions: Column: XBridge C18, 200 mm × 19 mm, 5 μm particles; Mobile phase A: 5:95 acetonitrile:water + 10 mM ammonium acetate; Mobile phase B: 95:5 acetonitrile:water + 10 mM ammonium acetate; Gradient: 0 min at 0% B, 28 min at 0-40% B, followed by 6 min at 100% B; Flow rate: 20 mL / min; Column temperature: 25 °C. Elution was collected by MS signal trigger.
[0282] Preparative HPLC Method 5: XBridge C18, 200 mm × 19 mm, 5 μm particles; Mobile phase A: 5:95 acetonitrile:water + 0.1% trifluoroacetic acid; Mobile phase B: 95:5 acetonitrile:water + 0.1% trifluoroacetic acid; Gradient: 0 min at 4% B, 23 min at 4-44% B, followed by 4 min at 100% B; Flow rate: 20 mL / min; Column temperature: 25 °C. Elution was collected by MS signal trigger. The eluates containing product were combined and evaporated to dryness by centrifugation.
[0283] The material was further purified by preparative LC / MS under the following conditions: Column: XBridge C18, 200 mm × 19 mm, 5 μm particles; Mobile phase A: 5:95 acetonitrile:water + 10 mM ammonium acetate; Mobile phase B: 95:5 acetonitrile:water + 10 mM ammonium acetate; Gradient: 0 min at 26% B, 20 min at 26-66% B, followed by 4 min at 100% B; Flow rate: 20 mL / min; Column temperature: 25 °C. Elution was collected by MS signal trigger.
[0284] Preparative HPLC method 6: Phenomenex Luna Axi C18, 100 mm × 30 mm, 5 μm particles; Mobile phase A: 5:95 acetonitrile:water + 0.1% trifluoroacetic acid; Mobile phase B: 95:5 acetonitrile:water + 0.1% trifluoroacetic acid; Gradient: hold at 20% B for 2 min, 20-100% B for 11 min, followed by hold at 100% B for 2 min; Flow rate: 25 mL / min; Elution collection triggered by UV signal.
[0285] Preparative HPLC method 7: Phenomenex Luna Axi C18, 100 mm × 30 mm, 5 μm particles; Mobile phase A: 5:95 acetonitrile:water + 0.1% trifluoroacetic acid; Mobile phase B: 95:5 acetonitrile:water + 0.1% trifluoroacetic acid; Gradient: hold at 7% B for 2 min, 7-100% B for 10 min, followed by hold at 100% B for 3 min; Flow rate: 30 mL / min; Elution collection triggered by UV signal.
[0286] Preparative HPLC method 8: XBridge C18, 200 mm × 19 mm, 5 μm particles; Mobile phase A: 5:95 acetonitrile:water + 10 mM ammonium acetate; Mobile phase B: 95:5 acetonitrile:water + 10 mM ammonium acetate; Gradient: 0 min at 5% B, 20 min at 5-55% B, followed by 4 min at 100% B; Flow rate: 20 mL / min; Column temperature: 25 °C. Elution was collected by MS signal trigger.
[0287] Preparative HPLC Method 9: XBridge C18, 200 mm × 19 mm, 5 μm particles; Mobile phase A: 5:95 acetonitrile:water + ammonium acetate; Mobile phase B: 95:5 acetonitrile:water + ammonium acetate; Gradient: 0 min at 0% B, 23 min at 0-30% B, followed by 4 min at 100% B; Flow rate: 20 mL / min; Column temperature: 25 °C. Elution was collected by MS signal trigger.
[0288] Preparative HPLC method 10: Phenomenex Luna Axi C18, 100 mm × 30 mm, 5 μm particles; Mobile phase A: 5:95 acetonitrile:water + 0.1% trifluoroacetic acid; Mobile phase B: 95:5 acetonitrile:water + 0.1% trifluoroacetic acid; Gradient: hold at 40% B for 3 min, 40-100% B for 4.5 min, followed by hold at 100% B for 3 min; Flow rate: 30 mL / min; Elution collection triggered by UV signal.
[0289] Example 1
[0290] 3-(1-oxo-5-(quinolin-2-yl)isoindololin-2-yl)piperidin-2,6-dione
[0291]
[0292] Preparation 1A: (S)-5-amino-4-(5-bromo-1-oxoisoindoline-2-yl)-5-oxovalerate tert-butyl ester
[0293] DIEA (20.2 mL, 115 mmol) was added to a suspension of (S)-4,5-diamino-5-oxovalerate tert-butyl hydrochloride (14.46 g, 60.6 mmol) in acetonitrile (231 mL) at 0 °C. After stirring for 15 min, the reaction mixture was treated with methyl 4-bromo-2-(bromomethyl)benzoate (22 g, 57.7 mmol) in parts as solids for 5 min. The reaction mixture was stirred at 0 °C for 30 min and then stirred overnight at room temperature. The reaction mixture was heated to 60 °C in an oil bath under a reflux condenser and maintained at that temperature overnight. The reaction mixture was cooled to room temperature with stirring. Upon cooling to room temperature, a precipitate formed. The flask was placed in a 0 °C bath with stirring. After 30 min, the solid was collected by filtration, washed with minimally cold acetonitrile, and air-dried to give 20.13 g (88% yield) of a white solid. Chiral analytical HPLC indicator material >98% ee. MS(ES): m / z = 397.1 [M+H] + . 1 H NMR (400MHz, CDCl3) δ7.76-7.71(m,1H),7.68-7.62(m,2H),6.22(br s,1H),5.31(br s,1H),4.91(dd,J=8.7,6.3Hz,1H),4.62-4.53(m,1H),4.51-4.40(m,1H),2.47-2.10(m,4H),1.44(s,9H).
[0294] Preparation 1B: (S)-5-amino-5-oxo-4-(1-oxo-5-(4,4,5,5-tetramethyl-1,3,2-dioxapentylborane-2-yl)isoindolin-2-yl)tert-butyl valerate
[0295] To a dry flask, add preparation 1A (10.0 g, 25.2 mmol), 4,4,4',4',5,5,5',5'-octamethyl-2,2'-bis(1,3,2-dioxapentylborane) (7.67 g, 30.2 mmol), and potassium acetate (7.41 g, 76 mmol), and purge with nitrogen. Suspend the solids in dioxane (100 mL) and degas with a nitrogen stream for 5 min under stirring. Treat the reaction mixture with [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium(II) (0.737 g, 1.007 mmol), degas for 5 min, seal, and heat to 60 °C for 18 h. Dilute the reaction mixture with EtOAc, filter through a diatomaceous earth stopper, and rinse with additional EtOAc. The filtrate was concentrated and purified by ISCO (0% → 20% B / DCM, where B = 15% EtOH / EtOAc + 0.1% TEA) via a 220 g silica gel column to give 9.9 g (89% yield) of preparation 1B as a white solid. MS (ES): m / z = 445.3 [M + H] + . 1 H NMR (400MHz, CDCl3) δ7.99-7.90(m,2H),7.88-7.83(m,1H),6.32(br s,1H),5.36(br s,1H),4.97-4.88(m,1H),4.58-4.41(m,2H),2.48-2.13(m,4H),1.44(s,9H),1.39(s,12H).
[0296] Example 1: 3-(1-oxo-5-(quinolin-2-yl)isoindololin-2-yl)piperidine-2,6-dione
[0297] Add preparation 1B (30 mg, 0.068 mmol) and 2-chloroquinoline (16.57 mg, 0.101 mmol) to a vial and purge with nitrogen. Suspend the solid in dioxane (540 μL), treat with cesium carbonate (2 M aqueous solution, 101 μL, 0.203 mmol), and degas with nitrogen for 5 min under stirring. Treat the reaction mixture with [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium(II) (4.94 mg, 6.75 μmol), degas for 5 min, seal, and heat at 90 °C overnight. Treat the reaction mixture with diatomaceous earth, dilute with EtOAc, filter, and concentrate. Divide the reaction mixture into two equal portions in screw-cap vials lined with Teflon. Add acetonitrile (0.3 mL) and benzenesulfonic acid (10.7 mg, 0.068 mmol) to one of these vials. The reaction vials were sealed and placed in a preheated 90°C bath and maintained at this temperature for 1.25 hours. The reaction mixture was concentrated under a nitrogen stream, diluted to 2 mL with DMF, and purified by preparative HPLC method 1 to give 7.1 mg of Example 1 (28% yield). Optical purity was not determined. MS (ES): m / z = 372.0 [M+H] + . 1 H NMR (400MHz, DMSO-d6) δ11.05(s,1H),8.58-8.49(m,2H),8.44(br d,J=8.0Hz,1H),8.25(br d,J=8.5Hz,1H),8.13(d,J=8.5Hz,1H),8.05(d,J=8.1Hz,1H),7.92(d,J=8.0Hz,1H),7.83(t,J=7.5Hz, 1H),7.71-7.61(m,1H),5.17(brdd,J=13.2,4.5Hz,1H),4.68-4.42(m,2H),3.00-2.89(m,1H),2.64(br d,J=18.3Hz,1H),2.49-2.39(m,1H),2.12-2.01(m,1H).
[0298] Example 2
[0299] 3-(5-(4-aminoisoquinolin-3-yl)-1-oxoisoindololin-2-yl)piperidine-2,6-dione
[0300]
[0301] Preparation 1B (20.9 mg, 0.047 mmol), 3-bromoisoquinoline-4-amine (10 mg, 0.045 mmol), and PdCl2(dppf)2 (3.28 mg, 4.48 μmol) were added to a vial, followed by dioxane (0.5 mL). Cesium carbonate (2 M aqueous solution, 67 μL, 0.134 mmol) was added. The vial was sealed and the air was replaced with nitrogen. The reaction mixture was heated in a microwave at 140 °C for 15 minutes. After cooling, the reaction mixture was diluted with EtOAc, washed with brine, dried over MgSO4, and concentrated. 1 mL of benzenesulfonic acid solution (0.72 g in 20 mL ACN) was added. The vial was sealed and heated in a microwave at 140 °C for 8 minutes. The reaction mixture was diluted with 1 mL DMSO and purified by preparative HPLC method 2 to give 8.8 mg (49% yield) of Example 2. Optical purity was not determined. MS(ES): m / z = 387.1 [M+H] + .1H NMR(500MHz,DMSO-d6)δ11.04(s,1H),8.82(s,1H),8.43(br d,J=8.4Hz,1H),8.16(br d,J=7.8Hz,1H),8.00-7.83(m,4H),7.81-7.74(m,1H),7.17(s,2H),5.17(br dd,J=13.3,5.0Hz,1H),4.61-4.41(m,2H),2.93(br d,J=11.8Hz,1H),2.64(br d,J=15.7Hz,1H),2.46(br dd,J=13.6,4.1Hz,1H),2.06(br dd,J=10.4,5.2Hz,1H).
[0302] Examples 3-45
[0303] The compounds in Table 1 were prepared using appropriate aryl bromides or aryl chlorides according to the procedure described for Example 2:
[0304]
[0305] Table 1
[0306]
[0307]
[0308]
[0309]
[0310]
[0311]
[0312]
[0313]
[0314]
[0315]
[0316]
[0317]
[0318]
[0319]
[0320]
[0321] a HPLC retention time using analytical HPLC method 1. NA = Unavailable.
[0322] Example 46
[0323] 3-{5-[5-amino-1-(2,2-dimethylpropyl)-4-oxo-1,4-dihydro-1,6-naphthidin-7-yl]-1-oxo-2,3-dihydro-1H-isoindol-2-yl}piperidin-2,6-dione
[0324]
[0325] Add 25 mg (0.056 mmol) of preparation 1B and benzenesulfonic acid solution (2 M acetonitrile solution, 0.268 mL, 0.536 mmol) to a vial. Seal the vial and microwave at 125 °C for 7 minutes. Concentrate the reaction mixture to dryness. Add 14.24 mg (0.054 mmol) of 5-amino-7-chloro-1-neopentyl-1,6-naphthidium-4(1H)-one, 6.19 mg (5.36 μmol) of Pd(PPh3)4, and 89 mg (0.643 mmol) of K2CO3, followed by 1 mL of DMF. Seal the vial and replace the air with nitrogen. Microwave the reaction mixture at 150 °C for 15 minutes. Dilute the reaction mixture with 0.8 mL of DMSO, filter, and purify by preparative HPLC method 2 to give 5.9 mg (22% yield) of Example 46. MS(ES): m / z = 474.2[M+H] + .1 HNMR(500MHz,DMSO-d6)δ11.03(s,1H),8.30(s,1H),8.24(br d,J=7.6Hz,1H),7.84(dd,J=9.6,8.1Hz,2H),7.33(s,1H),7.19(s,1H),7.09(s,1H),6.18(d, J=7.7Hz,1H),5.13(brdd,J=13.0,4.5Hz,1H),4.61-4.53(m,1H),4.48-4.39(m,1H),4.15(br s,2H),2.98-2.86(m,1H),2.69-2.59(m,1H),2.48-2.36(m,1H),2.12-2.00(m,1H),0.97(s,9H).
[0326] Example 47
[0327] 3-[5-(5-amino-4-oxo-1,4-dihydro-1,6-naphthid-7-yl)-1-oxo-2,3-dihydro-1H-isoindol-2-yl]piperidin-2,6-dione
[0328]
[0329] Add 25 mg (0.056 mmol) of preparation 1B and benzenesulfonic acid solution (2 M acetonitrile solution, 0.281 mL, 0.563 mmol) to a vial. Seal the vial and microwave at 125 °C for 7 minutes. Concentrate the reaction mixture to dryness. Add 11.01 mg (0.056 mmol) of 5-amino-7-chloro-1,6-naphthidium-4(1H)-one, 6.50 mg (5.63 μmol) of Pd(PPh3)4, and 93 mg (0.675 mmol) of K2CO3, followed by 1 mL of DMF. Seal the vial and replace the air with nitrogen. Microwave the reaction mixture at 150 °C for 15 minutes. Dilute the reaction mixture with 0.8 mL of DMSO, filter, and purify by preparative HPLC method 3 to give 2.5 mg (11% yield) of Example 47. MS (ES): m / z = 403.9 [M+H] + . 1H NMR (500MHz, DMSO-d6) δ11.04(s,1H),8.19(s,1H),8.10(br d,J=7.7Hz,1H),7.90-7.79(m,2H),7.27(s,1H),7.16(s,1H),7.06(s,2H),6.15(br d,J=6.6Hz,1H),5.14(br dd,J=12.3,5.1Hz,1H),4.57(br d,J=17.5Hz,1H),4.48-4.39(m,1H),2.98-2.85(m,1H),2.69-2.59(m,1H),2.48-2.36(m,1H),2.09-2.00(m,1H).
[0330] Example 48
[0331] N-{3-[2-(2,6-dioxopiperidin-3-yl)-1-oxo-2,3-dihydro-1H-isoindol-5-yl]isoquinolin-1-yl}acetamide
[0332]
[0333] Preparation 48A: N-(3-chloroisoquinoline-1-yl)acetamide
[0334] Add 3-chloroisoquinoline-1-amine (30 mg, 0.168 mmol), 5 mL of DCM, and acetyl chloride (65.9 mg, 0.840 mmol) to a 10 mL vial, followed by the addition of Schönsch base (0.044 mL, 0.252 mmol). Stir the reaction mixture at room temperature for 1 hour. Quench the reaction mixture with methanol (1 mL) and concentrate it. The crude product was used without purification. MS (ES): m / z = 221.0 [M+H] + .
[0335] Preparation 48B: N-{3-[2-(2,6-dioxopiperidin-3-yl)-1-oxo-2,3-dihydro-1H-isoindol-5-yl]isoquinoline-1-yl}acetamide
[0336] A vial was filled with preparation 48A (21.85 mg, 0.099 mmol), preparation 1B (44 mg, 0.099 mmol), Pd(PPh3)4 (11.44 mg, 9.90 μmol), and dioxane (1 mL). NaHCO3 (0.5 M aqueous solution, 0.594 mL, 0.297 mmol) was added. The vial was sealed and the air was replaced with nitrogen. The reaction mixture was heated in a microwave at 150 °C for 15 minutes. The reaction mixture was concentrated to dryness, and 2 mL of benzenesulfonic acid solution (0.72 g in 20 mL ACN) was added. The vial was sealed and heated in a microwave at 130 °C for 7 minutes. The solvent was removed, and the residue was dissolved in 2 mL of DMSO. The resulting mixture was filtered and purified by preparative HPLC method 4 to give 4.8 mg (11% yield) of Example 48. MS (ES): m / z = 430.3 [M+H] + .1H NMR(500MHz,DMSO-d6)δ10.65(s,1H),8.47(s,1H),8.44(s,1H),8.37(d,J= 7.9Hz,1H),8.10(d,J=8.3Hz,1H),8.08(d,J=8.3Hz,1H),7.89(d,J=8.0Hz, 1H),7.82(t,J=7.4Hz,1H),7.68(t,J=7.7Hz,1H),5.16(dd,J=13.2,5.1Hz, 1H),4.59(d,J=17.4Hz,1H),4.50-4.42(m,1H),2.99-2.88(m,1H),2.64(br dd,J=16.5,2.7Hz,1H),2.48-2.41(m,1H),2.29(s,3H),2.10-2.01(m,1H).
[0337] Example 49
[0338] 3-{5-[1-(dimethylamino)isoquinolin-3-yl]-1-oxo-2,3-dihydro-1H-isoindol-2-yl}piperidine-2,6-dione
[0339]
[0340] Preparation 49A: 3-Chloro-N,N-Dimethylisoquinoline-1-amine
[0341] 3-Chloroisoquinoline-1-amine (25 mg, 0.140 mmol), THF (2 mL), and methyl iodoform (49.7 mg, 0.350 mmol) were added to a vial, followed by NaH (56.0 mg, 1.400 mmol). The reaction mixture was stirred at room temperature for 1 hour. The reaction mixture was quenched by adding methanol (1 mL) and concentrated to dryness. The crude preparation 49A (39 mg, quantified) was used without purification.
[0342] MS(ES): m / z = 207.1 [M+H] + .
[0343] Example 49:
[0344] Add preparation 49A (20.5 mg, 0.099 mmol), (S)-5-amino-5-oxo-4-(1-oxo-5-(4,4,5,5-tetramethyl-1,3,2-dioxapentylborane-2-yl)isoindoline-2-yl)tert-butyl valerate (55.1 mg, 0.124 mmol), Pd(PPh3)4 (11.46 mg, 9.92 μmol), and dioxane (1 mL) to a vial, followed by the addition of NaHCO3 (0.5 M aqueous solution, 0.595 mL, 0.298 mmol). Seal the vial and purge the air with nitrogen. Heat the reaction mixture at 140 °C in a microwave for 10 minutes. Concentrate the reaction mixture to dryness, treat with 2 mL of benzenesulfonic acid solution (0.72 g in 20 mL ACN), and heat in a microwave at 130 °C for 7 minutes. The solvent was removed, and the residue was dissolved in 2 mL of DMSO, filtered, and purified by preparative HPLC method 5 to give 15.4 mg (38% yield) Example 49. MS (ES): m / z = 415.4 [M+H] + . 1 H NMR (500MHz, DMSO-d6) δ11.02 (s, 1H), 8.43 (s, 1H), 8.38 (d, J = 7.9Hz, 1H), 8. 16(d,J=8.5Hz,1H),8.00(s,1H),7.95(d,J=8.2Hz,1H),7.85(d,J=7.9Hz,1H) ,7.71(t,J=7.6Hz,1H),7.58(t,J=7.6Hz,1H),5.15(dd,J=13.4,5.2Hz,1H),4 .62-4.53(m,1H),4.49-4.41(m,1H),3.17(s,6H),2.98-2.87(m,1H),2.64(br d, J=17.7Hz, 1H), 2.44 (qd, J=13.2, 4.4Hz, 1H), 2.12-2.00 (m, 1H).
[0345] Example 50
[0346] 3-{5-[1-(methylamino)isoquinolin-3-yl]-1-oxo-2,3-dihydro-1H-isoindol-2-yl}piperidine-2,6-dione
[0347]
[0348] Preparation 50A: 3-Chloro-N-methylisoquinoline-1-amine
[0349] 3-Chloroisoquinoline-1-amine (60 mg, 0.336 mmol), THF (2 mL), and iodomethane (52.4 mg, 0.370 mmol) were added to a vial, followed by NaH (67.2 mg, 1.680 mmol). The reaction mixture was stirred at room temperature for 1 hour. The reaction mixture was quenched by adding methanol (1 mL) and concentrated to dryness. The material was purified by preparative HPLC method 6 to give 23 mg (36% yield) of preparation 50A. MS (ES): m / z = 193.1 [M+H] + .
[0350] Example 50:
[0351] This compound was prepared using Preparation 50A according to the general method for preparing 3-{5-[1-(dimethylamino)isoquinolin-3-yl]-1-oxo-2,3-dihydro-1H-isoindol-2-yl}piperidine-2,6-dione. MS (ES): m / z = 401.3 [M+H] + . 1 H NMR (500MHz, DMSO-d6) δ11.04(s,1H),8.43(s,1H),8.38(br d,J=7.8Hz,1H),8.22(br d,J=8.1Hz,1H),7.86-7.79(m,2H),7.70-7.62(m,2H),7.52(br t,J=7.5Hz,1H),5.16(br dd,J=13.0,4.5Hz,1H),4.62-4.53(m,1H),4.48-4.37(m,1H),3.13(br d,J=2.5Hz,3H),2.93(br dd,J=12.8,4.2Hz,1H),2.68-2.60(m,1H),2.48-2.39(m,1H),2.10-2.02(m,1H).
[0352] Example 51
[0353] 3-{5-[5-(methylamino)-1,6-naphthid-7-yl]-1-oxo-2,3-dihydro-1H-isoindol-2-yl}piperidin-2,6-dione
[0354]
[0355] Preparation 51A: 7-Chloro-N-methyl-1,6-naphthidine-5-amine
[0356] 5,7-Dichloro-1,6-naphthidine (250 mg, 1.256 mmol) and methylamine (40% aqueous solution, 2 mL) were added to a vial. The vial was sealed and heated at 40 °C overnight. The reaction mixture was concentrated to dryness and purified by preparative HPLC method 7 to give 121 mg (50% yield) of preparation 51A. MS (ES): m / z = 194.1 [M+H] + . 1 H NMR (400MHz, DMSO-d6) δ8.90 (dd, J=4.2, 1.3Hz, 1H), 8.67 (d, J=8.2Hz, 1H), 8.28 (br d, J=3.5Hz, 1H), 7.49 (dd, J=8.4, 4.3Hz, 1H), 6.95 (s, 1H), 2.96 (d, J=4.5Hz, 3H).
[0357] Example 51: 3-{5-[5-(methylamino)-1,6-naphthid-7-yl]-1-oxo-2,3-dihydro-1H-isoindol-2-yl}piperidin-2,6-dione
[0358] Add preparation 1B (40 mg, 0.090 mmol), preparation 51A (14.53 mg, 0.075 mmol), Pd(PPh3)4 (8.67 mg, 7.50 μmol), and dioxane (0.5 mL) to a vial, followed by adding NaHCO3 (0.5 M aqueous solution, 0.450 mL, 0.225 mmol). Seal the vial and purge the air with nitrogen. Heat the reaction mixture at 130 °C in a microwave for 15 minutes. Dilute the reaction mixture with EtOAc and brine. Separate the organic phase, dry over MgSO4, and concentrate. Dissolve the residue in 1 mL of benzenesulfonic acid solution (0.72 g in 20 mL ACN) and heat in a microwave at 130 °C for 10 minutes. Remove the solvent and dissolve the residue in 2 mL of DMSO, filter, and purify by preparative HPLC method 8 to give 9.0 mg (30% yield) of Example 51. MS(ES): m / z = 402.3[M+H] +.1H NMR(500MHz,DMSO-d6)δ11.04(s,1H),9.00-8.94(m,1H),8.68(br d,J=8.3Hz,1H),8.46(s,1H),8.40(d,J=8.2Hz,1H),7.85(d,J=8.0Hz,1H),7.67(s,1H),7.55(dd,J=8.3,4.4Hz,1H),5.16(br dd,J=13.3,4.9Hz,1H),4.58(d,J=17.3Hz,1H),4.49-4.39(m,1H),3.14(br s,3H),2.99-2.87(m,1H),2.69-2.59(m,1H),2.48-2.38(m,1H),2.12-2.00(m,1H).
[0359] Example 52
[0360] N-{3-[2-(2,6-dioxopiperidin-3-yl)-1-oxo-2,3-dihydro-1H-isoindol-5-yl]isoquinolin-1-yl}-N-methylacetamide
[0361]
[0362] Preparation 52A: N-(3-chloroisoquinoline-1-yl)-N-methylacetamide
[0363] Add 3-chloro-N-methylisoquinoline-1-amine (13 mg, 0.067 mmol), DCM (5 mL), and acetic anhydride (344 mg, 3.37 mmol) to a vial, followed by Schönsch base (0.018 mL, 0.101 mmol). Heat the reaction mixture at 80 °C for 1 hour. Concentrate the reaction mixture, and use the crude preparation 52A without purification.
[0364] Example 52: N-{3-[2-(2,6-dioxopiperidin-3-yl)-1-oxo-2,3-dihydro-1H-isoindol-5-yl]isoquinoline-1-yl}-N-methylacetamide
[0365] Add preparation 1B (35 mg, 0.079 mmol), preparation 52A (12.0 mg, 0.051 mmol), Pd(PPh3)4 (7.59 mg, 6.56 μmol), and dioxane (0.5 mL) to a vial, followed by the addition of NaHCO3 (0.5 M aqueous solution, 0.394 mL, 0.197 mmol). Seal the vial and purge the air with nitrogen. Microwave the reaction mixture at 130 °C for 15 minutes. Dilute the reaction mixture with EtOAc and brine. Separate the organic phase, dry over MgSO4, filter, and concentrate. Dissolve the resulting residue in 1 mL of benzenesulfonic acid solution (0.72 g in 20 mL ACN). Microwave the reaction mixture at 130 °C for 10 minutes, followed by heating at 155 °C for 15 minutes. The concentrated reaction mixture was dissolved in 2 mL of DMSO, filtered, and purified by preparative HPLC method 8 to give 6.5 mg (22% yield) in Example 52. MS (ES): m / z = 442.9 [M+H] + . 1 H NMR (500MHz, DMSO-d6) δ11.10-10.99(m,1H),8.68(br d,J=0.9Hz,1H),8.44(s,1H),8.36(brd,J=8.1Hz,1H),8.20(br d,J=6.7Hz,1H),8.03(br d,J=7.8Hz,1H),7.96-7.86(m,2H),7.85-7.76(m,1H),5.16(br dd,J=13.3,5.0Hz,1H),4.63-4.55(m,1H),4.51-4.42(m,1H),3.47(br s,3H),2.93(br d,J=3.5Hz,1H),2.68-2.60(m,1H),2.47-2.40(m,1H),2.10-2.02(m,1H),1.76(br s,3H).
[0366] Example 53
[0367] 3-[5-(6-amino-1,7-naphthid-8-yl)-1-oxo-2,3-dihydro-1H-isoindol-2-yl]piperidin-2,6-dione
[0368]
[0369] Preparation 53A: 8-bromo-1,7-naphthyl-6-amine
[0370] Acetic acid (0.1 mL) and hydrogen bromide (30% acetic acid solution, 170 mg, 0.629 mmol) were added to a vial and cooled to 0 °C. 3-(cyanomethyl)-2-cyanopyridine (30 mg, 0.210 mmol) was added. The reaction mixture was stirred at 0 °C for 10 min, then heated to room temperature and stirred for another 1 h. The reaction mixture was diluted with EtOAc (10 mL) and quenched by adding a saturated aqueous solution of NaHCO3. The layers were separated and the organic layer was concentrated to give 33 mg (70% yield) of preparation 53A. MS (ES): m / z = 224.0 [M+H] + .1H NMR (400MHz, DMSO-d6) δ8.60 (dd, J=4.0, 1.5Hz, 1H), 8.03 (dd, J=8.5, 1.3Hz, 1H), 7.49 (dd, J=8.5, 4.0Hz, 1H), 7.26-6.83 (br, 2H), 6.61 (s, 1H).
[0371] Example 53: 3-[5-(6-amino-1,7-naphthid-8-yl)-1-oxo-2,3-dihydro-1H-isoindol-2-yl]piperidin-2,6-dione
[0372] Add preparation 1B (44.1 mg, 0.099 mmol), preparation 53A (18.5 mg, 0.083 mmol), Pd(PPh3)4 (9.56 mg, 8.27 μmol), and dioxane (0.5 mL) to a vial, followed by adding NaHCO3 (0.5 M aqueous solution, 0.496 mL, 0.248 mmol). Seal the vial and purge the air with nitrogen. Heat the reaction mixture at 130 °C in a microwave for 15 minutes. Dilute the reaction mixture with EtOAc and brine. Separate the organic phase, dry over MgSO4, filter, and concentrate. Dissolve the resulting residue in 1 mL of benzenesulfonic acid solution (0.72 g in 20 mL ACN) and heat in a microwave at 130 °C for 15 minutes. Concentrate the reaction mixture, dissolve in 2 mL of DMSO, filter, and purify by preparative HPLC method 9 to give 12.2 mg (38% yield) of Example 53. MS(ES): m / z = 388.2[M+H] + . 1H NMR(500MHz,DMSO-d6)δ11.04(s,1H),8.57(dd,J=3.9,1.6Hz,1H),8.19(s,1H),8.11( d,J=8.3Hz,1H),8.06(dd,J=8.6,1.4Hz,1H),7.84(d,J=7.9Hz,1H),7.46(dd,J=8.5,3 .9Hz,1H),6.71(s,1H),5.17(dd,J=13.4,5.0Hz,1H),4.57(d,J=17.3Hz,1H),4.47-4. 38(m,1H),2.99-2.88(m,1H),2.68-2.59(m,1H),2.49-2.39(m,1H),2.11-2.01(m,1H).
[0373] Example 54
[0374] 3-[5-(3-amino-5-methoxyisoquinoline-1-yl)-1-oxo-2,3-dihydro-1H-isoindol-2-yl]piperidine-
[0375] 2,6-Diketone
[0376]
[0377] Preparation 54A: 1-Bromo-2-(Bromomethyl)-3-methoxybenzene
[0378] 1-Bromo-3-methoxy-2-methylbenzene (800 mg, 3.98 mmol), N-bromosuccinimide (744 mg, 4.18 mmol), and CCl4 (10 mL) were added to a vial, followed by AIBN (16.33 mg, 0.099 mmol). The vial was sealed and heated at 75°C overnight. The reaction mixture was cooled to room temperature. The precipitate was separated by pipetting the liquid and removing trace amounts of solvent under vacuum, yielding the product contaminated with succinimide. Crude preparation 54A was used without purification. 1 H NMR (400MHz, CDCl3) δ7.22-7.14(m,2H),6.85(d,J=8.1Hz,1H),4.76(s,2H),3.92(s,3H),0.04-0.03(m,1H).
[0379] Preparation 54B: 2-(2-bromo-6-methoxyphenyl)acetonitrile
[0380] To a vial, add preparation 54A (1150 mg, 4.11 mmol), potassium cyanide (401 mg, 6.16 mmol), and EtOH (10 mL), followed by water (3 mL). Stir the reaction mixture at 75 °C for 1 hour. Quench the reaction mixture with a saturated aqueous solution of NaHCO3 and dilute with EtOAc. Separate the organic layer, concentrate, and purify by ISCO using a 40 g column and elution with 1–35% EtOAc / Hex to give 799 mg (86% yield) of preparation 54B. 1 H NMR (400MHz, CDCl3) δ7.25-7.18 (m, 2H), 6.89 (dd, J = 7.2, 2.0Hz, 1H), 3.92 (s, 3H), 3.91 (s, 2H).
[0381] Preparation 54C: 2-(cyanomethyl)-3-methoxybenzonitrile
[0382] The preparation 54B (250 mg, 1.106 mmol), zinc dicyandioxide (78 mg, 0.664 mmol), Xantphos (19.20 mg, 0.033 mmol), and Pd2(dba)3 (30.4 mg, 0.033 mmol) were added to a vial, followed by 5 mL of DMF. The air was replaced with nitrogen, and the reaction mixture was heated at 130 °C for 1 hour. After cooling, the reaction mixture was quenched with an aqueous LiCl solution. The reaction mixture was diluted with EtOAc. The organic layer was separated, concentrated, and purified by preparative HPLC method 10 to give 115 mg (60% yield) of preparation 54C. 1 H NMR (400MHz, CDCl3) δ7.47 (t, J = 8.1 Hz, 1H), 7.32 (dd, J = 7.8, 1.0 Hz, 1H), 7.20 (d, J = 8.5 Hz, 1H), 3.99 (s, 3H), 3.91 (s, 2H).
[0383] Preparation 54D: 1-Bromo-5-methoxyisoquinoline-3-amine
[0384] Acetic acid (0.2 mL) and hydrogen bromide (30% acetic acid solution, 329 mg, 1.22 mmol) were added to a vial and cooled to 0 °C. Preparation 54C (35 mg, 0.203 mmol) was added. The vial was sealed and stirred at 0 °C for 10 minutes. The ice bath was removed and the reaction mixture was stirred for another hour. The reaction mixture was diluted with EtOAc (20 mL). The reaction mixture was quenched by adding a saturated aqueous solution of NaHCO3. The organic layer was separated and concentrated to give 48 mg (84% yield) of preparation 54D. 1H NMR (400MHz, CDCl3) δ7.67 (d, J = 8.7Hz, 1H), 7.23 (t, J = 8.1Hz, 1H), 7.10 (d, J = 0.8Hz, 1H), 6.87 (d, J = 7.5Hz, 1H), 4.51 (br s, 2H), 3.99 (s, 3H).
[0385] Example 54: 3-[5-(3-amino-5-methoxyisoquinolin-1-yl)-1-oxo-2,3-dihydro-1H-isoindol-2-yl]piperidine-2,6-dione
[0386] Add preparation 1B (39.5 mg, 0.089 mmol), preparation 54D (18 mg, 0.071 mmol), Pd(PPh3)4 (8.22 mg, 7.11 μmol), and dioxane (0.5 mL) to a vial, followed by adding NaHCO3 (0.5 M aqueous solution, 0.427 mL, 0.213 mmol). Seal the vial and purge the air with nitrogen. Heat the reaction mixture at 130 °C in a microwave for 15 minutes. Dilute the reaction mixture with EtOAc and brine and separate the layers. Dry the organic matter in MgSO4, filter, and concentrate. Dissolve the resulting residue in 2 mL of benzenesulfonic acid solution (0.72 g in 20 mL ACN) and heat in a microwave at 130 °C for 15 minutes. Remove the solvent and dissolve the residue in 2 mL of DMSO, filter, and purify by preparative HPLC method 8 to give 5.1 mg (17% yield) of Example 54. MS(ES): m / z = 417.1 [M+H] + . 1 H NMR (500MHz, DMSO-d6) δ11.03(s,1H),7.96(s,1H),7.89(d,J=7.6Hz,1H),7.81(s,1H),7.72(d,J=7 .0Hz,1H),7.27(d,J=8.5Hz,1H),7.05(t,J=7.9Hz,1H),7.01(s,1H),6.94(d,J=7.3Hz,1H),5.17(br dd,J=13.1,4.9Hz,1H),4.63-4.54(m,1H),4.49-4.41(m,1H),3.96(s,3H),2.98-2.93(m,1H),2.65(br dd,J=16.3,2.0Hz,1H),2.47-2.39(m,1H),2.12-2.04(m,1H).
[0387] Examples 55-67
[0388] The compounds in Table 2 were prepared using appropriate aryl bromides or aryl chlorides according to the procedure (step 5) described for Example 54:
[0389]
[0390] Table 2
[0391]
[0392]
[0393]
[0394]
[0395]
[0396]
[0397]
[0398] a HPLC retention time using analytical HPLC method 1. NA = Unavailable.
[0399] Examples 70-76
[0400] The compounds in Table 3 were prepared using appropriate aryl bromides or aryl chlorides according to the procedure described for Example 2:
[0401]
[0402] Table 3
[0403]
[0404]
[0405]
[0406]
[0407] a HPLC retention time using analytical HPLC method 1.
[0408] Examples 77 and 78
[0409] 6-[2-(2,6-dioxopiperidin-3-yl)-1-oxo-2,3-dihydro-1H-isoindol-5-yl]pyridazin-3-carboxynitrile (77) and 6-[2-(2,6-dioxopiperidin-3-yl)-1-oxo-2,3-dihydro-1H-isoindol-5-yl]pyridazin-3-carboxamide (78)
[0410]
[0411] The title compound was prepared using 6-chloropyridazine-3-carboxynitrile according to the general procedure described for Example 2. Both products were separated from the reaction mixture by preparative HPLC.
[0412] Example 77: MS(ES): m / z = 348.1 [M+H] + . 1 H NMR (500MHz, DMSO-d6) δ11.00(s,1H),8.51(d,J=8.9Hz,1H),8.43(s,1H),8.38(d,J=8.9Hz,1H),8.32(br d,J=8.2Hz,1H),7.95(d,J=7.9Hz,1H),5.10(br dd,J=13.1,4.6Hz,1H),4.66-4.56(m,1H),4.53-4.42(m,1H),2.94-2.82(m,1H),2.65(br d,J=16.2Hz,1H),2.43(br dd,J=12.7,4.4Hz,1H),2.14-2.01(m,1H).
[0413] Example 78: MS(ES): m / z = 366.0 [M+H] + . 1 H NMR(500MHz,DMSO-d6)δ11.04(s,1H),8.62(br s,1H),8.48(dt,J=8.8,1.8Hz,1H),8.43(s,1H),8.38-8.27(m,2H),7.95(d,J=8.1Hz,1 H),5.18-5.07(m,1H),4.66-4.56(m,1H),4.53-4.44(m,1H),2.95-2.85(m,1H),2.65(br d,J=16.3Hz,1H),2.44(br dd,J=13.9,4.1Hz,1H),2.14-2.01(m,1H).
[0414] Example 79
[0415] 3-[5-(6-amino-3-nitropyridin-2-yl)-1-oxo-2,3-dihydro-1H-isoindol-2-yl]piperidin-2,6-dione
[0416]
[0417] Add preparation 1B (25 mg, 0.056 mmol), 6-chloro-5-nitropyridine-2-amine (9.30 mg, 0.054 mmol), and PdCl2(dppf)2 (3.92 mg, 5.36 μmol) to a vial. Purge the vial with nitrogen. Add dioxane (1 mL) and NaHCO3 (0.5 M aqueous solution, 0.214 mL, 0.107 mmol). Seal the vial, purge with nitrogen, and heat in a microwave at 125 °C for 11 min. Cool the reaction mixture, dilute with EtOAc, wash with brine, dry over MgSO4, and concentrate. Dissolve the residue in 1 mL of benzenesulfonic acid in acetonitrile (0.72 g in 20 mL ACN) and microwave at 120 °C for 7 min. Purify the resulting residue by preparative HPLC to give 4.3 mg (21% yield) Example 79. MS(ES): m / z = 382.1 [M+H] + . 1 H NMR (500MHz, DMSO-d6) δ11.00(s,1H),8.18(d,J=9.2Hz,1H),7.78(d,J=7.9Hz,1H),7.62(s,1H),7.51(d,J=7.6Hz,1H),7.43(br s,2H),6.57(d,J=9.2Hz,1H),5.11(dd,J=13.3,5.0Hz,1H),4.55-4.46(m,1H),4.42-4.32(m ,1H),2.97-2.83(m,1H),2.67-2.59(m,1H),2.41(td,J=13.1,8.5Hz,1H),2.10-2.01(m,1H).
[0418] Examples 80 and 81
[0419] 4-Amino-2-[2-(2,6-dioxopiperidin-3-yl)-1-oxo-2,3-dihydro-1H-isoindol-5-yl]pyrimidin-5-carboxynitrile (80) and 4-amino-2-[2-(2,6-dioxopiperidin-3-yl)-1-oxo-2,3-dihydro-1H-isoindol-5-yl]pyrimidin-5-carboxamide (81)
[0420]
[0421] The title compound was prepared using 4-amino-2-chloropyrimidin-5-carboxynitrile according to the general procedure described for Example 79. Both products were separated from the reaction mixture by preparative HPLC.
[0422] Example 80: MS(ES): m / z = 363.0 [M+H] + . 1 H NMR (500MHz, DMSO-d6) δ10.99(s,1H),8.73(s,1H),8.51(s,1H),8.46(br d,J=7.9Hz,1H),8.14-7.90(m,2H),7.86(br d,J=7.9Hz,1H),5.08(br dd,J=13.1,5.2Hz,1H),4.63-4.51(m,1H),4.46-4.38(m,1H),2.93-2.82(m,1H),2.63(br dd,J=14.8,2.3Hz,1H),2.46-2.32(m,1H),2.04(br dd,J=12.1,5.6Hz,1H).
[0423] Example 81: MS(ES): m / z = 381.0 [M+H] + . 1 H NMR (500MHz, DMSO-d6) δ11.04(s,1H),8.85(s,1H),8.54(s,1H),8.50(d,J=8.1Hz,1H),8.18(br s,1H),7.86(d,J=8.1Hz,1H),7.56(br s,1H),5.20-5.12(m,1H),4.57(br d,J=17.3Hz,1H),4.50-4.38(m,1H),2.98-2.88(m,1H),2.69-2.59(m,1H),2.47-2.36(m,1H),2.12-2.00(m,1H).
[0424] Example 82
[0425] (3S)-3-[5-(1-aminoisoquinolin-3-yl)-1-oxo-2,3-dihydro-1H-isoindol-2-yl]piperidin-2,6-dione
[0426]
[0427] Preparation 82A: (S)-5-amino-4-(5-bromo-1-oxoisoindoline-2-yl)-5-oxovalerate tert-butyl ester
[0428] DIEA (6.09 mL, 34.9 mmol) was added to a suspension of (S)-4,5-diamino-5-oxovalerate tert-butyl hydrochloride (4.16 g, 17.43 mmol) in acetonitrile (54.1 mL). After stirring for 5 min, the reaction mixture was treated with methyl 4-bromo-2-(bromomethyl)benzoate (5.78 g, 15.16 mmol) as a small solid. After stirring at room temperature for 1 h, the reaction mixture was heated to 70 °C overnight in an oil bath under a reflux condenser. LC-MS indicated complete conversion to the product. The mixture was cooled to room temperature, diluted with EtOAc, and washed with 1 M HCl (2×), followed by 1.5 M K₂HPO₄ (2×), then brine, dried over MgSO₄, filtered, and concentrated. The resulting residue was purified by column chromatography (50 to 100% EtOAc / Hex) to give preparation 82A (82% yield). 1 H NMR (400MHz, chloroform-d) δ7.76-7.71(m,1H),7.68-7.62(m,2H),6.22(br s,1H),5.31(br s,1H),4.91(dd,J=8.7,6.3Hz,1H),4.62-4.53(m,1H),4.51-4.40(m,1H),2.47-2.10(m,4H),1.44(s,9H).
[0429] Preparation 82B: (S)-5-amino-5-oxo-4-(1-oxo-5-(4,4,5,5-tetramethyl-1,3,2-dioxapentylborane-2-yl)isoindolin-2-yl)tert-butyl valerate
[0430] To a dry 250 mL round-bottom flask, tert-butyl (S)-5-amino-4-(5-bromo-1-oxoisoindoline-2-yl)-5-oxovalerate (9.07 g, 22.83 mmol), 4,4,4',4',5,5,5',5'-octamethyl-2,2'-bis(1,3,2-dioxapentylborane) (6.96 g, 27.4 mmol), and potassium acetate (6.72 g, 68.5 mmol) were charged and purged with nitrogen. The solids were suspended in dioxane (90 mL) and degassed with a nitrogen stream for 5 min with stirring. The reaction mixture was treated with Pd(dppf)Cl2 (0.668 g, 0.913 mmol) for 5 min to degause, sealed, and heated to 60 °C under nitrogen for 18 h. LCMS showed complete conversion (LCMS showing both ester and acid). The reaction mixture was diluted with EtOAc, washed with brine, and dried over MgSO4. The filtrate was concentrated and purified by ISCO (0-20% B / DCM, where B = 15% EtOH / EtOAc + 0.1% TEA) through a 220 g silica gel column to give preparation 82B (7.7 g, 17.33 mmol, 76% yield) as a grayish-white solid. 1 The H NMR spectrum is consistent with the product.
[0431] Preparation 82C: (S)-5-amino-4-(5-(1-aminoisoquinolin-3-yl)-1-oxoisoindololin-2-yl)-5-oxovalerate tert-butyl ester
[0432] Add the following to a 100 mL round-bottom flask: Preparation 82B (7.47 g, 16.81 mmol), 3-bromoisoquinoline-1-amine (3 g, 13.45 mmol), PdCl2 (dtbpf) (0.263 g, 0.403 mmol), and TEA (9.37 mL, 67.2 mmol), followed by 40 mL of 2% TPGS aqueous solution. Seal the flask and purge the air with nitrogen. Heat the reaction mixture at 40 °C overnight. LC-MS showed the uncyclized product as the dominant peak. Dilute the reaction mixture with 5% EtOH / EtOAc and filter through a diatomaceous earth mat. Wash the viscous cake thoroughly with 5% EtOH / EtOAc, then separate the organic layer and wash with brine, dry with MgSO4, and filter. The filtrate was concentrated and purified by elution with 0-80% B / DCM (B = 15% EtOH / EtOAc + 0.1% TEA) using a 220 g silica column (equilibrated with 10% DCM / hexane) to give preparation 82C. 1H NMR (400MHz, methanol-d4) δ8.21(s,1H),8.14(dd,J=13.4,8.2Hz,2H),7.86(d,J=7.7Hz,1H),7.81(d,J=7.7Hz,1H),7.67(t,J=7.2Hz,1H),7.57-7.49(m,2 H),5.05-4.96(m,1H),4.75(d,J=17.4Hz,1H),4.63(d,J=17.5Hz,1H),4.1 2(q,J=7.2Hz,1H),2.38-2.19(m,4H),1.41(s,9H),0.92(d,J=6.7Hz,1H).
[0433] Example 82:
[0434] Add Preparation 82C (2.71 g, 5.88 mmol), benzenesulfonic acid (1.862 g, 11.77 mmol), and acetic acid (75 mL) to a round-bottom flask. Seal the flask and heat the reaction mixture at 100 °C. After 6.5 hours, place the flask in water at room temperature. After about 5 minutes, filter the precipitate, wash with 80 mL of room temperature acetic acid, then with 40 mL of room temperature MeCN, and then again with 40 mL of MeCN. Air-dry the solids to obtain 1.9 g of Example 82 (79% yield). Enantiomeric purity test showed chiral purity >99% ee. MS (ES): m / z = 387.1 [M+H] + .1H NMR(500MHz,DMSO-d6)δ11.05(s,1H),8.50(br d,J=8.4Hz,1H),8.17(s,1H),8.08(d,J=8.0Hz,1H),8.01-7.96(m,1H),7.96-7.91(m,2H),7.78-7.70(m,2H),5.16(br dd,J=13.0,4.1Hz,1H),4.62-4.54(m,1H),4.51-4.42(m,1H),3.00-2.87(m,1H),2.69-2.60(m,1H),2.49-2.36(m,1H),2.10-2.03(m,1H).
[0435] Example 83
[0436] (3R)-3-[5-(1-aminoisoquinolin-3-yl)-1-oxo-2,3-dihydro-1H-isoindol-2-yl]piperidin-2,6-dione
[0437]
[0438] Example 83 was prepared using (R)-4,5-diamino-5-oxovalerate tert-butyl ester according to the general procedure outlined for the synthesis in Example 82. MS (ES): m / z = 387.1 [M+H] + .1H NMR(500MHz,DMSO-d6)δ11.05(s,1H),8.50(br d,J=8.4Hz,1H),8.17(s,1H),8.08(d,J=8.0Hz,1H),8.01-7.96(m,1H),7.96-7.90(m,2H),7.76-7.70(m,2H),5.16(br dd,J=13.0,4.1Hz,1H),4.62-4.55(m,1H),4.49-4.43(m,1H),3.00-2.88(m,1H),2.70-2.60(m,1H),2.50-2.36(m,1H),2.11-2.03(m,1H).
[0439] Example 84
[0440] (3S)-3-[5-(1-amino-4-ethoxyisoquinolin-3-yl)-1-oxo-2,3-dihydro-1H-isoindol-2-yl]piperidin-2,6-dione
[0441]
[0442] Preparation 84A: 4-ethoxyisoquinoline
[0443] Potassium ethanolide (1.023 g, 12.16 mmol) was added to a solution of 4-bromoisoquinoline (2.3 g, 11.05 mmol) in DMPU (30 mL). The reaction flask was placed on a preheated hot plate at 105 °C for 20 minutes. The reaction mixture was cooled to room temperature and diluted with water. The product was extracted with diethyl ether (multiple extraction) and filtered through diatomaceous earth. The organic layer was concentrated and purified by ISCO using an 80 g silica gel column and elution with 0-100% diethyl ether / hexane to give preparation 84A. 1 ¹H NMR (400 MHz, chloroform-d) δ 8.91 (s, 1H), 8.26 (d, J = 8.5 Hz, 1H), 8.09 (s, 1H), 7.95 (d, J = 8.1 Hz, 1H), 7.71 (ddd, J = 8.3, 7.0, 1.3 Hz, 1H), 7.67–7.60 (m, 1H), 4.32 (q, J = 7.0 Hz, 2H), 1.59 (t, J = 7.0 Hz, 3H).
[0444] Preparation 84B: 3-bromo-4-ethoxyisoquinoline
[0445] DCE (30 mL) was added to a mixture of preparation 84A (385 mg, 2.223 mmol) and 1-bromopyrrolidine-2,5-dione (475 mg, 2.67 mmol) in a round-bottom flask. The reaction mixture was heated to 60 °C. After 16 hours, only trace amounts of the starting material remained. An additional 47.5 mg of NBS was added, and the reaction was allowed to proceed for another hour. The reaction mixture was concentrated to dryness and purified by ISCO using a 24 g silica gel column and elution with 0–100% diethyl ether / hexane to give 560 mg (77%) of preparation 84B. 1 ¹H NMR (400MHz, chloroform-d) δ 8.86 (s, 1H), 8.13 (dd, J = 8.5, 0.8Hz, 1H), 8.01 (d, J = 8.2Hz, 1H), 7.77 (ddd, J = 8.3, 7.0, 1.2Hz, 1H), 7.70–7.63 (m, 1H), 4.27 (q, J = 7.1Hz, 2H), 1.60 (t, J = 7.1Hz, 3H).
[0446] Preparation 84C: 2-Oxy-3-bromo-4-ethoxyisoquinoline
[0447] 3-Chloroperoxybenzoic acid (412 mg, 1.840 mmol) was added to a mixture of preparation 84B (400 mg, 1.587 mmol) dissolved in DCM (20 mL) at room temperature. The reaction mixture was stirred at room temperature for 5 hours. The reaction mixture was concentrated to dryness, diluted with EtOAc, washed with brine, dried over MgSO4, filtered, and subsequently concentrated to dryness to give preparation 84C (437 mg). MS (ES): m / z = 268.1 [M+H] + and 270.1 [M+H] + .
[0448] Preparation 84D: 3-bromo-1-chloro-4-ethoxyisoquinoline
[0449] Phosphoryl trichlorophosphate (3.49 mL, 37.3 mmol) was added to preparation 84C (200 mg, 0.746 mmol), and the mixture was stirred at room temperature. After 3 days, LCMS showed the product as the main peak. The reaction mixture was concentrated and purified by ISCO using a 24 g silica gel column and elution with 2 to 100% DCM / hexane to give preparation 84D. 1¹H NMR (400MHz, chloroform-d) δ 8.31 (dt, J = 8.4, 0.9 Hz, 1H), 8.18–8.12 (m, 1H), 7.83 (t, J = 7.6 Hz, 1H), 7.74 (t, J = 7.6 Hz, 1H), 4.31–4.23 (m, 2H), 1.65–1.58 (m, 3H).
[0450] Preparation 84E: 3-bromo-4-ethoxyisoquinoline-1-amine
[0451] Preparation 84D (40 mg, 0.140 mmol) and 28% NH3 aqueous solution (1.942 mL, 13.96 mmol) were added to a sealed tube, followed by the addition of MeOH (0.5 mL). The tube was sealed and heated to 140 °C for 2 hours. The product was observed by LCMS, but the reaction was incomplete. The reaction mixture was purified by preparative HPLC method 1 to give 13 mg of preparation 84E.
[0452] Example 84:
[0453] Add the prepared compound 84E (23.95 mg, 0.054 mmol), 3-bromo-4-ethoxyisoquinoline-1-amine (12 mg, 0.045 mmol), PdCl2 (dtbpf) (1.464 mg, 2.246 μmol), and 1,4-dioxane (1 mL) to a vial, followed by the addition of Cs2CO3 (1 M aqueous solution) (0.135 mL, 0.135 mmol). Seal the reaction mixture and purge the air with nitrogen. Heat the reaction mixture at 40 °C for 16 hours. LC-MS showed the uncyclized product as the dominant peak. Dilute the reaction mixture with EtOAc, wash with brine, separate the organic layer, and concentrate. Dissolve the crude material in 0.5 mL of AcOH and add 2 equivalents of PhSO3H. Microwave the reaction mixture at 120 °C for 10 minutes. The reaction mixture was concentrated to dryness, and the residue was dissolved in 1.8 mL of DMSO and purified by preparative HPLC method 1 to give 1.9 mg of Example 84 (10% yield). MS (ES): m / z = 431.3 [M+H] + . 1HNMR(500MHz,DMSO-d6)δ8.29-8.20(m,3H),8.05-7.98(m,J=8.2Hz,1H),7.85 -7.79(m,J=8.1Hz,1H),7.76(t,J=7.6Hz,1H),7.57(t,J=7.6Hz,1H),6.75(br s,2H),5.14(br dd,J=13.5,4.4Hz,1H),4.56(d,J=17.3Hz,1H),4.45-4.39(m,1H),3.73-3.58(m,2H),3.00- 2.90(m,1H),2.69-2.61(m,1H),2.49-2.36(m,1H),2.10-2.02(m,1H),1.24(t,J=6.9Hz,3H).
[0454] The compounds in Table 4 were prepared by following the general procedure described below. The aryl halides used were obtained from commercial sources or by following prior literature procedures. Optical rotation was not determined.
[0455] General Procedure 1: Add 1.0 equivalent of an aryl halide, 1.25 equivalents of Preparation 1B, 3 mol% PdCl2 (dtbpf), 1 mL of dioxane, and 5 equivalents of 3M K3PO4 aqueous solution to a 2 mL microwave-safe vial. Seal the vial and purge the air with nitrogen. Microwave the reaction mixture at 120°C for 10 minutes. Dilute the reaction mixture with EtOAc and brine. Separate the organic layer, dry it with MgSO4, and concentrate it. Transfer the crude material to another 2 mL microwave-safe vial, add 2 equivalents of PhSO3H and 1 mL of MeCN, and microwave the mixture at 120°C for 10 minutes. Concentrate the mixture and dissolve the residue in 1.8 mL of DMSO and purify it by preparative HPLC method 1.
[0456] Table 4
[0457]
[0458]
[0459]
[0460]
[0461]
[0462]
[0463]
[0464]
[0465]
[0466]
[0467]
[0468]
[0469]
[0470]
[0471] a HPLC retention time using analytical HPLC method 1.
[0472] General Procedure 2: Same as General Procedure 1, except that acetic acid is used instead of acetonitrile for the cyclization reaction.
[0473] General Procedure 3: Same as General Procedure 1, except that PdCl2(dppf)2 replaces PdCl2(dtbpf) as the catalyst.
[0474] Example 122
[0475] (3S)-3-[5-(1,8-naphthidin-2-yl)-1-oxo-2,3-dihydro-1H-isoindol-2-yl]piperidin-2,6-dione
[0476]
[0477] Example 122 was prepared according to general procedure 2. MS(ES): m / z = 373.3 [M+H] + HPLC a T Ret = 0.99 minutes. 1H NMR (500MHz, DMSO-d6) δ11.05(br s,1H),9.15(br d,J=2.3Hz,1H),8.64(d,J=8.5Hz,1H),8.58(s,1H),8.54(br d,J=8.0Hz,1H),8.49(br d,J=7.7Hz,1H),8.39(d,J=8.5Hz,1H),7.94(d,J=8.0Hz,1H),7.68(dd,J=8.1,4.2Hz,1H),5.18(br dd,J=13.3,5.1Hz,1H),4.66-4.60(m,1H),4.54-4.47(m,1H),3.01-2.90(m,1H),2.68-2.61(m,1H),2.50-2.40(m,1H),2.12-2.04(m,1H).
[0478] Example 123
[0479] (S)-3-(5-(3-aminoisoquinolin-1-yl)-1-oxoisoindololin-2-yl)piperidin-2,6-dione
[0480]
[0481] Example 123 was prepared according to general procedure 2. MS(ES): m / z = 387.2 [M+H] + HPLC a T Ret = 0.87 minutes. 1 H NMR (500MHz, DMSO-d6) δ7.89(d,J=7.6Hz,1H),7.83(s,1H),7.75-7.67(m,2H),7.62(d,J=8. 3Hz,1H),7.51-7.45(m,1H),7.12(t,J=7.6Hz,1H),6.72(s,1H),6.10-5.97(m,2H),5.17(br dd,J=13.3,4.8Hz,1H),4.61-4.55(m,1H),4.49-4.42(m,1H),3.00-2.88(m,1H),2.68-2.60(m,1H),2.49-2.36(m,1H),2.11-2.03(m,1H).
[0482] Example 124
[0483] (S)-N-(1-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindololin-5-yl)isoquinolin-3-yl)acetamide
[0484]
[0485] Example 124 is a byproduct obtained during the final synthetic step (cyclization using AcOH as a solvent) in the preparation of Example 123. MS (ES): m / z = 429.2 [M+H] + HPLC a T Ret = 1.21 minutes. 1 H NMR(500MHz,DMSO-d6)δ11.03(s,1H),10.66(s,1H),8.50(s,1H),7.99(d,J=8 .2Hz,1H),7.96-7.89(m,3H),7.81(d,J=7.8Hz,1H),7.73(t,J=7.5Hz,1H),7. 50(t,J=7.5Hz,1H),5.20-5.13(m,1H),4.63-4.56(m,1H),4.50-4.43(m,1H), 2.98-2.89(m,1H),2.68-2.61(m,1H),2.48-2.40(m,1H),2.16(s,3H),2.08(br dd, J = 10.1, 5.5 Hz, 1H).
[0486] Example 125
[0487] 3-{2-[(3S)-2,6-dioxopiperidin-3-yl]-1-oxo-2,3-dihydro-1H-isoindol-5-yl}isoquinoline-1-
[0488] Formonitrile
[0489]
[0490] Example 125 was prepared according to general procedure 2. MS(ES): m / z = 397.2 [M+H] + HPLC a T Ret = 1.40 minutes. 1H NMR(500MHz,DMSO-d6)δ11.06(s,1H),8.82-8.74(m,1H),8.31-8.24(m,1H),8.19-8.12(m,1H),8.05(br t,J=7.0Hz,1H),8.01-7.89(m,3H),7.89-7.83(m,1H),5.27-5.18(m,1H),4.68-4.60(m,1H),4 .57-4.48(m,1H),3.04-2.91(m,1H),2.71-2.63(m,1H),2.51-2.42(m,1H),2.15-2.06(m,1H).
[0491] Example 126
[0492] 3-{2-[(3S)-2,6-dioxopiperidin-3-yl]-1-oxo-2,3-dihydro-1H-isoindol-5-yl}isoquinoline-1-
[0493] Formamide
[0494]
[0495] Example 126 is a byproduct obtained during the final synthetic step (cyclization using AcOH as a solvent) in the preparation of Example 125. MS (ES): m / z = 415.2 [M+H] + HPLC a T Ret = 1.29 minutes. 1 H NMR (500MHz, DMSO-d6) δ8.74(s,1H),8.26(br d,J=7.9Hz,1H),8.14(br d,J=8.5Hz,1H),8.03(br t,J=7.5Hz,1H),7.97-7.88(m,3H),7.84-7.79(m,1H),7.66-7.62(m,1H),7.24(br s,1H),4.86-4.81(m,1H),4.80-4.74(m,1H),4.66-4.60(m,1H),2.57-2.55(m,1H),2.50-2.30(m,2H),2.24(s,3H),2.10-2.01(m,1H).
[0496] Example 127
[0497] (4S)-Acetic acid 7-{2-[(3S)-2,6-dioxoperidin-3-yl]-1-oxo-2,3-dihydro-1H-isoindol-5-yl}-2H,3H,4H-pyrano[2,3-b]pyridin-4-yl ester
[0498]
[0499] Example 127 was prepared according to General Procedure 2 using (S)-7-chloro-3,4-dihydro-2H-pyrano[2,3-b]pyridin-4-ol as the aryl halide. The alcohol was acetylated during the final synthetic step (cyclization using AcOH as the solvent). MS (ES): m / z = 436.2 [M+H] + HPLC a T Ret = 1.29 minutes. 1 H NMR (500MHz, DMSO-d6) δ11.01(s,1H),8.26(s,1H),8.17(d,J=7.6Hz,1H),7.87(d,J=7 .9Hz,1H),7.83(d,J=7.9Hz,1H),7.70(d,J=7.9Hz,1H),5.94(t,J=4.0Hz,1H),5.13(br dd,J=13.3,5.0Hz,1H),4.58-4.52(m,1H),4.51-4.40(m,2H),4.38-4.32(m,1H),2.96-2.87(m,1H),2.63(br d,J=17.7Hz,1H),2.49-2.37(m,1H),2.27-2.18(m,1H),2.08(s,3H).
[0500] Example 128
[0501] (4R)-Acetic acid 7-{2-[(3S)-2,6-dioxoperidin-3-yl]-1-oxo-2,3-dihydro-1H-isoindol-5-yl}-2H,3H,4H-pyrano[2,3-b]pyridin-4-yl ester
[0502]
[0503] Example 128 was prepared according to General Procedure 2 using (R)-7-chloro-3,4-dihydro-2H-pyrano[2,3-b]pyridin-4-ol as the aryl halide. The alcohol was acetylated during the final synthetic step (cyclization using AcOH as the solvent). MS (ES): m / z = 436.2 [M+H] + HPLC a T Ret = 1.30 minutes. 1H NMR (500MHz, DMSO-d6) δ8.25(s,1H),8.17(brd,J=8.2Hz,1H),7.87(d,J=7.6Hz,1H),7.83(d,J=7.9Hz,1H),7.70(d,J=7.6Hz,1H),5.93(br t,J=4.0Hz,1H),5.13(br dd,J=13.1,5.2Hz,1H),4.58-4.52(m,1H),4.50-4.40(m,2H),4.38-4.31(m,1H),2.9 6-2.87(m,1H),2.67-2.59(m,1H),2.48-2.36(m,1H),2.28-2.15(m,1H),2.08(s,3H).
[0504] Example 129
[0505] 3-{5-[7-chloro-4-(dimethylamino)isoquinolin-1-yl]-1-oxo-2,3-dihydro-1H-isoindol-2-yl}piperidin-2,6-dione
[0506]
[0507] Preparation 129A: 1,7-Dichloroisoquinoline-4-amine
[0508] At -78°C, BuLi (12.13 mL, 19.41 mmol) was added dropwise to a slurry of 4-bromo-1,7-dichloroisoquinoline (2.15 g, 7.76 mmol) in THF (40 mL). A dark brown solution was formed. After 30 minutes, diphenyl azidophosphate (1.678 mL, 7.76 mmol) was added. After 1 hour, Vitride was added. TM (9.47 mL, 31.1 mmol) was added to the reaction mixture. The reaction flask was then heated to 0 °C. After 30 minutes, the reaction mixture was quenched with ice water (10 mL) and filtered. The filter cake was washed with water and then with ethyl acetate. The combined organic layers were washed with a saturated aqueous solution of NaCl, dried over Na₂SO₄, filtered, and concentrated to give preparation 129A (210 mg) as a red solid.
[0509] Preparation 129B: 1,7-Dichloro-N,N-Dimethylisoquinoline-4-amine
[0510] Preparation 128A (450 mg, 2.1 mmol) was dissolved in DMF (10 mL) at 0 °C. Sodium hydride (152 mg, 6.34 mmol) was added in a single addition. The reaction mixture was stirred for 20 min, followed by dropwise addition of methyl iodoform (0.224 mL, 3.59 mmol). The reaction mixture was stirred for 1 h. The reaction was quenched with water. The reaction mixture was extracted with ethyl acetate, washed with a saturated aqueous solution of NaCl, and dried over sodium sulfate. The product was purified by ISCO column chromatography using silica gel column chromatography, eluting with 1 to 2% EtOAc / hexane, to give preparation 129B in 79% yield. 1 ¹H NMR (400MHz, chloroform-d) δ 8.20 (d, J = 2.3Hz, 1H), 8.05 (d, J = 9.1Hz, 1H), 7.85 (s, 1H), 7.61 (dd, J = 9.1, 2.0Hz, 1H), 2.87 (s, 6H).
[0511] Example 129:
[0512] Suzuki coupling and cyclization were achieved by following general procedure 1 using preparations 129B and 1B. MS (ES): m / z = 449.2 [M+H] + HPLC a T Ret = 1.31 minutes. 1 H NMR(500MHz,DMSO-d6)δ11.04(s,1H),8.32(s,1H),8.25(d,J=8.7Hz,1H),7 .96-7.89(m,2H),7.87(s,1H),7.83(dd,J=9.0,2.1Hz,1H),7.77(d,J=7.8H z,1H),5.19(t,J=1.0Hz,1H),4.60(d,J=1.0Hz,1H),4.47(d,J=1.0Hz,1H), 3.02-2.91(m,7H),2.67-2.61(m,1H),2.50-2.39(m,1H),2.14-2.03(m,1H).
[0513] Example 130
[0514] 1-Amino-3-[2-(2,6-dioxopiperidin-3-yl)-1-oxo-2,3-dihydro-1H-isoindol-5-yl]-N,N-dimethylisoquinoline-4-carboxamide
[0515]
[0516] Preparation 130A: Methyl 1,3-dichloroisoquinoline-4-carboxylate
[0517] LDA (5.55 mL, 11.11 mmol) was added dropwise to a solution of 1,3-dichloroisoquinoline (2 g, 10.10 mmol) in 40 mL of THF at -78 °C. After stirring at this temperature for 30 min, methyl chloroformate (1.017 mL, 13.13 mmol) was added. The mixture was stirred for another hour and then slowly heated to room temperature. The reaction was quenched with ice water. The reaction mixture was diluted with EtOAc. The organic layer was separated, washed with brine, and dried over sodium sulfate. The solvent was removed under reduced pressure, and the residue was purified by ISCO using an 80 g silica gel column with 5–100% DCM / hexane elution to give preparation 130A (2.34 g, 9.14 mmol, 90% yield). 1 ¹H NMR (400MHz, chloroform-d) δ 8.41 (d, J = 8.2Hz, 1H), 7.90–7.82 (m, 2H), 7.79–7.74 (m, 1H), 4.11 (s, 3H).
[0518] Preparation 130B: 1-Amino-3-chloroisoquinoline-4-carboxylic acid
[0519] Preparation 130A (1.00 g, 3.90 mmol) and 28% NH3 aqueous solution (10.86 mL, 78 mmol) were added to a sealed tube, followed by the addition of MeOH (0.5 mL). The reaction mixture was heated to 140 °C for 4 hours and then cooled. The mixture was rotary evaporated to remove most of the methanol and diluted with ice water. The precipitate (product) was filtered and air-dried. The solid residue was purified by preparative HPLC method 2 to give preparation 130B in 50% yield.
[0520] Preparation 130C: 1-Amino-3-chloro-N,N-dimethylisoquinoline-4-carboxamide
[0521] Preparation 130B (30 mg, 0.135 mmol), HATU (64.0 mg, 0.168 mmol), and DMF (1 mL) were added to a sealed tube, followed by the addition of triethylamine (0.038 mL, 0.270 mmol). After 10 minutes, dimethylamine (6.68 mg, 0.148 mmol) was added. The tube was sealed and heated to 50 °C for 2 hours. The reaction mixture was diluted with 15% EtOH / EtOAc and washed with 10% LiCl aqueous solution. The organic layer was concentrated and purified using preparative HPLC method 2 to give 14 mg (42% yield) of preparation 130C.
[0522] Example 130:
[0523] Suzuki coupling and cyclization were achieved by following general procedure 1 using preparations 130C and 1B. MS (ES): m / z = 458.1 [M+H] + HPLC a T Ret = 0.92 minutes. 1 H NMR(500MHz,DMSO-d6)δ11.03(s,1H),8.58(br d,J=7.9Hz,1H),7.98-7.93(m,1H),7.90(d,J=7.9Hz,1H),7.87(s,1H),7 .83-7.77(m,2H),7.66(d,J=8.5Hz,1H),5.20-5.14(m,1H),4.62-4.52(m ,1H),4.48-4.39(m,1H),3.00-2.93(m,1H),2.92(d,J=5.5Hz,3H),2.69- 2.61(m,1H),2.59(d,J=1.8Hz,3H),2.48-2.40(m,1H),2.12-2.03(m,1H).
[0524] Example 131
[0525] 3-[5-(1-amino-4-methylisoquinoline-3-yl)-1-oxo-2,3-dihydro-1H-isoindol-2-yl]piperidin-2,6-dione
[0526]
[0527] Preparation 131A: 3-Chloro-4-methylisoquinoline-1-amine
[0528] A solution of 1-amino-3-chloroisoquinoline-4-carboxylic acid (40 mg, 0.180 mmol) in 10 mL of THF was placed in an ice-water bath, and borane-THF (0.359 mL, 0.359 mmol) was added dropwise. After 90 minutes, significant byproducts (loss of hydroxyl groups) were observed. The reaction was quenched by adding a few drops of formaldehyde. The reaction mixture was concentrated, and the crude material was purified using preparative HPLC method 2 to give preparation 131A, a mixture of 1-amino-3-chloroisoquinoline-4-yl)methanol and 3-chloro-4-methylisoquinoline-1-amine in a 2:1 ratio.
[0529] Example 131:
[0530] Suzuki coupling and cyclization were achieved by following general procedure 1 using preparations 131A and 1B, resulting in Example 131. MS (ES): m / z = 401.3 [M+H] + HPLC a TRet = 1.24 minutes. 1 H NMR (500MHz, DMSO-d6) δ8.27(d,J=8.2Hz,1H),7.94(d,J=8.2Hz,1H),7.80(d,J=7.8 Hz,1H),7.77-7.71(m,2H),7.65(d,J=7.9Hz,1H),7.55(t,J=7.4Hz,1H),6.74(s,2H) ,5.17(dd,J=13.5,5.2Hz,1H),4.54(d,J=17.5Hz,1H),4.41(d,J=17.1Hz,1H),2.99 -2.90(m,1H),2.67-2.60(m,1H),2.48-2.41(m,1H),2.40(s,3H),2.10-2.02(m,1H).
[0531] Example 132
[0532] 3-[5-(6-amino-3-cyclopropylpyridin-2-yl)-1-oxo-2,3-dihydro-1H-isoindol-2-yl]piperidin-2,6-dione
[0533]
[0534] Preparation 132A: tert-butyl 5-amino-4-(5-(6-amino-3-bromopyridin-2-yl)-1-oxoisoindolin-2-yl)-5-oxovalerate
[0535] Preparation 1B (250 mg, 0.563 mmol) was added to a stirred solution of 5,6-dibromopyridin-2-amine (135 mg, 0.536 mmol) in a mixture of methanol (1 mL) and toluene (10 mL), followed by the addition of aqueous Na₂CO₃ (2.143 mL, 1.072 mmol). The mixture was purged with nitrogen for 5 min and then Pd(PPh₃)₄ (18.58 mg, 0.016 mmol) was added. The reaction mixture was heated to 110 °C for two days. The reaction mixture was cooled to room temperature and diluted with water (20 mL). The mixture was extracted with EtOAc (3 × 10 mL). The combined organic layers were washed with water (2 × 10 mL) and dried over anhydrous Na₂SO₄. The mixture was concentrated under reduced pressure and the crude product was purified by rapid silica gel column chromatography using 2 to 80% B / DCM [where B = 15% EtOH / EtOAc + 0.1% TEA] to give 69 mg of preparation 132A. MS(ES): m / z = 489.1 [M+H] + .
[0536] Example 132:
[0537] Cyclopropylboronic acid (3.95 mg, 0.046 mmol), preparation 132A (15 mg, 0.031 mmol), PdCl2 (dtbpf) (0.599 mg, 0.920 μmol), 1,4-dioxane (1 mL), and K2CO3 aqueous solution (0.092 mL, 0.092 mmol) were added to a 2 mL microwave-safe vial. The vial was sealed and the air was replaced with nitrogen. The reaction mixture was microwaved at 130 °C for 10 min. The reaction mixture was diluted with EtOAc, washed with brine, and the organic layer was separated and concentrated. The crude product was added to a solution of PhSO3H dissolved in MeCN (0.228 M) and microwaved at 120 °C for 10 min. The mixture was concentrated to dryness and purified using preparative HPLC method 1 to obtain Example 132. MS (ES): m / z = 377.0 [M+H] + HPLC a T Ret = 1.05 minutes. 1 H NMR (500MHz, DMSO-d6) δ7.78(d,J=8.5Hz,2H),7.75-7.70(m,1H),7.15(d,J=8.5Hz,1H),6.45(d,J=8.5Hz,1H),5.89-5.78(m,2H),5.16(br dd,J=13.3,5.0Hz,1H),4.53(d,J=1.0Hz,1H),4.41(d,J=1.0Hz,1H),2.99-2.89(m,1H),2.67-2.60(m ,1H),2.47-2.37(m,1H),2.10-2.00(m,1H),1.84-1.77(m,1H),0.79-0.72(m,2H),0.56-0.47(m,2H).
[0538] Example 133
[0539] 3-[5-(6-aminoisoquinolin-1-yl)-1-oxo-2,3-dihydro-1H-isoindol-2-yl]piperidin-2,6-dione
[0540]
[0541] Preparation 1B (44.4 mg, 0.100 mmol), 1-chloroisoquinoline-6-amine (17 mg, 0.095 mmol), PdCl2 (dtbpf) (6.96 mg, 9.52 μmol), and dioxane (1 mL) were added to a vial, followed by an aqueous solution of K2CO3 (0.190 mL, 0.190 mmol). The vial was sealed and the air was replaced with nitrogen. The reaction mixture was microwaved at 125 °C for 11 min. The reaction mixture was diluted with EtOAc, washed with brine, and the organic layer was separated and concentrated. The crude material was aliquoted into two equal samples. One sample of the crude intermediate was suspended in 1 mL of PhSO3H in MeCN (0.228 M), microwaved at 130 °C for 10 min, concentrated to dryness, and the residue was dissolved in 1.8 mL of DMSO and purified using preparative HPLC method 1 to obtain Example 133. MS(ES): m / z = 387.1 [M+H] + HPLC a T Ret = 0.62 minutes. 1 H NMR (500MHz, DMSO-d6) δ11.05(s,1H),8.23(d,J=6.4Hz,1H),8.03-7.95(m,2H),7.86(br d,J=7.6Hz,1H),7.78(br d,J=8.5Hz,2H),7.25-7.18(m,1H),7.00-6.97(m,1H),5.21(dd,J=13.3,5.0Hz,1H),4.62(d,J=1.0Hz,1H ), 4.51 (d, J = 1.0Hz, 1H), 3.00-2.90 (m, 1H), 2.65 (d, J = 1.0Hz, 1H), 2.50-2.37 (m, 1H), 2.13-2.04 (m, 1H).
[0542] The second sample of the crude intermediate was suspended in 1 mL of a solution of PhSO3H in AcOH (0.228 M) and microwaved at 120 °C for 10 min. The sample was concentrated to dryness, and the residue was dissolved in 1.8 mL of DMSO and purified using preparative HPLC method 1 to obtain Example 134.
[0543] Example 134
[0544] N-{1-[2-(2,6-dioxopiridin-3-yl)-1-oxo-2,3-dihydro-1H-isoindol-5-yl]isoquinoline-6-
[0545] Acetamide
[0546]
[0547] This substance was prepared as described in Example 133, see the preparation method above. MS (ES): m / z = 429.2 [M+H] + HPLC a T Ret = 0.98 minutes. 1 H NMR (500MHz, DMSO-d6) δ10.44(s,1H),8.52(d,J=5.8Hz,1H),8.46(s,1H),7.98(d,J=8.9Hz,1H),7.92(d,J=7.8Hz,1H),7.89(s,1H),7.80(s,1H) ,7.79(s,1H),7.65(dd,J=9.3,1.7Hz,1H),5.18(dd,J=13.1,5.2Hz,1H),4.60(d,J=1.0Hz,1H),4.48(d,J=1.0Hz,1H),3.01-2.90(m,1H),2.65(br d,J=17.1Hz,1H),2.50-2.38(m,1H),2.15(s,3H),2.12-2.05(m,1H).
[0548] Example 135
[0549] 3-{5-[6-amino-4-(chloromethyl)pyridin-2-yl]-1-oxo-2,3-dihydro-1H-isoindol-2-yl}piperidine-
[0550] 2,6-Diketone
[0551]
[0552] Preparation 135A: (S)-5-amino-4-(5-(6-amino-4-(hydroxymethyl)pyridin-2-yl)-1-oxoisoindoline-2-yl)-5-oxovalerate tert-butyl ester
[0553] To a 20 mL microwave-safe vial, add (2-amino-6-chloropyridin-4-yl)methanol (211 mg, 1.331 mmol), preparation 1B (739 mg, 1.663 mmol), PdCl2 (dtbpf) (43.4 mg, 0.067 mmol), dioxane (10 mL), and an aqueous solution of K3PO4 (2.218 mL, 6.65 mmol). Seal the vial and purge the air with nitrogen. Heat the reaction mixture in a microwave at 130 °C for 30 min. Dilute the reaction mixture with EtOAc, wash with brine, separate the organic layer, and concentrate. Purify the crude material by elution using a 40 g column at ISCO with 0–100% B / DCM; [where B = 15% EtOH / EtOAc + 0.1% TEA] to give 267 mg of preparation 135A.
[0554] Preparation 135B: (S)-5-amino-4-(5-(6-amino-4-(chloromethyl)pyridin-2-yl)-1-oxoisoindolin-2-yl)-5-oxovalerate tert-butyl ester
[0555] Preparation 135A (140 mg, 0.318 mmol) was dissolved in DCM (15 mL) and cooled in an ice-water bath, followed by dropwise addition of thionyl chloride (0.461 mL, 6.36 mmol). After 5 minutes, the ice bath was removed, and the reaction mixture was warmed to room temperature. After 1 hour, the reaction mixture was concentrated to dryness to give preparation 135B (100% yield).
[0556] Example 135:
[0557] 30 mg of preparation 136B and 1 mL of a 0.228 M solution of PhSO3H in acetonitrile were added to a 2 mL microwave-safe vial. The reaction mixture was heated in a microwave oven at 120 °C for 30 minutes. The reaction mixture was concentrated to dryness, and the residue was purified using preparative HPLC method 1 to obtain Example 135. MS (ES): m / z = 385.0 [M+H] + HPLC a T Ret = 1.02 minutes. 1HNMR(500MHz,DMSO-d6)δ11.02(s,1H),8.20-8.15(m,1H),8.09(br d,J=8.5Hz,1H),7.85(br d,J=7.9Hz,1H),7.27-7.21(m,1H),6.73-6.68(m,1H),5.15-5.09(m,1H),4.72(s,2H),4.59-4.53(m ,1H),4.47-4.40(m,1H),2.95-2.87(m,1H),2.68-2.63(m,1H),2.49-2.37(m,1H),2.09-2.02(m,1H).
[0558] Example 136
[0559] 3-(1-oxo-5-{5H,6H,7H,8H,9H-pyrido[2,3-b]azapyro-2-yl}-2,3-dihydro-1H-isoindol-2-yl)piperidin-2,6-dione
[0560]
[0561] Example 136 was prepared according to General Procedure 1 using commercially available tert-butyl 2-chloro-5,6,7,8-tetrahydro-9H-pyrido[2,3-b]azapyro-9-carboxylate as the aryl halide and preparation 1B. The Boc protecting group was removed during the cyclization step. MS (ES): m / z = 391.0 [M+H] + HPLC a T Ret = 1.10 minutes. 1 H NMR (500MHz, DMSO-d6) δ11.01(s,1H),8.23(s,1H),8.17(br d,J=7.9Hz,1H),7.80(d,J=7.9Hz,1H),7.50(br d,J=7.6Hz,1H),7.33(d,J=7.1Hz,1H),6.02(br s,1H),5.15(br dd,J=13.1,4.9Hz,1H),4.53(d,J=1.0Hz,1H),4.41(d,J=1.0Hz,1H),3.20-3.08(m,2H),2.99-2.89(m, 1H), 2.75-2.69 (m, 2H), 2.64 (d, J = 1.0Hz, 1H), 2.50-2.38 (m, 1H), 2.08-2.02 (m, 1H), 1.80-1.68 (m, 4H).
[0562] Example 137
[0563] 3-[1-oxo-5-(5,6,7,8-tetrahydro-1,8-naphthidin-2-yl)-2,3-dihydro-1H-isoindol-2-yl]piperidin-2,6-
[0564] diketone
[0565]
[0566] Example 137 was prepared according to General Procedure 1 using commercially available tert-butyl 7-chloro-3,4-dihydro-1,8-naphthyl-1(2H)-carboxylate as the aryl halide and preparation 1B. The Boc protecting group was removed during the cyclization step. MS (ES): m / z = 377.2 [M+H] + HPLC a T Ret = 0.97 minutes. 1 H NMR (500MHz, DMSO-d6) δ11.01(s,1H),8.03(s,1H),7.94(d,J=1.0Hz,1H),7.88(d,J=1.0Hz,1H),7.63(d,J=7 .5Hz,1H),7.12(d,J=7.5Hz,1H),5.14-5.06(m,1H),4.55(d,J=17.6Hz,1H),4.43(d,J=17.6Hz,1H),3.43(br t,J=5.3Hz,2H),2.95-2.85(m,J=5007.1Hz,1H),2.79(br t,J=6.1Hz,2H),2.64(br dd,J=15.7,1.7Hz,1H),2.50-2.35(m,1H),2.09-2.01(m,1H),1.90-1.82(m,2H).
[0567] Example 138
[0568] 3-{5-[6-(2,2-dimethylhydrazine-1-yl)pyridin-2-yl]-1-oxo-2,3-dihydro-1H-isoindol-2-yl}piperidin-2,6-dione
[0569]
[0570] Preparation 138A: 2-chloro-6-(2,2-dimethylhydrazyl)pyridine
[0571] 0.3 mL of AcOH was added to a stirred solution of paraformaldehyde (50.0 mg, 1.666 mmol) and 2-chloro-6-hydrazinopyridine-HCl salt (50 mg, 0.278 mmol) in a DCE (10 mL). The reaction mixture was heated to 60 °C for 10 min with stirring. Subsequently, NaBH(OAc)3 (177 mg, 0.833 mmol) was added and the reaction mixture was stirred at room temperature for 1 h. The reaction mixture was diluted with EtOAc, washed with 1 N aqueous KOH solution, dried over MgSO4, and concentrated. The crude material was purified by preparative HPLC method 2 to give 16 mg (34% yield) of preparation 138A. 1 ¹H NMR (400MHz, chloroform-d) δ 7.61 (t, J = 8.1 Hz, 1H), 7.29 (s, 1H), 6.95 (d, J = 8.5 Hz, 1H), 6.84 (d, J = 7.6 Hz, 1H), 3.12–3.07 (m, 6H)
[0572] Example 138:
[0573] Example 138 was prepared according to General Procedure 1 using 2-chloro-6-(2,2-dimethylhydrazine)pyridine as an aryl halide. MS (ES): m / z = 380.3 [M+H] + HPLC a T Ret = 1.05 minutes. 1 H NMR (500MHz, DMSO-d6) δ11.01(s,1H),8.29(s,1H),8.24(br d,J=8.0Hz,1H),7.86-7.78(m,2H),7.49(br d,J=7.2Hz,1H),6.87(d,J=8.3Hz,1H),5.15(br dd,J=13.4,5.1Hz,1H),4.54(d,J=17.2Hz,1H),4.42(d,J=17.1Hz,1H),3.00-2.92(m,1H), 2.68-2.59(m,1H),2.57-2.53(m,6H),2.49-2.39(m,1H),2.09-2.01(m,J=10.9,5.2Hz,1H).
[0574] Example 139
[0575] 3-(5-(1H-imidazo[4,5-b]pyridin-5-yl)-1-oxoisoindolin-2-yl)piperidin-2,6-dione
[0576]
[0577] Add preparation 1B (53.9 mg, 0.121 mmol), 5-bromo-1H-imidazo[4,5-b]pyridine (16 mg, 0.081 mmol), Pd(PPh3)4 (9.34 mg, 8.08 μmol), and NaHCO3 (0.5 M aqueous solution) (0.485 mL, 0.242 mmol) to a vial, followed by dioxane (0.5 mL). Seal the vial, evacuate the gas, and backfill with N2. Microwave the reaction mixture at 130 °C for 15 minutes. Concentrate the reaction mixture, then add 1 mL of benzenesulfonic acid in acetonitrile (1.44 g in 40 mL ACN), and microwave the reaction mixture at 155 °C for 10 minutes. The reaction mixture was concentrated and the crude material was purified by preparative LC / MS under the following conditions: column: XBridge C18, 200 mm × 19 mm, 5 μm particles; mobile phase A: 5:95 acetonitrile:water + ammonium acetate; mobile phase B: 95:5 acetonitrile:water + ammonium acetate; gradient: 0% B for 5 min, 0-22% B for 28 min, followed by 100% B for 0 min; flow rate: 20 mL / min; column temperature: 25 °C. The eluents containing the product were combined and evaporated to dryness by centrifugation. The material was further purified by preparative LC / MS under the following conditions: column: XBridge C18, 200 mm × 19 mm, 5 μm particles; mobile phase A: 5:95 acetonitrile:water + 0.05% trifluoroacetic acid; mobile phase B: 95:5 acetonitrile:water + 0.05% trifluoroacetic acid; gradient: 0 min at 0% B, 28 min at 0-20% B, followed by 0 min at 100% B; flow rate: 20 mL / min; column temperature: 25 °C. The eluents containing the product were combined and dried by centrifugation to obtain Example 139 (0.6 mg, 2%). ESIMS(M+H)+ = 362.2. HPLC peak t r =0.68 minutes (analytical HPLC method 2). Purity = 100%.
[0578] Example 140
[0579] 3-(5-(6-amino-4-methylpyridin-2-yl)-1-oxoisoindolin-2-yl)piperidin-2,6-dione
[0580]
[0581] Add preparation 1B (74.8 mg, 0.168 mmol), 6-chloro-4-methylpyridin-2-amine (16 mg, 0.112 mmol), Pd(PPh3)4 (12.97 mg, 0.011 mmol), and NaHCO3 (0.5 M aqueous solution) (0.673 mL, 0.337 mmol) to a vial, followed by dioxane (0.5 mL). Seal the vial, evacuate the gas, and backfill with N2. Microwave the reaction mixture at 130 °C for 15 minutes. Concentrate the reaction mixture, then add 1 mL of acetonitrile solution of benzenesulfonic acid (1.44 g in 40 mL ACN), and microwave the reaction mixture at 155 °C for 10 minutes. The crude material was purified by preparative LC / MS under the following conditions: column: XBridge C18, 200 mm × 19 mm, 5 μm particles; mobile phase A: 5:95 acetonitrile:water + 0.1% trifluoroacetic acid; mobile phase B: 95:5 acetonitrile:water + 0.1% trifluoroacetic acid; gradient: hold at 0% B for 5 min, 0-18% B for 28 min, followed by hold at 100% B for 0 min; flow rate: 20 mL / min; column temperature: 25 °C. The eluates containing the product were combined and evaporated to dryness by centrifugation. The material was further purified by preparative LC / MS under the following conditions: column: XBridge C18, 200 mm × 19 mm, 5 μm particles; mobile phase A: 5:95 acetonitrile:water + 10 mM ammonium acetate; mobile phase B: 95:5 acetonitrile:water + 10 mM ammonium acetate; gradient: 0 min at 0% B, 25 min at 0-30% B, followed by 0 min at 100% B; flow rate: 20 mL / min; column temperature: 25 °C. The eluates containing the product were combined and evaporated to dryness by centrifugation to obtain Example 140 (0.9 mg, 2%). ESIMS (M+H) + =351.3. HPLC peak t r =1.04 minutes (analytical HPLC method 2). Purity = 100%.
[0582] Example 141
[0583] 3-(5-(3,4-dihydro-2H-pyrido[3,2-b][1,4]oxazine-6-yl)-1-oxoisoindoline-2-yl)piperidine-
[0584] 2,6-Diketone
[0585]
[0586] Add preparation 1B (62.5 mg, 0.141 mmol), 6-chloro-3,4-dihydro-2H-pyrido[3,2-b][1,4]oxazine (16 mg, 0.094 mmol), Pd(PPh3)4 (10.84 mg, 9.38 μmol), and NaHCO3 (0.5 M aqueous solution) (0.563 mL, 0.281 mmol) to a vial, followed by dioxane (0.5 mL). Seal the vial, evacuate the gas, and backfill with N2. Microwave the reaction mixture at 130 °C for 15 min. Extract the reaction mixture with EtOAc (2×). Combine the organic phases, concentrate, and then dissolve in AcOH (0.5 mL) with benzenesulfonic acid (14.83 mg, 0.094 mmol). Seal the reaction mixture and microwave at 155 °C for 10 min. The reaction mixture was concentrated and the crude material was purified by preparative LC / MS under the following conditions: column: XBridge C18, 200 mm × 19 mm, 5 μm particles; mobile phase A: 5:95 acetonitrile:water + ammonium acetate; mobile phase B: 95:5 acetonitrile:water + ammonium acetate; gradient: 0 min at 6% B, 20 min at 6-46% B, followed by 0 min at 100% B; flow rate: 20 mL / min; column temperature: 25 °C. The eluates containing the product were combined and evaporated to dryness by centrifugation to give Example 141 (2.1 mg, 6%). ESIMS (M+H) + =379.3. HPLC peak t r =1.28 minutes (analytical HPLC method 2). Purity = 99%.
[0587] Example 142
[0588] 3-(5-(6-aminopyrazin-2-yl)-1-oxoisoindololin-2-yl)piperidine-2,6-dione
[0589]
[0590] Add preparation 1B (53.1 mg, 0.120 mmol), 6-bromopyrazin-2-amine (16 mg, 0.092 mmol), Pd(PPh3)4 (10.63 mg, 9.20 μmol), and NaHCO3 (0.5 M aqueous solution) (0.552 mL, 0.276 mmol) to a vial, followed by dioxane (0.5 mL). Seal the vial, evacuate the gas, and backfill with N2. Microwave the reaction mixture at 130 °C for 15 min. Extract the reaction mixture with EtOAc (2×). Combine the organic phases, concentrate, and dry under high vacuum, then dissolve in AcOH (0.5 mL) and add benzenesulfonic acid (14.54 mg, 0.092 mmol). Seal the reaction mixture and microwave at 155 °C for 10 min. The reaction mixture was concentrated and the crude material was purified by preparative LC / MS under the following conditions: column: XBridge C18, 200 mm × 19 mm, 5 μm particles; mobile phase A: 5:95 acetonitrile:water + ammonium acetate; mobile phase B: 95:5 acetonitrile:water + ammonium acetate; gradient: 0 min at 0% B, 23 min at 0-55% B, followed by 0 min at 100% B; flow rate: 20 mL / min; column temperature: 25 °C. The eluent was collected by MS signal trigger. The eluents containing product were combined and evaporated to dryness by centrifugation. The material was further purified by preparative LC / MS under the following conditions: column: XBridge C18, 200 mm × 19 mm, 5 μm particles; mobile phase A: 5:95 acetonitrile:water + 0.1% trifluoroacetic acid; mobile phase B: 95:5 acetonitrile:water + 0.1% trifluoroacetic acid; gradient: 0 min at 0% B, 25 min at 0-30% B, followed by 0 min at 100% B; flow rate: 20 mL / min; column temperature: 25 °C. The eluates containing the product were combined and evaporated to dryness by centrifugation to obtain Example 142 (1.7 mg, 5%). ESIMS (M+H) + =338.2. HPLC peak t r =0.98 minutes (analytical HPLC method 2). Purity = 97%.
[0591] Example 143
[0592] 3-(5-(2-amino-6-methylpyrimidin-4-yl)-1-oxoisoindoline-2-yl)piperidin-2,6-dione
[0593]
[0594] Add preparation 1B (61.4 mg, 0.138 mmol), 4-bromo-6-methylpyrimidin-2-amine (20 mg, 0.106 mmol), Pd(PPh3)4 (12.29 mg, 10.64 μmol), and NaHCO3 (0.5 M aqueous solution) (0.638 mL, 0.319 mmol) to a vial, followed by dioxane (0.5 mL). Seal the vial, evacuate the gas, and backfill with N2. Microwave the reaction mixture at 130 °C for 15 min. Extract the reaction mixture with EtOAc (2×). Combine the organic phases, concentrate, and dry under high vacuum, then dissolve in AcOH (0.5 mL) and add benzenesulfonic acid (16.82 mg, 0.106 mmol). Seal the reaction mixture and microwave at 155 °C for 10 min. The reaction mixture was concentrated and the crude material was purified by preparative LC / MS under the following conditions: column: XBridge C18, 200 mm × 19 mm, 5 μm particles; mobile phase A: 5:95 acetonitrile:water + ammonium acetate; mobile phase B: 95:5 acetonitrile:water + ammonium acetate; gradient: 0 min at 0% B, 20 min at 0-40% B, followed by 0 min at 100% B; flow rate: 20 mL / min; column temperature: 25 °C. The eluent was collected by MS signal triggering. The eluents containing product were combined and evaporated to dryness by centrifugation. The material was further purified by preparative LC / MS under the following conditions: column: XBridge C18, 200 mm × 19 mm, 5 μm particles; mobile phase A: 5:95 acetonitrile:water + 0.05% trifluoroacetic acid; mobile phase B: 95:5 acetonitrile:water + 0.05% trifluoroacetic acid; gradient: hold at 0% B for 5 min, 0-28% B for 28 min, followed by hold at 100% B for 0 min; flow rate: 20 mL / min; column temperature: 25 °C. The eluates containing the product were combined and evaporated to dryness by centrifugation to obtain Example 143 (4.5 mg, 12%). ESIMS (M+H) + =352.1. HPLC peak t r =1.06 minutes (analytical HPLC method 2). Purity = 100%.
[0595] Example 144
[0596] 3-(5-(4,6-dimethylpyridin-2-yl)-1-oxoisoindoline-2-yl)piperidin-2,6-dione
[0597]
[0598] Add preparation 1B (75 mg, 0.169 mmol), 2-bromo-4,6-dimethylpyridine (0.021 mL, 0.161 mmol), Pd(PPh3)4 (18.63 mg, 0.016 mmol), and NaHCO3 (0.5 M aqueous solution) (0.967 mL, 0.484 mmol) to a vial, followed by dioxane (0.5 mL). Seal the vial, evacuate the gas, and backfill with N2. Microwave the reaction mixture at 130 °C for 15 min. Extract the reaction mixture with EtOAc (2×). Combine the organic phases, concentrate, and dry under high vacuum, then dissolve in AcOH (0.5 mL) and add benzenesulfonic acid (25.5 mg, 0.161 mmol). Seal the reaction mixture and microwave at 155 °C for 10 min. The reaction mixture was concentrated and the crude material was purified by preparative LC / MS under the following conditions: column: XBridge C18, 200 mm × 19 mm, 5 μm particles; mobile phase A: 5:95 acetonitrile:water + ammonium acetate; mobile phase B: 95:5 acetonitrile:water + ammonium acetate; gradient: 0 min at 11% B, 20 min at 11-51% B, followed by 0 min at 100% B; flow rate: 20 mL / min; column temperature: 25 °C. The eluates containing the product were combined and evaporated to dryness by centrifugation to give Example 144 (4.8 mg, 9%). ESIMS (M+H) + =350.2. HPLC peak t r = 1.43 minutes (analytical HPLC method 2). Purity = 100%.
[0599] Example 145
[0600] 3-(5-(5-chloro-3-hydroxyisoquinolin-1-yl)-1-oxoisoindololin-2-yl)piperidine-2,6-dione
[0601]
[0602] Add preparation 1B (45.7 mg, 0.103 mmol), 1,5-dichloroisoquinoline-3-ol (20 mg, 0.093 mmol), Pd(PPh3)4 (10.80 mg, 9.34 μmol), and NaHCO3 (0.5 M aqueous solution) (0.561 mL, 0.280 mmol) to a vial, followed by dioxane (0.5 mL). Seal the vial, evacuate the gas, and backfill with N2. Microwave the reaction mixture at 130 °C for 15 min. Extract the reaction mixture with EtOAc (2×). Combine the organic phases, concentrate, and dry under high vacuum, then dissolve in AcOH (0.5 mL) and add benzenesulfonic acid (16.26 mg, 0.103 mmol). Seal the reaction mixture and microwave at 155 °C for 10 min. The reaction mixture was concentrated and the crude material was purified by preparative LC / MS under the following conditions: column: XBridge C18, 200 mm × 19 mm, 5 μm particles; mobile phase A: 5:95 acetonitrile:water + 0.05% trifluoroacetic acid; mobile phase B: 95:5 acetonitrile:water + 0.05% trifluoroacetic acid; gradient: 0 min at 10% B, 27 min at 10-55% B, followed by 0 min at 100% B; flow rate: 20 mL / min; column temperature: 25 °C. The eluent was collected by MS signal triggering. The eluents containing the product were combined and evaporated to dryness by centrifugation to give Example 145 (5.6 mg, 14%). ESIMS (M+H) + =422.2. HPLC peak t r =1.43 minutes. Purity = 98%. (Analytical HPLC Method 2)
[0603] Example 146
[0604] 3-(5-(6-methoxy-4-methylpyridin-2-yl)-1-oxoisoindoline-2-yl)piperidin-2,6-dione
[0605]
[0606] Add preparation 1B (62.0 mg, 0.140 mmol), 2-chloro-6-methoxy-4-methylpyridine (0.017 mL, 0.127 mmol), Pd(PPh3)4 (14.67 mg, 0.013 mmol), and NaHCO3 (0.5 M aqueous solution) (0.761 mL, 0.381 mmol) to a vial, followed by dioxane (0.5 mL). Seal the vial, evacuate the gas, and backfill with N2. Microwave the reaction mixture at 130 °C for 15 min. Extract the reaction mixture with EtOAc (2×). Combine the organic phases, concentrate, and dry under high vacuum, then dissolve in AcOH (0.5 mL) and add benzenesulfonic acid (22.08 mg, 0.140 mmol). Seal the reaction mixture and microwave at 155 °C for 10 min. The reaction mixture was concentrated and the crude material was purified by preparative LC / MS under the following conditions: column: XBridge C18, 200 mm × 19 mm, 5 μm particles; mobile phase A: 5:95 acetonitrile:water + ammonium acetate; mobile phase B: 95:5 acetonitrile:water + ammonium acetate; gradient: 0 min at 18% B, 25 min at 18-58% B, followed by 0 min at 100% B; flow rate: 20 mL / min; column temperature: 25 °C. The eluent was collected by MS and UV signal triggering. The eluents containing product were combined and evaporated to dryness by centrifugation. The material was further purified by preparative LC / MS under the following conditions: column: XBridge C18, 200 mm × 19 mm, 5 μm particles; mobile phase A: 5:95 acetonitrile:water + 0.05% trifluoroacetic acid; mobile phase B: 95:5 acetonitrile:water + 0.05% trifluoroacetic acid; gradient: 0 min at 16% B, 25 min at 16-56% B, followed by 0 min at 100% B; flow rate: 20 mL / min; column temperature: 25 °C. The eluates containing the product were combined and evaporated to dryness by centrifugation to give Example 146 (4.9 mg, 10%). ESIMS (M+H) + =366.2. HPLC peak t r =1.61 minutes. Purity = 99%. (Analytical HPLC method 2).
[0607] Example 147
[0608] 3-(5-(6-hydroxy-4-methylpyridin-2-yl)-1-oxoisoindoline-2-yl)piperidin-2,6-dione
[0609]
[0610] Trimethylchlorosilane (31.7 μL, 0.248 mmol) was added to a suspension of Example 145 and sodium iodide (37.2 mg, 0.248 mmol) in MeCN (827 μL) under a nitrogen atmosphere. The resulting mixture was heated overnight at 80 °C. The solvent was evaporated, and the crude material was purified by preparative LC / MS under the following conditions: column: XBridge C18, 200 mm × 19 mm, 5 μm particles; mobile phase A: 5:95 acetonitrile:water + ammonium acetate; mobile phase B: 95:5 acetonitrile:water + ammonium acetate; gradient: 0 min at 0% B, 20 min at 0-40% B, followed by 0 min at 100% B; flow rate: 20 mL / min; column temperature: 25 °C. The eluent was collected by MS signal trigger. The eluents containing the product were combined and evaporated to dryness by centrifugation to obtain Example 147 (3.6 mg, 24%). ESIMS (M+H) + =352.2. HPLC peak t r =1.05 minutes. Purity = 95%. (Analytical HPLC Method 2)
[0611] Example 148
[0612] 2-Amino-6-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)-4-methylnicotinonitrile
[0613]
[0614] Add preparation 1B (58.3 mg, 0.131 mmol), 2-amino-6-chloro-4-methylnicotinonitrile (20 mg, 0.119 mmol), Pd(PPh3)4 (13.79 mg, 0.012 mmol), and NaHCO3 (0.5 M aqueous solution) (0.716 mL, 0.358 mmol) to a vial, followed by dioxane (0.5 mL). Seal the vial, evacuate the gas, and backfill with N2. Microwave the reaction mixture at 130 °C for 15 min. Extract the reaction mixture with EtOAc (2×). Combine the organic phases, concentrate, and dry under high vacuum, then dissolve in AcOH (0.5 mL) and add benzenesulfonic acid (20.76 mg, 0.131 mmol). Seal the reaction mixture and microwave at 155 °C for 10 min. The reaction mixture was concentrated and the crude material was purified by preparative LC / MS under the following conditions: column: XBridge C18, 200 mm × 19 mm, 5 μm particles; mobile phase A: 5:95 acetonitrile:water + ammonium acetate; mobile phase B: 95:5 acetonitrile:water + ammonium acetate; gradient: 0 min at 5% B, 25 min at 5-45% B, followed by 0 min at 100% B; flow rate: 20 mL / min; column temperature: 25 °C. The eluent was collected by MS signal trigger. The eluents containing the product were combined and evaporated to dryness by centrifugation to give Example 148 (3.7 mg, 8%). ESIMS (M+H) + =376.2. HPLC peak t r =1.25 minutes. Purity = 97%. (Analytical HPLC method 2).
[0615] Example 149
[0616] 2-Amino-6-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindoline-5-yl)isonicotinonitrile
[0617]
[0618] Add preparation 1B (37.0 mg, 0.083 mmol), 2-amino-6-bromoisocyanate (15 mg, 0.076 mmol), Pd(PPh3)4 (8.75 mg, 7.57 μmol), and NaHCO3 (0.5 M aqueous solution) (0.454 mL, 0.227 mmol) to a vial, followed by dioxane (0.5 mL). Seal the vial, evacuate the gas, and backfill with N2. Microwave the reaction mixture at 130 °C for 15 min. Extract the reaction mixture with EtOAc (2×). Combine the organic phases, concentrate, and dry under high vacuum, then dissolve in AcOH (0.5 mL) and add benzenesulfonic acid (13.18 mg, 0.083 mmol). Seal the reaction mixture and microwave at 155 °C for 10 min. The reaction mixture was concentrated and the crude material was purified by preparative LC / MS under the following conditions: column: XBridge C18, 200 mm × 19 mm, 5 μm particles; mobile phase A: 5:95 acetonitrile:water + ammonium acetate; mobile phase B: 95:5 acetonitrile:water + ammonium acetate; gradient: 0% B for 3 min, 0-37% B for 20 min, followed by 100% B for 0 min; flow rate: 20 mL / min; column temperature: 25 °C. The eluent was collected by MS signal trigger. The eluents containing the product were combined and evaporated to dryness by centrifugation to give Example 149 (0.3 mg, 1%). ESIMS (M+H) + =362.3. HPLC peak t r =1.20 minutes. Purity = 98%. (Analytical HPLC method 2).
[0619] Example 150
[0620] 3-(5-(1-amino-5,6,7,8-tetrahydroisoquinoline-3-yl)-1-oxoisoindololin-2-yl)piperidine-2,6-dione
[0621]
[0622] Preparation 150A.2-(5,6,7,8-tetrahydroisoquinolin-1-yl)isoindoline-1,3-dione
[0623] A solution of 5,6,7,8-tetrahydroisoquinoline-1-amine (150 mg, 1.012 mmol) and isobenzofuran-1,3-dione (150 mg, 1.012 mmol) in AcOH (50-60 μL) was heated overnight at 90 °C. The reaction was quenched with a saturated aqueous solution. The reaction mixture was diluted with EtOAc. The layers were separated. The aqueous phase was extracted with EtOAc (3×). The organic phases were combined, dried over Na2SO4, filtered, and concentrated to give a yellow residue. The crude material was dissolved in a minimal amount of CH2Cl2 and chromatographically analyzed. The chromatography was performed using an ISCO silica gel press (40 g column, 40 mL / min, 0-100% EtOAc / hexane for 14 min, t). r Purification was carried out over 11 minutes to give preparation 150A (23.4 mg, 0.084 mmol, 8.31% yield) as a white solid. ESIMS(M+H) + =279.3.
[0624] Preparation 150B.2-Oxy-1-(1,3-dioxoisoindoline-2-yl)-5,6,7,8-tetrahydroisoquinoline
[0625] To a solution of preparation 150A (23.4 mg, 0.084 mmol) in CH₂Cl₂ (420 μL), add m-CPBA (29.0 mg, 0.168 mmol). Stir the reaction mixture overnight at room temperature. Then add m-CPBA (29.0 mg, 0.168 mmol) and DCM (1 mL). Stir the reaction mixture overnight at room temperature. Quench the reaction with a saturated aqueous solution of Na₂S₂O₃. Dilute the reaction mixture with CH₂Cl₂. Separate the layers. Extract the aqueous phase with CH₂Cl₂ (3×). Dry the combined organic phases with Na₂SO₄, filter, and concentrate to give preparation 150B (25 mg, 100%) as a grayish-white solid. ESIMS(M+H) + =295.1.
[0626] Preparation 150C. 2-(3-chloro-5,6,7,8-tetrahydroisoquinolin-1-yl)isoindoline-1,3-dione
[0627] Et3N (18.66 μL, 0.134 mmol) was added to a solution of preparation 150B (37.3 mg, 0.134 mmol) in POCl3 (1722 μL, 18.47 mmol). The reaction mixture was heated at 80 °C for 2 hours, then cooled to room temperature. The reaction mixture was carefully poured into an ice-cold solution of saturated aqueous NaHCO3 solution, followed by extraction with EtOAc (3×). The organic phases were combined, dried over Na2SO4, and filtered. The crude material was dissolved in a minimal amount of CH2Cl2 and chromatographically analyzed. The chromatography was performed using an ISCO silica gel chromatography system (12 g column, 30 mL / min, 0-100% EtOAc / hexane for 14 min, t...). r Purification was carried out over 9 minutes to obtain a white, membrane-like preparation at 150°C (3.8 mg, 10.94 μmol, 8.17% yield). ESIMS(M+H) + =313.2.
[0628] Preparation 150D. 3-Chloro-5,6,7,8-Tetrahydroisoquinoline-1-amine
[0629] Triethylamine (16.42 μL, 0.118 mmol) was added to a solution of preparation 150C (33.5 mg, 0.107 mmol) in EtOH (536 μL), followed by the addition of hydrazine (3.70 μL, 0.118 mmol). The reaction mixture was stirred at room temperature. The reaction mixture was diluted with water and extracted with EtOAc (3×). The organic phases were combined, dried over Na2SO4, and filtered. The crude material was dissolved in a minimal amount of CH2Cl2 and chromatographically analyzed. The chromatography was performed using an ISCO silica gel chromatography system (12 g column, 30 mL / min, 0-100% EtOAc / hexane for 15 min, t). r Purification was carried out over 9 minutes to give a white solid, 150D (9.7 mg, 0.050 mmol, 47.1% yield). ESIMS(M+H) + =183.1.
[0630] Example 152:
[0631] The preparation 150D (26.0 mg, 0.058 mmol), 3-chloro-5,6,7,8-tetrahydroisoquinoline-1-amine (9.7 mg, 0.053 mmol), Pd(PPh3)4 (6.14 mg, 5.31 μmol), and NaHCO3 (0.5 M aqueous solution) (0.319 mL, 0.159 mmol) were added to a vial, followed by dioxane (0.5 mL). The vial was sealed, evacuated, and backfilled with N2. The reaction mixture was microwaved at 130 °C for 15 min. The reaction mixture was extracted with EtOAc (2×). The organic phases were combined, concentrated, and dried under high vacuum, then dissolved in AcOH (0.5 mL) and benzenesulfonic acid (9.24 mg, 0.058 mmol) was added. The reaction vial was sealed and microwaved at 155 °C for 10 min. The reaction mixture was concentrated and the crude material was purified by preparative LC / MS under the following conditions: column: XBridge C18, 200 mm × 19 mm, 5 μm particles; mobile phase A: 5:95 acetonitrile:water + 0.05% trifluoroacetic acid; mobile phase B: 95:5 acetonitrile:water + 0.05% trifluoroacetic acid; gradient: 0 min at 0% B, 20 min at 0-50% B, followed by 0 min at 100% B; flow rate: 20 mL / min; column temperature: 25 °C. The eluates containing the product were combined and evaporated to dryness by centrifugation to obtain Example 150 (1.3 mg, 6%). ESIMS (M+H) + =391.3. HPLC peak t r =1.50 minutes. Purity = 100%. (Analytical HPLC method 2).
[0632] Example 151
[0633] 3-(5-(6-amino-4,5-dimethylpyridin-2-yl)-1-oxoisoindoline-2-yl)piperidin-2,6-dione
[0634]
[0635] Preparation 151A. 2-(3,4-dimethylpyridin-2-yl)isoindoline-1,3-dione
[0636] A solution of 3,4-dimethylpyridin-2-amine (150 mg, 1.228 mmol) and isobenzofuran-1,3-dione (182 mg, 1.228 mmol) in AcOH (6139 μL) was heated overnight at 90 °C. The reaction was quenched with a saturated aqueous solution of NaHCO3. The reaction mixture was diluted with EtOAc. The layers were separated. The aqueous phase was extracted with EtOAc (3×). The organic phases were combined, dried over Na2SO4, filtered, and concentrated to give a yellow residue. The crude material was dissolved in a minimal amount of CH2Cl2 and chromatographically analyzed. The chromatography was performed using an ISCO instrument (40 g column, 40 mL / min, 0-100% EtOAc / hexane for 21 min, t r Purification was carried out over 11 minutes to give preparation 153A (63.8 mg, 0.253 mmol, 20.60% yield) as a white solid. ESIMS(M+H) + =253.2.
[0637] Preparation 151B.1-Oxy-2-(1,3-dioxoisoindoline-2-yl)-3,4-dimethylpyridine
[0638] m-CPBA (87 mg, 0.506 mmol) was added to a solution of preparation 151A (63.8 mg, 0.253 mmol) in CH2Cl2 (1265 μL). The reaction mixture was stirred overnight at room temperature. The reaction was quenched with a saturated aqueous solution of Na2S2O3. The reaction mixture was diluted with CH2Cl2. The layers were separated. The aqueous phase was extracted with CH2Cl2 (3×). The combined organic phases were dried over Na2SO4, filtered, and concentrated to give preparation 151B (68 mg, 100%) as a grayish-white solid. ESIMS(M+H) + =269.3.
[0639] Preparation 151C.2-(6-chloro-3,4-dimethylpyridin-2-yl)isoindoline-1,3-dione
[0640] TEA (35.2 μL, 0.253 mmol) was added to a solution of preparation 151B (67.8 mg, 0.253 mmol) in POCl3 (3251 μL, 34.9 mmol). The reaction mixture was heated at 80 °C for 2 hours, then cooled to room temperature. The reaction mixture was carefully poured into an ice-cold solution of saturated aqueous NaHCO3, followed by extraction with EtOAc (3×). The organic phases were combined, dried over Na2SO4, and filtered. The crude material was dissolved in a minimal amount of CH2Cl2 and chromatographically analyzed. The chromatography was performed using an ISCO silica gel chromatography system (24 g column, 35 mL / min, 0-100% EtOAc / hexane for 15 min, t...). rPurification was carried out over 9 minutes to give a white solid, 151C (31 mg, 0.108 mmol, 42.8% yield). ESIMS(M+H) + =287.1.
[0641] Preparation 151D. 6-Chloro-3,4-dimethylpyridin-2-amine
[0642] Triethylamine (16.58 μL, 0.119 mmol) was added to a solution of 151C (31 mg, 0.108 mmol) in EtOH (541 μL), followed by hydrazine (3.73 μL, 0.119 mmol). The reaction mixture was stirred at room temperature for 2 hours. The reaction mixture was diluted with water and extracted with EtOAc (3×). The organic phases were combined, dried over Na2SO4, and filtered. The crude material was dissolved in a minimal amount of CH2Cl2 and chromatographically analyzed. The chromatography was performed using an ISCO silica gel chromatography system (12 g column, 30 mL / min, 0-100% EtOAc / hexane for 14 min, t). r Purification was carried out over 9.5 minutes to give a white solid, 151D (5.8 mg, 0.035 mmol, 32.5% yield). ESIMS(M+H) + =156.9.
[0643] Example 151:
[0644] To a vial, add tert-butyl 5-amino-5-oxo-4-(1-oxo-5-(4,4,5,5-tetramethyl-1,3,2-dioxapentylborane-2-yl)isoindolin-2-yl)valerate (61.8 mg, 0.139 mmol), preparation 151D (21.8 mg, 0.139 mmol), Pd(PPh3)4 (161 mg, 0.139 mmol), and NaHCO3 (0.5 M aqueous solution) (0.835 mL, 0.418 mmol), followed by dioxane (0.5 mL). Seal the vial, evacuate the gas, and backfill with N2. Microwave the reaction mixture at 130 °C for 15 min. Extract the reaction mixture with EtOAc (2×). The organic phases were combined, concentrated, and dried under high vacuum. They were then dissolved in AcOH (0.5 mL) and benzenesulfonic acid (22.02 mg, 0.139 mmol) was added. The reaction vials were sealed and heated in a microwave at 155 °C for 10 min. The reaction mixture was concentrated, and the crude material was purified by preparative LC / MS under the following conditions: column: XBridge C18, 200 mm × 19 mm, 5 μm particles; mobile phase A: 5:95 acetonitrile:water + ammonium acetate; mobile phase B: 95:5 acetonitrile:water + ammonium acetate; gradient: 8% B for 2 min, 8-48% B for 20 min, followed by 100% B for 0 min; flow rate: 20 mL / min; column temperature: 25 °C. The eluates containing the product were combined and dried by centrifugation to give Example 151 (2.2 mg, 4%). ESIMS (M+H) + =365.2. HPLC peak t r =1.35 minutes. Purity = 100%. (Analytical HPLC Method 2)
[0645] Example 152
[0646] 6-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindoline-5-yl)-4-methylnicotinonitrile
[0647]
[0648] Add preparation 1B (96 mg, 0.216 mmol), 6-chloro-4-methylnicotinonitrile (30 mg, 0.197 mmol), Pd(PPh3)4 (22.72 mg, 0.020 mmol), and NaHCO3 (0.5 M aqueous solution) (1.180 mL, 0.590 mmol) to a vial, followed by dioxane (0.5 mL). Seal the vial, evacuate the gas, and backfill with N2. Microwave the reaction mixture at 130 °C for 15 min. Extract the reaction mixture with EtOAc (2×). Combine the organic phases, concentrate, and dry under high vacuum, then dissolve in AcOH (0.5 mL) and add benzenesulfonic acid (34.2 mg, 0.216 mmol). Seal the reaction vial and microwave at 155 °C for 10 min. The reaction mixture was concentrated and the crude material was purified by preparative LC / MS under the following conditions: column: XBridge C18, 200 mm × 19 mm, 5 μm particles; mobile phase A: 5:95 acetonitrile:water + ammonium acetate; mobile phase B: 95:5 acetonitrile:water + ammonium acetate; gradient: 0 min at 8% B, 20 min at 8-48% B, followed by 0 min at 100% B; flow rate: 20 mL / min; column temperature: 25 °C. The eluates containing the product were combined and evaporated to dryness by centrifugation to give Example 154 (7.3 mg, 10%). ESIMS (M+H) + =361.2. HPLC peak t r =1.28 minutes. Purity = 96%. (Analytical HPLC Method 2)
[0649] Example 153
[0650] 3-(5-(6-amino-5-methoxy-4-methylpyridin-2-yl)-1-oxoisoindolin-2-yl)piperidin-2,6-dione
[0651]
[0652] Preparation 153A. 2-(3-methoxy-4-methylpyridin-2-yl)isoindoline-1,3-dione
[0653] A solution of 3-methoxy-4-methylpyridin-2-amine (350 mg, 2.53 mmol) and isobenzofuran-1,3-dione (375 mg, 2.53 mmol) in AcOH (5.730 mL) was heated overnight at 90 °C. The reaction was quenched with a saturated aqueous solution of NaHCO3. The reaction mixture was diluted with EtOAc. The layers were separated. The aqueous phase was extracted with EtOAc (3×). The organic phases were combined, dried over Na2SO4, filtered, and concentrated to give a yellow residue. The crude material was dissolved in a minimal amount of CH2Cl2 and chromatographically analyzed. The chromatography was performed using an ISCO silica gel press (40 g column, 40 mL / min, 0-100% EtOAc / hexane for 22 min, t r Purification was carried out over 12 minutes to give preparation 153A (243 mg, 0.861 mmol, 34.0% yield) as a white solid. ESIMS(M+H) + =269.4.
[0654] Preparation 153B. 1-Oxy-2-(1,3-dioxoisoindoline-2-yl)-3-methoxy-4-methylpyridine
[0655] m-CPBA (313 mg, 1.812 mmol) was added to a solution of preparation 153A (243 mg, 0.906 mmol) in CH2Cl2 (4529 μL). The reaction mixture was stirred overnight at room temperature. The reaction was quenched with a saturated aqueous solution of Na2S2O3. The reaction mixture was diluted with CH2Cl2. The layers were separated. The aqueous phase was extracted with CH2Cl2 (3×). The combined organic phases were dried over Na2SO4, filtered, and concentrated to give preparation 153B (257 mg, 100%) as a grayish-white solid. ESIMS(M+H) + =285.3.
[0656] Preparation 153C.2-(6-chloro-3-methoxy-4-methylpyridin-2-yl)isoindoline-1,3-dione
[0657] TEA (0.126 mL, 0.904 mmol) was added to a solution of preparation 153B (243 mg, 0.904 mmol) in POCl3 (11.628 mL, 125 mmol). The reaction mixture was heated at 80 °C for 2 hours, then cooled to room temperature. The reaction mixture was carefully poured into an ice-cold solution of saturated aqueous NaHCO3, followed by extraction with EtOAc (3×). The organic phases were combined, dried over Na2SO4, and filtered. The crude material was dissolved in a minimal amount of CH2Cl2 and chromatographically analyzed. The chromatography was performed using an ISCO silica gel chromatography system (40 g column, 40 mL / min, 0-100% EtOAc / hexane for 15 min, t).r Purification was carried out over 9 minutes to obtain a white solid, 153C (217 mg, 0.717 mmol, 79% yield). ESIMS(M+H) + =303.1.
[0658] Preparation 153D. 6-Chloro-3-methoxy-4-methylpyridine-2-amine
[0659] Triethylamine (110 μL, 0.789 mmol) was added to a solution of 153C (217 mg, 0.717 mmol) in EtOH (3584 μL), followed by the addition of hydrazine (24.75 μL, 0.789 mmol). The reaction mixture was stirred at room temperature for 2 hours. The reaction mixture was diluted with water and extracted with EtOAc (3×). The organic phases were combined, dried over Na2SO4, and filtered. The crude material was dissolved in a minimal amount of CH2Cl2 and chromatographically analyzed. The chromatography was performed using an ISCO silica gel chromatography system (40 g column, 40 mL / min, 0-100% EtOAc / hexane for 15 min, t). r Purification was carried out over 9.5 minutes to give a white solid, 153D (85.1 mg, 0.493 mmol, 68.8% yield). ESIMS(M+H) + =173.0.
[0660] Example 153:
[0661] Add preparation 1B (122 mg, 0.274 mmol), preparation 153D (43 mg, 0.249 mmol), Pd(PPh3)4 (28.8 mg, 0.025 mmol), and NaHCO3 (0.5 M aqueous solution) (1495 μL, 0.747 mmol) to a vial, followed by dioxane (1246 μL). Seal the vial, evacuate the gas, and backfill with N2. Microwave the reaction mixture at 130 °C for 15 min. Extract the reaction mixture with EtOAc (3×). Combine the organic phases, dry over Na2SO4, filter, and concentrate to obtain an orange residue, which is further dried under high vacuum. Dissolve the crude material in 1.6 mL AcOH and add benzenesulfonic acid (43.3 mg, 0.274 mmol). Seal the reaction vial and microwave at 155 °C for 10 min. The solvent was evaporated, and the crude material was purified by preparative LC / MS under the following conditions: column: XBridge C18, 200 mm × 19 mm, 5 μm particles; mobile phase A: 5:95 acetonitrile:water + ammonium acetate; mobile phase B: 95:5 acetonitrile:water + ammonium acetate; gradient: 0 min at 7% B, 30 min at 7-43% B, followed by 0 min at 100% B; flow rate: 20 mL / min; column temperature: 25 °C. The eluates containing the product were combined and evaporated to dryness by centrifugation to obtain Example 153 (4.9 mg, 5%). ESIMS (M+H) + =381.2. HPLC peak t r =1.22 minutes. Purity = 100%. (Analytical HPLC method 2).
[0662] Example 154
[0663] 3-(5-(6-amino-5-methoxy-4-methylpyridin-2-yl)-1-oxoisoindolin-2-yl)piperidin-2,6-dione
[0664]
[0665] Preparation 154A. 2-Chloro-4-(chloromethyl)pyridine
[0666] A solution of (2-chloropyridin-4-yl)methanol (0.100 g, 0.697 mmol), methanesulfonyl chloride (0.109 mL, 1.393 mmol), and triethylamine (0.204 mL, 1.463 mmol) in DMF (1.393 mL) was stirred at room temperature for 1.5 hours. The solution became turbid and a solid precipitated. The reaction was quenched with water. The reaction mixture was diluted with EtOAc. The layers were separated. The aqueous phase was extracted with EtOAc (2×). The organic phases were combined, dried over Na2SO4, filtered, and concentrated to obtain the residue. The crude material was dissolved in a minimal amount of CH2Cl2 and chromatographically analyzed. Silica gel chromatography was performed using an ISCO machine (24 g column, 35 mL / min, 0-100% EtOAc / hexane for 15 minutes, t). r Purification was carried out over 8 minutes to obtain a colorless liquid preparation 154A (65.6 mg, 0.405 mmol, 58.1% yield). ESIMS(M+H) + =161.9.
[0667] Preparation 154B. 4-((benzyloxy)methyl)-2-chloropyridine
[0668] NaH (39.4 mg, 0.985 mmol) was added to a solution of phenylmethanol (100 μL, 0.966 mmol) in DMF (966 μL). The reaction mixture was stirred at room temperature for 15 min, followed by the addition of preparation 156A (31.3 mg, 0.193 mmol). After 2 h, the reaction was quenched with water. The reaction mixture was diluted with EtOAc. The layers were separated. The aqueous phase was extracted with EtOAc (2×). The organic phases were combined, dried over Na2SO4, filtered, and concentrated to obtain the residue. The crude material was dissolved in a minimal amount of CH2Cl2 and chromatographically analyzed. The chromatography was performed using an ISCO instrument (12 g column, 30 mL / min, 0-100% EtOAc / hexane for 19 min, t) using silica gel chromatography. r Purification was performed over 8.5 minutes to give preparation 154B (26.3 mg, 0.113 mmol, 58.3% yield). ESI MS (M+H) + =234.4.
[0669] Example 154:
[0670] A vial was filled with tert-butyl 5-amino-5-oxo-4-(1-oxo-5-(4,4,5,5-tetramethyl-1,3,2-dioxapentylborane-2-yl)isoindolin-2-yl)valerate (54.4 mg, 0.122 mmol), preparation 154B (26 mg, 0.111 mmol), Pd(PPh3)4 (12.86 mg, 0.011 mmol), and NaHCO3 (0.5 M aqueous solution) (668 μL, 0.334 mmol), followed by dioxane (556 μL). The vial was sealed, evacuated, and backfilled with N2. The reaction mixture was microwaved at 130 °C for 15 min. The reaction mixture was extracted with EtOAc (3×). The organic phases were combined, dried over Na2SO4, filtered, and concentrated to give an orange residue, which was further dried under high vacuum. The crude material was dissolved in 1.6 mL of AcOH and benzenesulfonic acid (19.36 mg, 0.122 mmol) was added. The reaction mixture was sealed and heated in a microwave at 155 °C for 10 min. The reaction mixture was concentrated and the crude material was purified by preparative LC / MS under the following conditions: column: XBridge C18, 200 mm × 19 mm, 5 μm particles; mobile phase A: 5:95 acetonitrile:water + 0.05% trifluoroacetic acid; mobile phase B: 95:5 acetonitrile:water + 0.05% trifluoroacetic acid; gradient: 0 min at 8% B, 20 min at 8-48% B, followed by 0 min at 100% B; flow rate: 20 mL / min; column temperature: 25 °C. The eluates containing the product were combined and evaporated to dryness by centrifugation to give Example 154 (1.2 mg, 2%). ESIMS (M+H) + =442.2. HPLC peak t r =1.76 minutes. Purity = 99%. (Analytical HPLC method 2).
[0671] Example 155
[0672] 3-[5-(6-methoxypyridin-2-yl)-1-oxo-2,3-dihydro-1H-isoindol-2-yl]piperidin-2,6-dione
[0673]
[0674] Preparation 155A: Methyl 4-iodo-2-methylbenzoate
[0675] Solid sodium nitrite (3.76 g, 54.5 mmol) was added to a solution of methyl 4-amino-2-methylbenzoate (4.5 g, 27.2 mmol) in DMSO (75 mL) at room temperature. The reaction mixture was heated to 40 °C in an oil bath. Hydrogen iodide (55% aqueous solution, 25.3 g, 109 mmol) in DMSO (38 mL) was added dropwise. After the addition was complete, the reaction mixture was stirred at 40 °C for 15 minutes. The reaction mixture was cooled to room temperature and poured into a water / ether (300 mL / 300 mL). Sodium thiosulfate was slowly added to the mixture with stirring until the mixture was decolorized and the layers separated. The aqueous layer was extracted again with ether. The combined organic matter was washed again with a dilute solution of sodium thiosulfate in water (about 2 g in 100 mL of water), followed by washing with water (100 mL), and then with brine. The organic matter was dried over MgSO4, filtered, and concentrated. The reaction was repeated on the same scale and under the same protocol. The crude products from both operations were combined and purified by ISCO (330 g column, 5% EtOAc / Hex; isocratic) to give the oily preparation 155A, 13.44 g (89% yield). 1 H NMR (400MHz, CDCl3) δ7.69-7.66(m,1H),7.64-7.61(m,2H),3.91(s,3H),2.57(s,3H).
[0676] Preparation 155B: Methyl 2-(bromomethyl)-4-iodobenzoate
[0677] N-bromosuccinimide (14.96 g, 84 mmol) and AIBN (0.265 g, 1.616 mmol) were added to a solution of preparation 155A (17.85 g, 64.7 mmol) in isopropyl acetate (211 mL). The resulting suspension was placed in a preheated 70 °C bath. A very slow nitrogen flow (injected via a syringe and output to a bubbler via another syringe) was maintained above the reaction mixture to aid in the removal of bromine. The reaction mixture was heated at 70 °C for 5 hours, cooled to room temperature, and concentrated. The resulting solid was stirred in diethyl ether and filtered to remove the solid, followed by washing with diethyl ether. The solid was discarded. The ether was washed twice with a solution of sodium sulfite (5 g) in water (400 mL), followed by washing with water and then with brine. The organic matter was dried over MgSO4, filtered, and concentrated. The material was purified by Isco (2% EtOAc / Hex, held for 5 min, then increased to 7% isocratic) to give an impure product as a gel-like solid. The material was suspended in a minimum amount of hexane. The resulting solid was collected in a Buchner funnel to give 13.3 g (58% yield) of preparation 155B. 1H NMR (400MHz, CDCl3) δ7.86 (d, J = 1.8Hz, 1H), 7.78-7.73 (m, 1H), 7.72-7.67 (m, 1H), 4.89 (s, 2H), 3.96 (s, 3H).
[0678] Preparation 155C: 3-(5-iodo-1-oxoisoindolin-2-yl)piperidine-2,6-dione
[0679] A Schneider base (10.9 mL, 62.5 mmol) was added to a suspension of 3-aminopiperidine-2,6-dione hydrochloride (5.15 g, 31.3 mmol) in acetonitrile (95 mL). After stirring for 5 minutes, the reaction mixture was treated with a small amount of preparation 157B (10.09 g, 28.4 mmol) as a solid for 5 minutes. After stirring at room temperature for 1 hour, the reaction vessel was fitted with a reflux condenser and slowly heated to 70 °C in an oil bath and maintained at this temperature for 2 days. The reaction mixture was cooled to room temperature and stirred overnight. The resulting precipitate was collected in a Buchner funnel and washed with additional acetonitrile. The solid was air-dried to give 8.9 g (85% yield) of preparation 155C as a white powder. 1 H NMR (400MHz, DMSO-d6) δ10.99(s,1H),8.06(s,1H),7.89(d,J=6.8Hz,1H),7.52(d,J=8.0Hz,1H),5.11(dd,J=13.4,5.2Hz ,1H),4.49-4.41(m,1H),4.36-4.28(m,1H),2.98-2.84(m,1H),2.70-2.56(m,1H),2.43-2.29(m,1H),2.06-1.96(m,1H).
[0680] Example 155:
[0681] Tripotassium phosphate (21.2 mg, 100 μmol) was added to a nitrogen-purging vial containing a suspension (degassed) of the preparation 155C (18.5 mg, 50 μmol), 2-methoxy-6-(4,4,5,5-tetramethyl-1,3,2-dioxapentylborane-2-yl)pyridine (23.5 mg, 100 μmol), and XPhos Pd G2 (2.0 mg, 2.5 μmol) in DMF (500 μL). The reaction mixture was stirred in a microwave reactor at 90 °C. After 3 hours, the reaction mixture was filtered, diluted with EtOAc (5 mL), and washed with a saturated aqueous solution of ammonium chloride (2 mL). The aqueous phase was back-extracted with EtOAc (5 mL), and the combined organic layers were concentrated under vacuum. The crude material was purified by preparative HPLC (column: XBridge C18, 200 mm × 19 mm, 5 μm particles; mobile phase A: 5:95 acetonitrile:water + ammonium acetate; mobile phase B: 95:5 acetonitrile:water + ammonium acetate; gradient: 0 min at 13% B, 20 min at 13-53% B, followed by 0 min at 100% B; flow rate: 20 mL / min; column temperature: 25 °C) to obtain 4.9 mg (28% yield) Example 155. LCMS (analytical HPLC method 1): T Ret = 1.44 minutes; m / z = 352.1 [M+H] + . 1 H NMR (500MHz, DMSO-d6) δ11.01(s,1H),8.32(s,1H),8.26(d,J=7.9Hz,1H),7.89-7.78(m,2H),7.67(d,J=7.5Hz,1H),6.85(d,J=8.2Hz,1H),5.14(br dd,J=13.2,4.9Hz,1H),4.55(d,J=17.4Hz,1H),4.42(d,J=17.1Hz,1H),3.98(s, 3H),2.98-2.86(m,1H),2.67-2.58(m,1H),2.48-2.37(m,1H),2.10-1.98(m,1H).
[0682] Examples 156 and 157
[0683] 3-[5-(1-methoxyisoquinolin-3-yl)-1-oxo-2,3-dihydro-1H-isoindol-2-yl]piperidin-2,6-dione (156) and 3-[1-oxo-5-(1-oxo-1,2-dihydroisoquinolin-3-yl)-2,3-dihydro-1H-isoindol-2-yl]
[0684] Piperidine-2,6-dione (156)
[0685]
[0686] Preparation 156A: 3-bromo-1-methoxyisoquinoline
[0687] A suspension of 1,3-dibromoisoquinoline (215 mg, 750 μmol) and sodium methoxide (40.5 mg, 750 mmol) in toluene (3.0 mL) was stirred at 110 °C. Additional sodium methoxide (203 mg, 3750 μmol) was added at 1.5 h and 5 h. After a total time of 20.5 h, the reaction mixture was cooled to room temperature, quenched with water (0.1 mL), and concentrated under vacuum. The crude product was dissolved in a small amount of DCM, adsorbed onto a SiO2 stopper, and purified by rapid chromatography (SiO2, 40 g column, 1% EtOAc / hexane, isocratic, 40 mL / min) to give 160 mg (90% yield) of preparation 156A as a white solid. MS (ES): m / z = 238.1, 240.1 [M+H] + . 1 ¹H NMR (500MHz, chloroform-d) δ 8.19 (dd, J = 8.3, 1.0 Hz, 1H), 7.69–7.62 (m, 2H), 7.53 (ddd, J = 8.3, 5.9, 2.3 Hz, 1H), 7.44 (d, J = 0.8 Hz, 1H), 4.14 (s, 3H).
[0688] Examples 156 and 157:
[0689] A solution of potassium carbonate (46.4 mg, 0.336 mmol) in water (336 μL) was added to a solution of preparation 156A (40.0 mg, 0.168 mmol) and preparation 1B (149 mg, 0.336 mmol) in 1,4-dioxane (0.50 mL). The reaction vessel was evacuated and backfilled with nitrogen three times, followed by the addition of PdCl2 (dppf) (6.2 mg, 8.4 μmol). The resulting mixture was stirred at 100 °C. After 45 minutes, the reaction mixture was filtered, diluted with EtOAc (5 mL), and washed with a saturated aqueous solution of ammonium chloride (2 mL). The aqueous phase was back-extracted with EtOAc (5 mL), and the combined organic layers were concentrated under vacuum. The crude intermediate was suspended in acetonitrile (840 μL), followed by the addition of benzenesulfonic acid (26.6 mg, 168 μmol). The resulting mixture was stirred at 90 °C. After 3 hours, the second portion of benzenesulfonic acid (26.6 mg, 168 μmol) was added and stirring was resumed at 90 °C. After a total time of 4.5 hours, the reaction mixture was cooled to room temperature and concentrated under vacuum. The crude material was purified by preparative HPLC (column: XBridge C18, 200 mm × 19 mm, 5 μm particles; mobile phase A: 5:95 acetonitrile:water + ammonium acetate; mobile phase B: 95:5 acetonitrile:water + ammonium acetate; gradient: 0 min at 7% B, 30 min at 7-69% B, followed by 0 min at 100% B; flow rate: 20 mL / min; column temperature: 25 °C) to give Example 156 (14.8 mg, 22% yield). LCMS (analytical HPLC method 1): T Ret = 1.9 minutes; m / z = 402.2 [M+H] + . 1 H NMR (500MHz, DMSO-d6) δ11.03(s,1H),8.45(s,1H),8.40(br d,J=8.4Hz,1H),8.20(br d,J=8.2Hz,1H),8.17(s,1H),8.00(d,J=8.4Hz,1H),7.86(d,J=7.9Hz,1H),7.80(t,J=7.6Hz,1H),7.65(t,J=7.9Hz,1H),5.15(br dd,J=13.5,4.7Hz,1H),4.58(d,J=17.1Hz,1H),4.44(d,J=16.9Hz,1H),4.21(s, 3H),2.98-2.88(m,1H),2.67-2.59(m,1H),2.47-2.39(m,1H),2.10-1.99(m,1H).
[0690] Separation of the second product from the same preparation: Example 157 (14.3 mg, 22% yield). LCMS (Analytical HPLC Method 1): T Ret = 1.26 minutes; m / z = 388.2 [M+H] + . 1 H NMR(500MHz,DMSO-d6)δ11.65(br s,1H),11.03(s,1H),8.23(d,J=8.1Hz,1H),8.01(s,1H),7.91(d,J=7.6Hz,1H),7 .84(d,J=8.0Hz,1H),7.80-7.72(m,2H),7.54(ddd,J=8.1,5.1,3.1Hz,1H),7.04( s,1H),5.13(brdd,J=13.4,4.7Hz,1H),4.54(d,J=17.5Hz,1H),4.42(d,J=17.6Hz ,1H),2.97-2.85(m,1H),2.68-2.60(m,1H),2.49-2.39(m,1H),2.11-2.00(m,1H).
[0691] Example 158
[0692] 3-(5-{1-phenylmethyl-1H-pyrrolo[3,2-c]pyridin-6-yl}-1-oxo-2,3-dihydro-1H-isoindole-2-
[0693] (2,6-dione)piperidine-2,6-dione
[0694]
[0695] Preparation 158A: 1-Benzyl-6-chloro-1H-pyrrolo[3,2-c]pyridine
[0696] Bromotoluene (65 μL, 550 μmol) was added to a suspension of 6-chloro-1H-pyrrolo[3,2-c]pyridine (76 mg, 500 μmol) and potassium carbonate (138 mg, 1.00 mmol) in acetonitrile (5.0 mL). The resulting mixture was stirred at 80 °C. After 20 hours, a second portion of bromotoluene (24 μL, 200 μmol) was added, followed by resumption of stirring at 80 °C. After a total time of 24 hours, the reaction mixture was cooled to room temperature, filtered, and concentrated under vacuum. The crude material was purified by preparative HPLC (column: XBridge C18, 200 mm × 19 mm, 5 μm particles; mobile phase A: 5:95 acetonitrile:water + 0.05% trifluoroacetic acid; mobile phase B: 95:5 acetonitrile:water + 0.05% trifluoroacetic acid; gradient: 0 min at 13% B, 20 min at 13-53% B, followed by 0 min at 100% B; flow rate: 20 mL / min; column temperature: 25 °C). The eluates containing the product were combined and evaporated to dryness by centrifugation. The material was further purified by preparative HPLC (column: XBridge C18, 200 mm × 19 mm, 5 μm particles; mobile phase A: 5:95 acetonitrile:water + ammonium acetate; mobile phase B: 95:5 acetonitrile:water + ammonium acetate; gradient: 0 min at 28% B, 20 min at 28-68% B, followed by 0 min at 100% B; flow rate: 20 mL / min; column temperature: 25 °C) to give 20.1 mg (17% yield) of preparation 158A. MS (ES): m / z = 243.3 [M+H] + . 1 H NMR(500MHz, chloroform-d)δ8.68(d,J=0.8Hz,1H),7.37-7.29(m,3H),7.22(t,J=0.9Hz,1H) ,7.14(d,J=3.3Hz,1H),7.12-7.07(m,2H),6.63(dd,J=3.3,0.9Hz,1H),5.27(s,2H).
[0697] Example 158:
[0698] A solution of potassium carbonate (22.9 mg, 0.166 mmol) in water (0.33 mL) was added to a solution of preparation 158A (20.1 mg, 0.083 mmol) and preparation 1B (55.2 mg, 0.124 mmol) in 1,4-dioxane (0.50 mL). The reaction vessel was evacuated and backfilled with nitrogen three times, followed by the addition of XPhos Pd G2 (3.3 mg, 4.14 μmol). The resulting mixture was stirred at 100 °C. After 4.5 h, the reaction mixture was filtered, diluted with EtOAc (5 mL), and washed with a saturated aqueous solution of ammonium chloride (2 mL). The aqueous phase was back-extracted with EtOAc (5 mL), and the combined organic layers were concentrated under vacuum. The crude residue was suspended in acetonitrile (1.0 mL), followed by the addition of benzenesulfonic acid (26.2 mg, 0.166 mmol). The resulting mixture was stirred at 90 °C. After 15 hours, the reaction mixture was cooled to room temperature and concentrated under vacuum. The crude material was purified by preparative HPLC (column: XBridge C18, 200 mm × 19 mm, 5 μm particles; mobile phase A: 5:95 acetonitrile:water + 0.05% trifluoroacetic acid; mobile phase B: 95:5 acetonitrile:water + 0.05% trifluoroacetic acid; gradient: 0 min at 4% B, 20 min at 4-44% B, followed by 0 min at 100% B; flow rate: 20 mL / min; column temperature: 25 °C) to obtain 15.9 mg (40% yield) in Example 158. LCMS (analytical HPLC method 1): T Ret = 1.25 minutes; m / z = 451.2 [M+H] + . 1 H NMR(500MHz,DMSO-d6)δ11.02(s,1H),9.20(s,1H),8.57(s,1H),8.24(s,1H),8.14(br d,J=8.3Hz,1H),7.99-7.91(m,2H),7.40-7.23(m,5H),7.02(d,J=2.8Hz,1H),5.68(s,2H),5.15(dd,J=13.1,5.1Hz,1H),4 .59(d,J=17.9Hz,1H),4.47(d,J=17.3Hz,1H),2.98-2.86(m,1H),2.69-2.58(m,1H),2.48-2.38(m,1H),2.10-2.01(m,1H).
[0699] Examples 159-161
[0700] The compounds in Table 5 were prepared using appropriate aryl chlorides according to the procedure described for Example 157:
[0701]
[0702] Table 5
[0703]
[0704]
[0705] a HPLC retention time using analytical HPLC method 1.
[0706] Examples 162-166
[0707] The compounds in Table 6 were prepared using appropriate aryl bromides according to the procedure described for Example 144:
[0708]
[0709] Table 6
[0710]
[0711]
[0712] a HPLC retention time using analytical HPLC method 1.
[0713] Example 167
[0714] N-(6-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)-3,4-dimethylpyridin-2-yl)acetamide
[0715]
[0716] Acetyl chloride (5.37 mg, 0.068 mmol) was added to a solution of Example 151 (20 mg, 0.046 mmol) dissolved in DCM (3 mL), followed by the addition of Schönsch base (0.016 mL, 0.091 mmol). The reaction mixture was stirred at room temperature for 4 hours and then concentrated to dryness. The resulting residue was dissolved in 1.5 mL of 2 M solution of PhSO3H in AcOH and microwaved at 130 °C for 0.5 hours, followed by purification by preparative HPLC method 1 to give the title product in 49% yield.
[0717] Preparative HPLC method: XBridge C18, 200 mm × 19 mm, 5 μm particles; Mobile phase A: 5:95 acetonitrile:water + 10 mM ammonium acetate; Mobile phase B: 95:5 acetonitrile:water + 10 mM ammonium acetate; Gradient: 0 min at 15% B, 25 min at 15-50% B, followed by 6 min at 100% B; Flow rate: 20 mL / min; Column temperature: 25 °C.
[0718] MS(ES): m / z = 407.1 [M+H] + . 1 H NMR(500MHz,DMSO-d6)δ10.01-10.09(m,1H)8.27(s,1H)8.21(br d,J=7.96Hz,1H)7.79-7.85(m,2H)5.10-5.17(m,1H)4.51-4.58(m,1H)4.38-4.46(m,1H)2.88-2.99(m,1H)2.63(br d,J=18.66Hz,1H)2.41-2.46(m,1H)2.39(s,3H)2.10-2.10(m,1H)2.10(br s,2H)2.09(s,3H)2.00-2.07(m,1H).
[0719] Example 168
[0720] 2-Amino-6-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindoline-5-yl)pyridine-3,5-dicarboxynitrile
[0721]
[0722] Preparation 168A.(S)-5-amino-4-(5-(6-amino-3,5-dicyanopyridin-2-yl)-1-oxoisoindolin-2-yl)-5-oxovalerate tert-butyl ester
[0723] At room temperature, tert-butyl (750 mg, 1.688 mmol) of (S)-5-amino-5-oxo-4-(1-oxo-5-(4,4,5,5-tetramethyl-1,3,2-dioxapentylborane-2-yl)isoindolin-2-yl)valerate (750 mg, 1.688 mmol) in a stirred solution of 1,4-dioxane (5 mL) was added to a sealed tube containing 2-amino-6-chloropyridin-3,5-dicarboxynitrile (271 mg, 1.519 mmol), followed by a 1 mL solution of potassium carbonate (583 mg, 4.22 mmol) in water. The reaction mixture was degassed for 15 min under atmospheric pressure (nitrogen). PdCl2(dppf)-CH2Cl2 adduct (68.9 mg, 0.084 mmol) was added to this reaction mixture under nitrogen at room temperature, and degassed again for 5 min. The tube was sealed, heated to 100 °C, and stirred for 2 h. The reaction progress was monitored by TLC. The reaction mixture was cooled to room temperature. The reaction mixture was filtered through a diatomaceous earth pad in a Buchner funnel. The filtrate was concentrated under reduced pressure to give 950 mg of crude material, which was purified by silica gel column chromatography (Isolera) using 50 to 80% EtOAc-hexane as eluent to give tert-butyl (S)-5-amino-4-(5-(6-amino-3,5-dicyanopyridin-2-yl)-1-oxoisoindoline-2-yl)-5-oxovalerate (500 mg, 1.003 mmol, 59.4%) as a pale yellow solid.
[0724] Example 168:
[0725] Benzenesulfonic acid (172 mg, 1.086 mmol) was added to a stirred solution of (S)-5-amino-4-(5-(6-amino-3,5-dicyanopyridin-2-yl)-1-oxoisoindoline-2-yl)-5-oxovalerate (500 mg, 1.086 mmol) in acetonitrile (5 mL) under microwave irradiation. The reaction mixture was sealed and irradiated in a microwave reactor at 120 °C for 30 min. After the reaction was complete (monitored by LCMS), the solid precipitated upon cooling to room temperature. The solid was filtered through a Buchner funnel and dried under vacuum to give 2-amino-6-(2-(2,6-dioxopyridin-3-yl)-1-oxoisoindoline-5-yl)pyridin-3,5-dicarboxynitrile (195 mg, 0.484 mmol, 44.6%) as a pale yellow solid.
[0726] LCMS: Column: Kinetex XB-C18 (75×30) mm, 2.6 μm; Mobile phase A: 5 mM ammonium formate. Mobile phase B: ACN. Flow rate: 1.0 mL / min; Purity = 96.95% (RT = 1.07 min).
[0727] HPLC: Column: Kinetex Biphenyl (100×4.6) mm, 2.6 μm; Mobile phase A: 0.05% TFA aqueous solution; Mobile phase B: ACN; Flow rate: 1.0 mL / min; Purity = 95.9% (RT = 5.95 min).
[0728] 1 H-NMR (400MHz, DMSO-d6) δ11.04(s,1H),8.62(s,1H),8.10(m,2H),8.00(s,1H),7.90(d,J=1.20Hz,2H),5.17(dd,J=5.20,13.20Hz, 1H), 4.56 (d, J = 17.60Hz, 1H), 4.43 (d, J = 17.60Hz, 1H), 2.89-2.98 (m, 1H), 2.53-2.68 (m, 1H), 2.41-2.50 (m, 1H), 2.03-2.08 (m, 1H).
[0729] Example 169
[0730] 2-Amino-6-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindoline-5-yl)-5-fluoronicotinonitrile
[0731]
[0732] Preparation 169A: (S)-5-amino-5-oxo-4-(1-oxo-5-(4,4,5,5-tetramethyl-1,3,2-dioxapentylborane-2-yl)isoindolin-2-yl)tert-butyl valerate
[0733] Potassium acetate (3.71 g, 37.8 mmol) and bis(pinacolyl)diboron (4.79 g, 18.88 mmol) were added to a stirred solution of (S)-5-amino-4-(5-bromo-1-oxoisoindoline-2-yl)-5-oxovalerate (5 g, 12.59 mmol) in 1,4-dioxane (80 mL) under a nitrogen atmosphere. The reaction mixture was degassed with N2 gas for 10 min, followed by the addition of PdCl2(dppf)-CH2Cl2 adduct (1.028 g, 1.259 mmol). The resulting reaction mixture was heated at 80 °C for 4 h. The reaction mixture was cooled to room temperature and filtered through a diatomaceous earth mat. The filtrate was diluted with EtOAc (450 mL) and water (200 mL) and the layers were separated. The organic layer was washed with brine (50 mL), dried over Na2SO4, and then... The crude substance (15 g) was concentrated under reduced pressure and purified by silica gel column chromatography (Isolera) using 50 to 60% EtOAc-hexane as eluent to obtain (S)-5-amino-5-oxo-4-(1-oxo-5-(4,4,5,5-tetramethyl-1,3,2-dioxapentylborane-2-yl)isoindolin-2-yl)tert-butyl valerate (4.6 g, 8.38 mmol, 66.6%) as a pale red solid.
[0734] Preparation 169B.(S)-5-amino-4-(5-(6-amino-5-cyano-3-fluoropyridin-2-yl)-1-oxoisoindolin-2-yl)-5-oxovalerate tert-butyl ester
[0735] At room temperature, tert-butyl (500 mg, 1.125 mmol) of (S)-5-amino-5-oxo-4-(1-oxo-5-(4,4,5,5-tetramethyl-1,3,2-dioxapentylborane-2-yl)isoindolin-2-yl)valerate (500 mg, 1.125 mmol) in 1,4-dioxane (4 mL) with stirring was added to a sealed tube, followed by a solution of potassium carbonate (389 mg, 2.81 mmol) in water (0.8 mL). The reaction mixture was degassed under nitrogen for 15 min. PdCl2(dppf)-CH2Cl2 adduct (45.9 mg, 0.056 mmol) was added to this reaction mixture under nitrogen at room temperature, and degassed again for 5 min. The tube was sealed, heated to 100 °C, and stirred for 2 h. The reaction progress was monitored by TLC and LCMS. The reaction mixture was cooled to room temperature and filtered through a diatomaceous earth bed. The filtrate was concentrated under reduced pressure to give 650 mg of crude material, which was purified by silica gel column chromatography (Isolera) using 50% to 80% EtOAc / petroleum ether as eluent to give (S)-5-amino-4-(5-(6-amino-5-cyano-3-fluoropyridin-2-yl)-1-oxoisoindoline-2-yl)-5-oxovalerate tert-butyl ester (300 mg, 0.604 mmol, 53.6%) as a pale yellow solid.
[0736] Example 169:
[0737] Benzenesulfonic acid (105 mg, 0.662 mmol) was added to a stirred solution of (S)-5-amino-4-(5-(6-amino-5-cyano-3-fluoropyridin-2-yl)-1-oxoisoindolin-2-yl)-5-oxovalerate tert-butyl ester (300 mg, 0.662 mmol) in acetonitrile (3 mL). The reaction vial was sealed and irradiated in a microwave reactor at 120 °C for 30 min. The reaction progress was monitored by LCMS. After the reaction was complete, the mixture was concentrated under reduced pressure to obtain 400 mg of crude material, which was purified by preparative HPLC to give 2-amino-6-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)-5-fluoronicotinamide cyanate (56 mg, 0.127 mmol, 19.20% yield) as a grayish-white solid.
[0738] Details of the preparative HPLC method: Column: YMC C18 (250×20) mm, 5 μm, mobile phase A: 0.1% formic acid aqueous solution, mobile phase B: acetonitrile, flow rate: 15 mL / min.
[0739] Analytical data: HPLC: Column: Kinetex Biphenyl (100×4.6) mm, 2.6 μm; Mobile phase A: 0.05% TFA aqueous solution; Mobile phase B: ACN; Flow rate: 1.0 mL / min; RT = 7.243 min; Purity = 96.46%. LCMS: Column: Kinetex XB-C18 (75×30) mm, 2.6 μm; Mobile phase A: 5 mM ammonium formate; Mobile phase B: ACN; Flow rate: 1.0 mL / min; RT = 1.11 min; Purity = 98.01%. 1 HNMR (400MHz, DMSO-d6) δ11.03(s,1H),8.01(d,J=10.80Hz,1H),7.94(s,1H),7.85(t,J=9.60Hz,2H),5.16(dd,J=5.20,13.20Hz,1 H), 4.55 (d, J = 17.60Hz, 1H), 4.41 (d, J = 17.60Hz, 1H), 2.89-2.98 (m, 1H), 2.60-2.68 (m, 1H), 2.41-2.50 (m, 1H), 2.03-2.08 (m, 1H).
[0740] Example 170
[0741] 3-(5-(6-amino-4-phenylpyridin-2-yl)-1-oxoisoindoline-2-yl)piperidin-2,6-dione
[0742]
[0743] Preparation 170A.(S)-5-amino-4-(5-(6-amino-4-phenylpyridin-2-yl)-1-oxoisoindolin-2-yl)-5-oxovalerate tert-butyl ester
[0744] A mixture of (S)-5-amino-5-oxo-4-(1-oxo-5-(4,4,5,5-tetramethyl-1,3,2-dioxapentylborane-2-yl)isoindolin-2-yl)tert-butyl valerate (0.5 g, 1.125 mmol), 6-chloro-4-phenylpyridin-2-amine (0.184 g, 0.900 mmol), and potassium carbonate (0.389 g, 2.81 mmol) was treated in a sealed tube with pre-degassed 1,4-dioxane (16 mL) and water (4 mL) (4:1). The reaction mixture was purged with N2 for 10 min, followed by the addition of the PdCl2(dppf)-CH2Cl2 adduct (0.046 g, 0.056 mmol). The tube was immediately sealed and stirred at 100 °C for 3 h. After the reaction was complete, the reaction vessel was cooled to ambient temperature. The reaction mixture was diluted with ethyl acetate (50 mL), filtered through a diatomaceous earth bed, and concentrated under vacuum to give a crude product. The crude product was purified by silica gel (230 to 400 mesh) column chromatography (Grace, 25 g snap, anhydrous packaging) by elution with 0-20% ethyl acetate / petroleum ether. The eluates were combined and concentrated under reduced pressure to give (S)-5-amino-4-(5-(6-amino-4-phenylpyridin-2-yl)-1-oxoisoindololin-2-yl)-5-oxovalerate tert-butyl ester (0.291 g, 0.549 mmol, 48.8%) as a light brown solid.
[0745] Example 170:
[0746] Benzenesulfonic acid (40.6 mg, 0.257 mmol) was added to a stirred solution of (S)-5-amino-4-(5-(6-amino-4-phenylpyridin-2-yl)-1-oxoisoindolin-2-yl)-5-oxovalerate tert-butyl ester 1 (125 mg, 0.257 mmol) in acetonitrile (1.6 mL). The reaction vial was sealed and irradiated in a microwave reactor at 120 °C for 30 min. After the reaction was complete, the mixture was concentrated under reduced pressure to obtain 350 mg of crude substance, which was purified by preparative HPLC to give 3-(5-(6-amino-4-phenylpyridin-2-yl)-1-oxoisoindolin-2-yl)piperidin-2,6-dione (13 mg, 0.030 mmol, 11.8%) as a grayish-white solid.
[0747] Details of the preparative purification method: Column: YMC C18 (250×20) mm, 5 μm, mobile phase A: 0.1% formic acid aqueous solution, mobile phase B: acetonitrile, flow rate: 15 mL / min.
[0748] Analytical data: HPLC: Column: Kinetex Biphenyl (100×4.6) mm, 2.6 μm; Mobile phase A: 0.05% TFA aqueous solution; Mobile phase B: ACN; Flow rate: 1.0 mL / min; RT = 5.248 min; Purity = 96.4%. LCMS: Column: Kinetex XB-C18 (75×30) mm, 2.6 μm; Mobile phase A: 5 mM ammonium formate; Mobile phase B: ACN; Flow rate: 1.0 mL / min; RT = 1.10 min; Purity = 92.45%. 1 HNMR(400MHz,DMSO-d6)δ11.03(s,1H),8.30(s,1H),8.23(d,J=8.00Hz,1H) ,7.79-7.84(m,3H),7.51-7.56(m,4H),6.84(s,1H),6.45(bs,2H),5.15(dd ,J=5.20,13.20Hz,1H),4.55(d,J=17.60Hz,1H),4.42(d,J=17.60Hz,1H),2 .88-2.96(m,1H),2.65-2.69(m,1H),2.39-2.43(m,1H),2.02-2.05(m,1H).
[0749] Example 171
[0750] 6-Amino-2-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindoline-5-yl)-4-(trifluoromethyl)nicotinic acid-
[0751] nitrile
[0752]
[0753] Preparations 171A and 171B: 2-amino-6-chloro-4-(trifluoromethyl)nicotinonitrile and 6-amino-2-chloro-4-(trifluoromethyl)nicotinonitrile
[0754]
[0755] A thoroughly stirred solution of 2,6-dichloro-4-(trifluoromethyl)nicotinonitrile (650 mg, 2.70 mmol) and ammonium hydroxide (1.050 mL, 27.0 mmol) in ethanol (10 mL) in 50 mL of Tinyclave was heated at 50 °C for 12 hours. After the reaction was complete, the solvent was concentrated under reduced pressure to obtain the crude material. This was purified by rapid silica gel (230 to 400 mesh) column chromatography using 10% to 30% EtOAc / petroleum ether to give 2-amino-6-chloro-4-(trifluoromethyl)nicotinonitrile-171A (30 mg, 0.126 mmol, 4.67%) as a white solid. The second compound was eluted with 40% EtOAc / petroleum ether to give 6-amino-2-chloro-4-(trifluoromethyl)nicotinonitrile-171B (301 mg, 1.267 mmol, 47.0%) as a white solid.
[0756] Preparation 171C.(S)-5-amino-4-(5-(6-amino-3-cyano-4-(trifluoromethyl)pyridin-2-yl)-1-oxoisoindolin-2-yl)-5-oxovalerate tert-butyl ester
[0757] A 30 mL microwave-safe solution of sodium bicarbonate (284 mg, 3.38 mmol, 2 M, 1 mL) was added to a well-stirred solution containing (S)-5-amino-5-oxo-4-(1-oxo-5-(4,4,5,5-tetramethyl-1,3,2-dioxapentylborane-2-yl)isoindolin-2-yl)valerate (600 mg, 1.350 mmol) and 6-amino-2-chloro-4-(trifluoromethyl)nicotinonitrile-171B (299 mg, 1.350 mmol) at ambient temperature. The resulting reaction mixture was degassed by bubbling nitrogen into the reaction mixture for 10 minutes. Tetra(triphenylphosphine)palladium(0) (46.8 mg, 0.041 mmol) was then added to the reaction mixture, and the resulting reaction mixture was heated in a microwave reactor at 120 °C for 1 hour. After cooling to room temperature, the reaction mixture was poured into water (30 mL) and extracted with EtOAc (2 × 50 mL). The organic phases were combined, washed with brine (30 mL), dried over anhydrous Na₂SO₄, and concentrated under reduced pressure to give a crude residue. The residue was purified by silica gel column chromatography (Biotage, eluted with 50% ethyl acetate / petroleum ether) to give tert-butyl (S)-5-amino-4-(5-(6-amino-3-cyano-4-(trifluoromethyl)pyridin-2-yl)-1-oxoisoindololin-2-yl)-5-oxovalerate (401 mg, 0.755 mmol, 55.9%) as a brown solid.
[0758] Example 171
[0759] Benzenesulfonic acid (126 mg, 0.794 mmol) was added to a 30 mL microwave-safe vial containing a well-stirred solution of (S)-5-amino-4-(5-(6-amino-3-cyano-4-(trifluoromethyl)pyridin-2-yl)-1-oxoisoindolin-2-yl)-5-oxovalerate tert-butyl ester (400 mg, 0.794 mmol) in anhydrous acetonitrile (4.0 mL). The contents were heated in a microwave reactor at 120 °C for 2 hours. After the reaction was complete, excess solvent was removed from the reaction mixture under reduced pressure to give the crude compound. Purification by preparative HPLC yielded 6-amino-2-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)-4-(trifluoromethyl)nicotinonitrile (177.94 mg, 0.413 mmol, 52.0%) as a white solid.
[0760] Preparative HPLC method details: Column: XBridge C18 (150×19) mm, 5 μm, mobile phase A: 0.1% TFA aqueous solution, mobile phase B: acetonitrile, flow rate: 15 mL / min.
[0761] Analytical data: LCMS: Column-XBridge C8 (50 × 4.6 mm) 5 μm, wavelength: 220 nm; mobile phase: 0.1% TFA aqueous solution + acetonitrile. RT = 1.96 min. MS (ES): m / z = 430.0 (M + H) + Purity 99.42%. HPLC: Kinetex EVO C18 (100×4.6) mm, 2.6 μm. Mobile phase A: 0.05% TFA aqueous solution; Mobile phase B: ACN; Flow rate: 1.0 mL / min. RT = 7.14 min, Purity: 99.69%. 1 H NMR(400MHz,DMSO-d6)δ11.02(s,1H),7.97-7.84(m,5H),6.96(s,1H),5.17(dd,J=4.80,13.40Hz,1 H),4.58-4.41(m,2H),2.97-2.89(m,1H),2.52-2.61(m,1H),2.43-2.42(m,1H),2.08-2.05(m,1H).
[0762] Example 172
[0763] 2-Amino-6-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindoline-5-yl)-4-propylnicotinonitrile
[0764]
[0765] Preparation 172A. 6-Hydroxy-2-oxo-4-propyl-1,2-dihydropyridine-3-carboxynitrile
[0766] In a sealed tube, KOH (3.55 g, 63.2 mmol) was slowly added to a stirred solution of ethyl 3-oxohexanoate (10 g, 63.2 mmol) and 2-cyanoacetamide (5.31 g, 63.2 mmol) in ethanol (100 mL). The mixture was stirred at 85 °C for 18 hours. After the reaction was complete, the reaction mixture was cooled to room temperature. The precipitated solid was filtered off and dissolved in warm water (100 mL). The solution was acidified with 40 mL of 4N HCl to give a grayish-white residue, which was filtered off and washed with water and cold diethyl ether. The solid residue was dried under vacuum to give 6-hydroxy-2-oxo-4-propyl-1,2-dihydropyridine-3-carboxynitrile (7.5 g, 41.8 mmol, 66.2%) as a grayish-white powder.
[0767] Preparation 172B. 2,6-Dichloro-4-propylnicotinonitrile
[0768] Phosphoryl chloride (10 mL) was added dropwise to a mixture of 6-hydroxy-2-oxo-4-propyl-1,2-dihydropyridine-3-carboxylonitrile (3 g, 16.84 mmol) and tetramethylammonium chloride (3.69 g, 33.7 mmol) in a sealed tube under a nitrogen atmosphere at room temperature. The mixture was then heated at 145 °C for 20 h. After 20 h, TLC analysis indicated that the starting material was completely depleted. The reaction mixture was then cooled to room temperature, poured onto crushed ice, and stirred for 2 h. The solution was extracted with ethyl acetate (150 mL), dried over sodium sulfate, and concentrated to give a viscous syrupy 2,6-dichloro-4-propylnicotinonitrile (2.6 g, 12.07 mmol, 71.7%).
[0769] Preparations 172C and 172D: 2-amino-6-chloro-4-propylnicotinonitrile and 6-amino-2-chloro-4-propylnicotinonitrile
[0770] At ambient temperature, 15 mL of aqueous NH3 solution was added to a well-stirred solution of 2,6-dichloro-4-propylnicotinonitrile (2.0 g, 9.30 mmol) in ethanol (25 mL). The reaction mixture was then heated at 50 °C for 16 hours. After the reaction was complete, the solvent was concentrated under reduced pressure to give a mixture of regiomeric isomers. The crude material was purified by rapid silica gel column chromatography (230 to 400 mesh) with 10% to 15% EtOAc / petroleum ether to give 2-amino-6-chloro-4-propylnicotinonitrile-171C as a white solid (170 mg, 0.864 mmol, 9.29% yield). The second isomer was eluted with 30% EtOAc to give 6-amino-2-chloro-4-propylnicotinonitrile-171D as a white solid (340 mg, 1.732 mmol, 18.62% yield).
[0771] Preparation 172E.(S)-5-amino-4-(5-(6-amino-5-cyano-4-propylpyridin-2-yl)-1-oxoisoindoline-2-yl)-5-oxovalerate tert-butyl ester
[0772] A solution of sodium bicarbonate (129 mg, 1.533 mmol) in water (1 mL) was added to a 10 mL microwave-safe vial containing a well-stirred solution of (S)-5-amino-5-oxo-4-(1-oxo-5-(4,4,5,5-tetramethyl-1,3,2-dioxapentylborane-2-yl)isoindolin-2-yl)valerate (250 mg, 0.562 mmol) and 2-amino-6-chloro-4-propylnicotinonitrile (100 mg, 0.511 mmol) in 1,4-dioxane (5 mL). The resulting reaction mixture was degassed by bubbling nitrogen into the reaction mixture for 10 minutes. Subsequently, tetrakis(triphenylphosphine)palladium (0) (59.1 mg, 0.051 mmol) was added to the reaction mixture, and the resulting reaction mixture was heated in a MW reactor at 120 °C under microwave irradiation for 1 hour. The reaction mixture was then poured into water (20 mL) and extracted with EtOAc (2 × 50 mL). The organic phases were combined and washed with brine (20 mL). The combined organic phases were dried over anhydrous Na₂SO₄, filtered, and concentrated under reduced pressure to give a crude residue. The crude material was purified by rapid silica gel column chromatography (230 to 400 mesh) with 50% to 60% EtOAc / petroleum ether to give (S)-5-amino-4-(5-(6-amino-5-cyano-4-propylpyridin-2-yl)-1-oxoisoindoline-2-yl)-5-oxovalerate tert-butyl ester (130 mg, 0.152 mmol, 29.8%) as a grayish-white solid.
[0773] Example 172
[0774] Benzenesulfonic acid (24.84 mg, 0.157 mmol) was added to a stirred solution of (S)-5-amino-4-(5-(6-amino-5-cyano-4-propylpyridin-2-yl)-1-oxoisoindolin-2-yl)-5-oxovalerate tert-butyl ester (75 mg, 0.157 mmol) in anhydrous acetonitrile (4.0 mL) in a microwave-safe vial under a nitrogen atmosphere. The vial was sealed and irradiated in a microwave reactor at 130 °C for 1 hour. After the reaction was complete, the reaction mixture was concentrated to obtain a crude product as a grayish-white solid. Purification by preparative HPLC yielded 2-amino-6-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)-4-propylnicotinonitrile TFA (55 mg, 0.106 mmol, 67.5% yield) as a white solid.
[0775] Preparative HPLC method details: Column: XSelect C18 (150×19) mm, 5 μm; Mobile phase A: 0.1% TFA aqueous solution, Mobile phase B: acetonitrile, Flow rate: 15 mL / min.
[0776] Analytical data: LCMS: Column: Kinetex XB-C18 (75×3.0) mm, 2.6 μm; Mobile phase A: 5 mM ammonium formate. Mobile phase B: ACN, flow rate: 1.0 mL / min; RT = 1.826, MS (ES): m / z = 404.2 [M+H] + HPLC purity: Column: Kinetex EVO C18 (100×4.6) mm, 2.6 μm; Mobile phase A: 0.05% TFA aqueous solution; Mobile phase B: ACN. Flow rate: 1.0 mL / min; RT = 6.927 min; HPLC purity: 99.68%. 1 HNMR: 400MHZ(DMSO): δ11.01(s,1H),8.28-8.21(m,2H),7.93(d,J=8.0Hz,1H),7.31(s,1H),6.93(br s,1H),5.15(dd,J=5.20,13.20Hz,1H),5.15(dd,J=5.20,13.20Hz,1H),2.90(m,1H),2.70-2 .50(m,3H),2.46-2.33(m,3H),2.08-2.01(m,1H),1.74-1.68(m,2H),0.97(t,J=7.60Hz,3H). 19 FNMR: 400MHz (DMSO): δ -74.52.
[0777] Example 173
[0778] 6-Amino-2-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindoline-5-yl)-4-propylnicotinonitrile
[0779]
[0780] Preparation 173A.(S)-5-amino-4-(5-(6-amino-3-cyano-4-propylpyridin-2-yl)-1-oxoisoindolin-2-yl)-5-oxovalerate tert-butyl ester
[0781] A solution of sodium bicarbonate (129 mg, 1.533 mmol) in water (1 mL) was added to a 30 mL microwave-safe vial containing a well-stirred solution of (S)-5-amino-5-oxo-4-(1-oxo-5-(4,4,5,5-tetramethyl-1,3,2-dioxapentylborane-2-yl)isoindolin-2-yl)valerate (250 mg, 0.562 mmol) and 6-amino-2-chloro-4-propylnicotinonitrile-172D (100 mg, 0.511 mmol) in 1,4-dioxane (5 mL). The resulting reaction mixture was degassed by bubbling nitrogen into the reaction mixture for 10 minutes. Tetra(triphenylphosphine)palladium (0) (59.1 mg, 0.051 mmol) was then added to the reaction mixture, and the resulting reaction mixture was heated to 120 °C for 1 hour in a MW reactor under microwave irradiation. The reaction mixture was then poured into water (30 mL) and extracted with EtOAc (2 × 50 mL). The organic phases were combined and washed with brine (20 mL). The combined organic phases were dried over anhydrous Na₂SO₄, filtered, and concentrated under reduced pressure to give a crude residue. The crude material was purified by rapid silica gel (230 to 400 mesh) column purification with 50% to 60% EtOAc / petroleum ether to give (S)-5-amino-4-(5-(6-amino-3-cyano-4-propylpyridin-2-yl)-1-oxoisoindoline-2-yl)-5-oxovalerate tert-butyl ester (205 mg, 0.388 mmol, 76%) as a grayish-white solid.
[0782] Example 173
[0783] Benzenesulfonic acid (66.2 mg, 0.419 mmol) was added to a stirred solution of (S)-5-amino-4-(5-(6-amino-3-cyano-4-propylpyridin-2-yl)-1-oxoisoindolin-2-yl)-5-oxovalerate tert-butyl ester (200 mg, 0.419 mmol) in anhydrous acetonitrile (4.0 mL) in a microwave-safe vial under a nitrogen atmosphere. The vial was sealed and irradiated in a microwave at 130 °C for 1 hour. After the reaction was complete, the reaction mixture was concentrated to obtain a crude product as a grayish-white solid. Purification by preparative HPLC yielded a white solid 6-amino-2-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)-4-propylnicotinonitrile TFA (49 mg, 0.093 mmol, 22.3%).
[0784] Details of the preparative HPLC method: Column: XSelect C18 (150×19) mm, 5 μm; Mobile phase A: 0.1% TFA aqueous solution; Mobile phase B: acetonitrile; Flow rate: 15 mL / min.
[0785] Analytical data: LCMS: Column: Kinetex XB-C18 (75×3.0) mm, 2.6 μm; Mobile phase A: 5 mM ammonium formate; Mobile phase B: ACN; Flow rate: 1.0 mL / min; RT = 1.340; MS (ES): m / z = 404.2 [M+H] + HPLC purity: Column: XBridge C8 (50×4.6) mm, 3.5 μm; Mobile phase: A: 0.1% TFA aqueous solution; Mobile phase B: acetonitrile; Flow rate: 2.0 mL / min; RT = 2.788 min. Purity: 99.83%. 1 HNMR: 400MHz(DMSO): δ11.03(s,1H),7.93(s,1H),7.84(s,2H),7.12(br s,2H),6.44(s,1H),5.16(dd,J=4.80,13.40Hz,1H),4.48(dd,J=17.20,52.80Hz,2H),2.94(m,1 H),2.60-2.66(m,3H),2.50(m,1H),2.05(m,1H),1.66(q,J=7.20Hz,2H),0.97(t,J=7.20Hz,3H). 19 FNMR: 400MHz (DMSO): δ -74.73.
[0786] Example 174
[0787] 6-Amino-4-(difluoromethyl)-2-(2-(2,6-dioxopiridin-3-yl)-1-oxoisoindoline-5-yl)nicotinonitrile
[0788]
[0789] Preparation 174A.(S)-5-amino-4-(5-(6-amino-3-cyano-4-(difluoromethyl)pyridin-2-yl)-1-oxoisoindoline-2-yl)-5-oxovalerate tert-butyl ester
[0790] A solution of sodium bicarbonate (155 mg, 1.842 mmol) in water (1 mL) was added to a 30 mL microwave-safe vial containing a well-stirred solution of (S)-5-amino-5-oxo-4-(1-oxo-5-(4,4,5,5-tetramethyl-1,3,2-dioxapentylborane-2-yl)isoindolin-2-yl) in 1,4-dioxane (5 mL). The resulting reaction mixture was degassed by bubbling nitrogen into the reaction mixture for 10 minutes. Tetra(triphenylphosphine)palladium (0) (71.0 mg, 0.061 mmol) was then added to the reaction mixture, and the resulting reaction mixture was heated for 1 hour in a MW reactor under microwave irradiation at 120 °C. The reaction mixture was then poured into water (30 mL) and extracted with EtOAc (2 × 50 mL). The organic phases were combined and washed with brine (20 mL). The combined organic phases were dried over anhydrous Na₂SO₄, filtered, and concentrated under reduced pressure to give a crude residue. The crude residue was purified by rapid silica gel column chromatography (230 to 400 mesh) with 40–50% EtOAc / petroleum ether to give tert-butyl (S)-5-amino-4-(5-(6-amino-3-cyano-4-(difluoromethyl)pyridin-2-yl)-1-oxoisoindololin-2-yl)-5-oxovalerate (195 mg, 0.367 mmol, 59.7%) as a viscous brown syrup.
[0791] Example 174
[0792] Benzenesulfonic acid (65.2 mg, 0.412 mmol) was added to a stirred solution of (S)-5-amino-4-(5-(6-amino-5-cyano-4-(difluoromethyl)pyridin-2-yl)-1-oxoisoindolin-2-yl)-5-oxovalerate tert-butyl ester (200 mg, 0.412 mmol) in anhydrous acetonitrile (4.0 mL) in a microwave-safe vial under a nitrogen atmosphere. The vial was sealed and irradiated in a microwave at 130 °C for 1 hour. After the reaction was complete, the reaction mixture was concentrated to obtain a crude product as a grayish-white solid. Purification by preparative HPLC yielded 6-amino-4-(difluoromethyl)-2-(2-(2,6-dioxopirin-3-yl)-1-oxoisoindolin-5-yl)nicotinonitrile (55 mg, 0.133 mmol, 32.4%) as a white solid.
[0793] Details of the preparative HPLC method: Column: XBridge C18 (250×19) mm, 5 μm; Mobile phase A: 0.1% formic acid aqueous solution; Mobile phase B: acetonitrile; Flow rate: 15 mL / min.
[0794] Analytical data: LCMS: Column: Kinetex XB-C18 (75×3.0) mm, 2.6 μm; Mobile phase A: 5 mm ammonium formate; Mobile phase B: ACN; Flow rate: 1.0 mL / min; RT = 1.153; MS (ES): m / z = 412.2 [M+H] + HPLC purity: Column: Kinetex EVO C18 (100×4.6) mm, 2.6 μm; Mobile phase A: 0.05% TFA aqueous solution; Mobile phase B: ACN; Flow rate: 1.0 mL / min; RT = 5.230 min. Purity: 99.85%. 1 HNMR: 400MHz (DMSO): δ11.02(s,1H),7.95(s,1H),7.90-7.83(m,2H),7.64(s,2H),7.15(t,J=53.60Hz,1H),6.80(s,1H),5.17(dd,J =5.20,13.20Hz,1H),4.49(dd,J=17.60,52.00Hz,2H),2.98-2.88(m,1H),2.70-2.62(m,1H),2.50-2.42(m,1H),2.09-2.03(m,1H).
[0795] Example 175
[0796] 2-Amino-6-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindoline-5-yl)-5-(trifluoromethyl)nicotinic acid-
[0797] nitrile
[0798]
[0799] Preparations 175A and 175B: 2-amino-6-chloro-5-(trifluoromethyl)nicotinonitrile and 6-amino-2-chloro-5-(trifluoromethyl)nicotinonitrile
[0800] Ammonium hydroxide (10 mL, 257 mmol) was added to a stirred solution of 2,6-dichloro-5-(trifluoromethyl)nicotinonitrile (800 mg, 3.32 mmol) in ethanol (15 mL). The reaction mixture was heated in a pressure vessel at 50 °C. After 48 hours, the mixture was cooled in an ice bath and concentrated under reduced pressure to give 1 g of crude material. This crude material was purified by silica gel column chromatography (Isolera) using 10–20% EtOAc-hexane as eluent to obtain a white solid mixture of 2-amino-6-chloro-5-(trifluoromethyl)nicotinonitrile and 6-amino-2-chloro-5-(trifluoromethyl)nicotinonitrile (250 mg, 71.0%) as a locative isomer.
[0801] Preparations 175C and 175C.(S)-5-amino-4-(5-(6-amino-5-cyano-3-(trifluoromethyl)pyridin-2-yl)-1-oxoisoindolin-2-yl)-5-oxovalerate tert-butyl ester and (S)-5-amino-4-(5-(6-amino-3-cyano-5-(trifluoromethyl)pyridin-2-yl)-1-oxoisoindolin-2-yl)-5-oxovalerate tert-butyl ester
[0802] At room temperature, tert-butyl (400 mg, 0.900 mmol) of (S)-5-amino-5-oxo-4-(1-oxo-5-(4,4,5,5-tetramethyl-1,3,2-dioxapentylborane-2-yl)isoindolin-2-yl)valerate (400 mg, 0.900 mmol) in 1,4-dioxane (2 mL) with stirring was added to a solution of 2-amino-6-chloro-5-(trifluoromethyl)nicotinonitrile (180 mg, 0.810 mmol), followed by a solution of potassium carbonate (311 mg, 2.251 mmol) in water (0.5 mL). The reaction mixture was degassed under nitrogen for 15 min. PdCl2(dppf)-CH2Cl2 adduct (36.8 mg, 0.045 mmol) was added to this reaction mixture under nitrogen and degassed again for 5 min. The tube was sealed, heated to 100 °C, and stirred for 2 h. The reaction progress was monitored by TLC. The reaction mixture was cooled to room temperature and filtered through a diatomaceous earth pad. The filtrate was concentrated under reduced pressure to give 850 mg of crude material, which was purified by silica gel column chromatography (Isolera) using 60 to 70% EtOAc-petroleum ether as eluent to give a mixture of (S)-5-amino-4-(5-(6-amino-5-cyano-3-(trifluoromethyl)pyridin-2-yl)-1-oxoisoindoline-2-yl)-5-oxovalerate tert-butyl ester (150 mg, 0.281 mmol, 31.2%) as a brown solid.
[0803] Example 175
[0804] Benzenesulfonic acid (62.8 mg, 0.397 mmol) was added to a stirred solution of (S)-5-amino-4-(5-(6-amino-5-cyano-3-(trifluoromethyl)pyridin-2-yl)-1-oxoisoindolin-2-yl)-5-oxovalerate (150 mg, 0.397 mmol) in acetonitrile (3 mL). The reaction vial was sealed and irradiated in a microwave reactor at 120 °C for 1 hour. The mixture was concentrated under reduced pressure to obtain 250 mg of crude material, which was purified by preparative HPLC to yield two regiomeric isomers.
[0805] Preparative HPLC method details: Column: Sunfire C18 (150×19) mm, 5 μm, mobile phase A: 0.1% TFA aqueous solution, mobile phase B: acetonitrile, flow rate: 15 mL / min.
[0806] The following analytical data are for isomer 1: 2-amino-6-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindoline-5-yl)-5-(trifluoro-methyl)nicotinonitrile (7 mg, 0.016 mmol, 4.0%), a pale yellow solid. HPLC: Column: Kinetex Biphenyl (100 × 4.6) mm, 2.6 μm; Mobile phase A: 0.05% TFA aqueous solution; Mobile phase B: ACN; Flow rate: 1.0 mL / min; RT = 6.891 min; Purity = 97.63%. LCMS: Column: Kinetex XB-C18 (75 × 30) mm, 2.6 μm; Mobile phase A: 5 mM ammonium formate; Mobile phase B: ACN; Flow rate: 1.0 mL / min; RT = 1.51 min; Purity = 99.47%. 1 H-NMR (400MHz, DMSO-d6) δ11.01(s,1H),8.41(s,1H),7.82(d,J=8.00Hz,1H),7.74(bs,2H),7.65(s,1H),7.54(d,J=8.00Hz,1H),5.11(dd,J=4. 80,13.40Hz,1H),4.53(d,J=17.60Hz,1H),4.39(d,J=17.60Hz,1H),2.8 5-2.93(m,1H),2.61-2.65(m,1H),2.40-2.43(m,1H),2.06-2.07(m,1H).
[0807] Example 176
[0808] 2-Amino-4-(difluoromethyl)-6-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindoline-5-yl)nicotinonitrile
[0809]
[0810] Preparation 176A.(S)-5-amino-4-(5-(6-amino-5-cyano-4-(difluoromethyl)pyridin-2-yl)-1-oxoisoindolin-2-yl)-5-oxovalerate tert-butyl ester
[0811] A solution of 2.0 M sodium bicarbonate (225 mg, 2.67 mmol) in water (1.0 mL) was added to a 30 mL microwave-safe vial containing a well-stirred solution of (S)-5-amino-5-oxo-4-(1-oxo-5-(4,4,5,5-tetramethyl-1,3,2-dioxapentylborane-2-yl)isoindolin-2-yl) in anhydrous 1,4-dioxane (9.0 mL) under a nitrogen atmosphere. The resulting reaction mixture was degassed by bubbling nitrogen into the reaction mixture for 10 minutes. Tetra(triphenylphosphine)palladium(0) (37.1 mg, 0.032 mmol) was then added to the reaction mixture, and the reaction mixture was heated in a microwave reactor at 120 °C for 1 hour. After the reaction was complete, the reaction mixture was poured into water (20 mL) and extracted with EtOAc (2 × 50 mL). The organic phases were combined, washed with brine (30 mL), dried over anhydrous Na₂SO₄, and concentrated under reduced pressure to give a crude residue. This residue was mixed with a previous batch of crude residue (102 mg) and purified by silica gel column chromatography (Biotage) using 0 to 100% ethyl acetate / petroleum ether to give (S)-5-amino-4-(5-(6-amino-5-cyano-4-(difluoromethyl)pyridin-2-yl)-1-oxoisoindololin-2-yl)-5-oxovalerate tert-butyl ester (301 mg, 0.447 mmol, 41.8%) as a brown solid.
[0812] Example 176
[0813] Benzenesulfonic acid (98 mg, 0.618 mmol) was added to a 30 mL microwave-safe vial containing a well-stirred solution of (S)-5-amino-4-(5-(6-amino-5-cyano-4-(difluoromethyl)pyridin-2-yl)-1-oxoisoindolin-2-yl)-5-oxovalerate tert-butyl ester (300 mg, 0.618 mmol) in anhydrous acetonitrile (3.0 mL). The contents were heated in a microwave reactor at 120 °C for 2 hours. After the reaction was complete, excess solvent was removed from the reaction mixture under reduced pressure to give the crude compound. Purification by preparative HPLC yielded 2-amino-4-(difluoromethyl)-6-(2-(2,6-dioxopiridin-3-yl)-1-oxoisoindolin-5-yl)nicotinonitrile (101.20 mg, 0.244 mmol, 39.5%) as a grayish-white solid.
[0814] Details of the preparative purification method: Column: XBridge C18 (250×19) mm, 5 μm, mobile phase A: 0.1% TFA aqueous solution, mobile phase B: acetonitrile, flow rate: 15 mL / min.
[0815] Analytical data: LCMS: Column: Kinetex XB-C18 (75×30) mm, 2.6 μm; Mobile phase A: 5 mM ammonium formate, Mobile phase B: ACN, Flow rate: 1.0 mL / min; RT = 1.49 min, Purity = 92.25%. MS (ES): m / z = 412.2 (M+H) + HPLC: Kinetex EVO C18 (100×4.6) mm, 2.6 μm. Mobile phase A: 0.05% TFA aqueous solution; Mobile phase B: ACN; Flow rate: 1.0 mL / min. RT = 7.14 min, Purity: 99.29%. 1 H-NMR (400MHz, DMSO-d6) δ11.03(s,1H),8.33(s,1H),8.26(dd,J=1.20,8.00 Hz,1H),7.88(d,J=8.40Hz,1H),7.55(s,1H),7.43(s,2H),7.17(t,J=54.00H z,1H),5.18-5.14(m,1H),4.56(d,J=17.60Hz,1H),4.43(d,J=17.20Hz,1H), 2.98-2.89(m,1H),2.68-2.64(m,1H),2.40-2.33(m,1H),2.08-2.05(m,1H).
[0816] Example 177
[0817] 2-Amino-6-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindoline-5-yl)-4-(trifluoromethyl)nicotinic acid-
[0818] nitrile
[0819]
[0820] Preparation 177A. 2-Amino-6-chloro-4-(trifluoromethyl)nicotinonitrile
[0821] A well-stirred solution of 2,6-dichloro-4-(trifluoromethyl)nicotinonitrile (2.0 g, 8.30 mmol) and ammonium hydroxide (1.616 mL, 41.5 mmol) in ethanol (20 mL) in 50 mL Tinyclave was heated at 50 °C for 12 hours. After the reaction was complete, the solvent was concentrated under reduced pressure to obtain the crude material. This crude material was purified by rapid silica gel (230 to 400 mesh) column chromatography using 10% to 30% EtOAc / petroleum ether to give 2-amino-6-chloro-4-(trifluoromethyl)nicotinonitrile-177A (61 mg, 0.265 mmol, 3.20%) as a white solid.
[0822] Preparation 177B.(S)-5-amino-4-(5-(6-amino-5-cyano-4-(trifluoromethyl)pyridin-2-yl)-1-oxoisoindoline-2-yl)-5-oxovalerate tert-butyl ester
[0823] A solution of 2.0 M sodium bicarbonate (85 mg, 1.015 mmol) in water (0.2 mL) was added to a well-stirred solution of 2-amino-6-chloro-4-(trifluoromethyl)nicotinonitrile (90 mg, 0.406 mmol) and (S)-5-amino-5-oxo-4-(1-oxo-5-(4,4,5,5-tetramethyl-1,3,2-dioxaporon-2-yl)isoindolin-2-yl)tert-butyl valerate (180 mg, 0.406 mmol) in a 30 mL microwave-safe vial under a nitrogen atmosphere. The resulting reaction mixture was degassed by bubbling nitrogen into the reaction mixture for 10 minutes. Tetra(triphenylphosphine)palladium(0) (14.08 mg, 0.012 mmol) was then added to the reaction mixture, and the reaction mixture was heated in a microwave reactor at 120 °C for 1 hour. After cooling to room temperature, the reaction mixture was poured into water (30 mL) and extracted with EtOAc (2 × 50 mL). The organic phases were combined, washed with brine (30 mL), dried over anhydrous Na₂SO₄, and concentrated under reduced pressure to give a crude residue. The residue was purified by silica gel column chromatography (Biotage, eluted with 90% ethyl acetate / petroleum ether) to give (S)-5-amino-4-(5-(6-amino-5-cyano-4-(trifluoromethyl)pyridin-2-yl)-1-oxoisoindololin-2-yl)-5-oxovalerate tert-butyl ester (130 mg, 0.167 mmol, 41.1%) as a light brown solid.
[0824] Example 177
[0825] Benzenesulfonic acid (40.8 mg, 0.258 mmol) was added to a 30 mL microwave-safe vial containing a well-stirred solution of (S)-5-amino-4-(5-(6-amino-5-cyano-4-(trifluoromethyl)pyridin-2-yl)-1-oxoisoindolin-2-yl)-5-oxovalerate tert-butyl ester (130 mg, 0.258 mmol) in anhydrous acetonitrile (2.0 mL). The contents were heated in a microwave reactor at 120 °C for 2 hours. After the reaction was complete as indicated by LC-MS, excess solvent was removed from the reaction mixture under reduced pressure to give the crude compound. The crude compound was purified by preparative HPLC to give 2-amino-6-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)-4-(trifluoromethyl)nicotinonitrile (45 mg, 0.101 mmol, 39.0%) as a grayish-white solid.
[0826] Preparative HPLC method details: Column: Sunfire C18 (150×19) mm, 5 μm, mobile phase A: 0.1% TFA aqueous solution, mobile phase B: acetonitrile, flow rate: 15 mL / min.
[0827] Analytical data: LCMS: Column - Kinetex XB-C18 (75 × 3.0) mm, 2.6 μm, mobile phase A: 5 mM ammonium formate, and mobile phase B: ACN. RT = 1.96 min. MS (ES): m / z = 428.2 (MH) + LCMS purity 99.91%. HPLC: Kinetex EVO C18 (100 × 4.6) mm, 2.6 μm. Mobile phase A: 0.05% TFA aqueous solution; Mobile phase B: ACN; Flow rate: 1.0 mL / min. RT = 7.14 min, purity: 96.11%. 1 H-NMR (400MHz, DMSO-d6): δ11.02(s,1H),8.33-8.30(m,2H),7.88(d,J=8.00Hz,1H),7.66(d,J=10.40Hz,3H),5. 18-5.14(m,1H),4.58-4.42(m,2H),2.97-2.89(m,1H),2.65-2.53(m,1H),2.48-2.41(m,1H),2.07-2.02(m,1H).
[0828] Example 178
[0829] 2-Amino-6-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindoline-5-yl)-4-isopropylnicotinonitrile
[0830]
[0831] Preparations 178A and 178B: 2-amino-6-chloro-4-isopropylnicotinonitrile and 6-amino-2-chloro-4-isopropylnicotinonitrile
[0832] Ammonium hydroxide aqueous solution (40 mL, 1027 mmol) was added to a well-stirred solution of 2,6-dichloro-4-isopropylnicotinonitrile (1.0 g, 4.65 mmol) in ethanol (10 mL) at ambient temperature. The reaction mixture was heated at 50 °C for 16 hours. After the reaction was complete, the solvent was concentrated under reduced pressure to give a crude mixture of site-isomeric compounds. The residue was purified by silica gel column chromatography (Biotage, eluted with 20% ethyl acetate / petroleum ether) to give 2-amino-6-chloro-4-isopropylnicotinonitrile-178A (0.1 g, 0.504 mmol, 10.8%) and 6-amino-2-chloro-4-isopropylnicotinonitrile-178B (0.24 g, 1.173 mmol, 25.2%) as white solids.
[0833] Preparation 178C.(S)-5-amino-4-(5-(6-amino-5-cyano-4-isopropylpyridin-2-yl)-1-oxoisoindolin-2-yl)-5-oxovalerate tert-butyl ester
[0834] A 10 mL microwave-safe solution of sodium bicarbonate (0.095 g, 1.13 mmol) in water was added to a 10 mL microwave-safe vial containing a well-stirred solution of (S)-5-amino-5-oxo-4-(1-oxo-5-(4,4,5,5-tetramethyl-1,3,2-dioxapentylborane-2-yl)isoindolin-2-yl)valerate (0.2 g, 0.45 mmol), 2-amino-6-chloro-4-isopropylnicotinonitrile (0.088 g, 0.45 mmol), and 2-amino-6-chloro-4-propylnicotinonitrile (100 mg, 0.511 mmol) in 1,4-dioxane (5 mL). The resulting reaction mixture was degassed by bubbling nitrogen into the reaction mixture for 10 minutes. Tetra(triphenylphosphine)palladium(0) (0.052 g, 0.045 mmol) was added, and the resulting reaction mixture was heated at 120 °C in MW for 1 hour. After cooling, the reaction mixture was poured into water (20 mL) and extracted with EtOAc (2 × 50 mL). The combined organic layers were washed with brine (20 mL), dried over anhydrous Na₂SO₄, filtered, and concentrated under reduced pressure to give a crude residue. The crude substance was purified by rapid silica gel (230 to 400 mesh) column chromatography (Biotage, eluted with 50–60% ethyl acetate / petroleum ether) to give (S)-5-amino-4-(5-(6-amino-5-cyano-4-isopropylpyridin-2-yl)-1-oxoisoindolin-2-yl)-5-oxovalerate tert-butyl ester (0.12 g, 0.174 mmol, 38.7%) as a light brown liquid.
[0835] Example 178
[0836] Benzenesulfonic acid (0.040 g, 0.251 mmol) was added to a stirred solution of (S)-5-amino-4-(5-(6-amino-5-cyano-4-isopropylpyridin-2-yl)-1-oxoisoindoline-2-yl)-5-oxovalerate tert-butyl ester (0.12 g, 0.251 mmol) in anhydrous acetonitrile (4.0 mL) in a microwave-safe vial under a nitrogen atmosphere. The vial was sealed and irradiated in a microwave at 130 °C for 1 hour. After the reaction was complete, the reaction mixture was concentrated to obtain a crude product as a grayish-white solid. The product was purified by preparative HPLC. The eluent was lyophilized to give 2-amino-6-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindoline-5-yl)-4-isopropylnicotinonitrile TFA (35 mg, 0.062 mmol, 24.87% yield).
[0837] Details of the preparative HPLC method: Column: XBridge C-18 (150×19) mm 5 μm; Mobile phase A: 0.1% TFA aqueous solution, Mobile phase B: Acetonitrile, Flow rate: 15 mL / min.
[0838] Analysis data: LCMS: RT = 1.78 min. ACN / H₂O + ammonium formate, Kinetex XB-C18 (75 × 3.0) mm, 2.6 μm, (wavelength = 220 nm); MS (ES): m / z = 404.2 [M+1] + HPLC: Mobile phase A: 0.05% TFA aqueous solution; Mobile phase B: ACN; Flow rate: 1.0 mL / min. Kinetex EVO C18 (100 × 4.6) mm, 2.6 μm, RT = 6.75 min, purity: 95.55%. Kinetex Biphenyl (100 × 4.6) mm, 2.6 μm, RT = 7.20 min, purity: 92.39%. 1 HNMR(400MHz,DMSO-d6)δ11.02(s,1H),8.32(s,1H),8.25(d,J=7.60Hz,1H) ,7.84(d,J=8.00Hz,1H),7.32(s,1H),6.94(bs,2H),5.14-5.18(m,1H),4.53 -4.57(m,1H),4.40-4.44(m,1H),3.10-3.17(m,1H),2.89-2.97(m,1H),2.60 -2.68(m,1H),2.34-2.43(m,1H),2.03-2.10(m,1H),1.30(d,J=1.60Hz,6H).
[0839] Example 179
[0840] 6-Amino-2-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindoline-5-yl)-4-isopropylnicotinonitrile
[0841]
[0842] Preparation 179A.(S)-5-amino-4-(5-(6-amino-3-cyano-4-isopropylpyridin-2-yl)-1-oxoisoindolin-2-yl)-5-oxovalerate tert-butyl ester
[0843] Under a nitrogen atmosphere, at ambient temperature, a 30 mL microwave-safe vial containing tert-butyl (S)-5-amino-5-oxo-4-(1-oxo-5-(4,4,5,5-tetramethyl-1,3,2-dioxapentylborane-2-yl)isoindolin-2-yl)valerate (0.2 g, 0.450 mmol) and 6-amino-2-chloro-4-isopropylnicotinonitrile (0.088 g, 0.450 mmol) in 1,4-dioxane (5 mL) was added to a degassed water solution (2 mL). The resulting reaction mixture was further degassed by bubbling nitrogen into the reaction mixture for 10 minutes. Tetra(triphenylphosphine)palladium(0) (0.052 g, 0.045 mmol) was then added to the reaction mixture. The reaction mixture was heated at 120 °C for 1 hour under MW irradiation. After cooling to room temperature, the reaction mixture was poured into water (30 mL) and extracted with EtOAc (2 × 50 mL). The combined organic layers were washed with brine (20 mL), dried over anhydrous Na₂SO₄, filtered, and concentrated under reduced pressure to give a crude residue. The crude substance was purified by rapid silica gel (230 to 400 mesh) column chromatography (Biotage, eluting with 50-60% ethyl acetate / petroleum ether) to give (S)-5-amino-4-(5-(6-amino-3-cyano-4-isopropylpyridin-2-yl)-1-oxoisoindoline-2-yl)-5-oxovalerate tert-butyl ester (0.13 g, 0.220 mmol, 48.9%) as a light brown liquid.
[0844] Example 179
[0845] Benzenesulfonic acid (0.043 g, 0.272 mmol) was added to a stirred solution of (S)-5-amino-4-(5-(6-amino-3-cyano-4-isopropylpyridin-2-yl)-1-oxoisoindolin-2-yl)-5-oxovalerate tert-butyl ester (0.13 g, 0.272 mmol) in anhydrous acetonitrile (4.0 mL) in a microwave-safe vial. The reaction vial was sealed and heated at 130 °C for 1 hour under microwave irradiation. After the reaction was complete, the reactants were concentrated to obtain a crude product as a grayish-white solid. Purification was performed using preparative HPLC, and the pure eluent was lyophilized to obtain 6-amino-2-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindoline-5-yl)-4-isopropylnicotinonitrile (23 mg, 0.056 mmol, 20.43% yield) as a white solid.
[0846] Preparative HPLC method details: Column: XBridge C-18 (150x19) mm 5 μm. Mobile phase A: 0.1% formic acid aqueous solution, Mobile phase B: acetonitrile, Flow rate: 15 mL / min.
[0847] Analytical data: LCMS: Column - Kinetex XB-C18 (75×3.0) mm, 2.6 μm, wavelength = 220 nm; Mobile phase: 5 mM ammonium formate aqueous solution + acetonitrile. RT = 1.43 min. MS (ES): m / z = 404.2 [M+1] + HPLC: Mobile phase A: 0.05% TFA aqueous solution; Mobile phase B: ACN: 0.05% TFA aqueous solution; Flow rate: 1.0 mL / min. Kinetex EVO C18 (100 × 4.6) mm, 2.6 μm, RT = 5.14 min, purity: 95.55%. Kinetex Biphenyl (100 × 4.6) mm, 2.6 μm, RT = 5.78 min, purity: 92.39%. 1 HNMR 400MHZ(DMSO)δ11.02(s,1H),7.93(s,1H),7.84(s,2H),7.12(s,2H),6.50(s,1H),5.15-5.17(m,1H),4.52-4.56(m,1H),4.39-4. 43(m,1H),3.07-3.12(m,1H),2.97-2.98(m,1H),2.64-2.68(m,1H),2.51-2.60(m,1H),2.04-2.07(m,1H),1.27(d,J=6.40Hz,6H).
[0848] Example 180
[0849] 6-Amino-2-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindoline-5-yl)-5-methylnicotinonitrile
[0850]
[0851] Preparation 180A. 1-Oxy-2-chloro-5-cyano-3-methylpyridine
[0852] Trifluoroacetic anhydride (1.851 mL, 13.11 mmol) and urea peroxide (1.233 g, 13.11 mmol) were added to a well-stirred 100 mL single-necked round-bottom flask containing a thoroughly stirred solution of 6-chloro-5-methylnicotinonitrile (2.0 g, 13.11 mmol) in anhydrous dichloromethane (20 mL) at 0 °C under a nitrogen atmosphere. The reaction mixture was stirred at ambient temperature for 12 hours. The reaction progress was monitored by TLC. After the reaction was complete, the reaction was quenched with 10% saturated bicarbonate solution (50 mL). The aqueous layer was extracted with dichloromethane (2 × 100 mL). The combined organic layers were dried over anhydrous Na₂SO₄, filtered, and concentrated under reduced pressure to give the crude compound. The residue was purified by silica gel column chromatography (Biotage, eluted with 60% EtOAc / petroleum ether) to give 1-2-chloro-5-cyano-3-methylpyridine (1.01 g, 5.32 mmol, 40.6%) as a yellow solid.
[0853] Preparation 180B. 2,6-Dichloro-5-methylnicotinonitrile
[0854] A solution of 1-oxy-2-chloro-5-cyano-3-methylpyridine (1.0 g, 5.93 mmol) in POCl3 (5.53 mL, 59.3 mmol) was heated at 90 °C for 3 h. The reaction progress was monitored by TLC. After the reaction was complete, the reaction mixture was cooled to room temperature and concentrated under reduced pressure to remove excess POCl3. The residue was poured into crushed ice (50 mL) and extracted with EtOAc (2 × 50 mL). The combined organic layers were washed with saturated sodium bicarbonate solution (50 mL) and brine (50 mL), dried over anhydrous Na2SO4, and concentrated to give a crude residue. The residue was purified by silica gel column chromatography (Biotage, eluted with 20% EtOAc / petroleum ether) to give 2,6-dichloro-5-methylnicotinonitrile (0.890 g, 4.03 mmol, 67.9%) as a brown solid.
[0855] Preparation 180B. 6-Amino-2-chloro-5-methylnicotinonitrile
[0856] A well-stirred solution of 2,6-dichloro-4-(trifluoromethyl)nicotinonitrile (2.0 g, 8.30 mmol) and ammonium hydroxide (1.616 mL, 41.5 mmol) in ethanol (20 mL) in 50 mL Tinyclave was heated at 50 °C for 12 hours. After the reaction was complete, the solvent was removed under reduced pressure to obtain the crude material. This was purified by rapid silica gel (230 to 400 mesh) column chromatography using 10% to 30% EtOAc / petroleum ether to give 6-amino-2-chloro-5-methylnicotinonitrile (135 mg, 0.746 mmol, 15.5%) and 2-amino-6-chloro-5-methylnicotinonitrile-181B (25 mg, 0.115 mmol, 2.4%) as white solids.
[0857] Preparation 180C.(S)-5-amino-4-(5-(6-amino-3-cyano-5-methylpyridin-2-yl)-1-oxoisoindololin-2-yl)-5-oxovalerate tert-butyl ester
[0858] A solution of 2.0 M sodium bicarbonate (163 mg, 1.939 mmol) in water (0.3 mL) was added to a well-stirred solution of 6-amino-2-chloro-5-methylnicotinonitrile-180B (130 mg, 0.776 mmol) and (S)-5-amino-5-oxo-4-(1-oxo-5-(4,4,5,5-tetramethyl-1,3,2-dioxapentylborane-2-yl)isoindolin-2-yl)tert-butyl valerate (345 mg, 0.776 mmol) in a 30 mL microwave-safe vial under a nitrogen atmosphere. The resulting reaction mixture was degassed by bubbling nitrogen into the reaction mixture for 10 min. Tetra(triphenylphosphine)palladium(0) (26.9 mg, 0.023 mmol) was then added to the reaction mixture, and the reaction mixture was heated in a microwave reactor at 120 °C for 1 h. The reaction progress was monitored by TLC and LCMS. The reaction mixture was then poured into water (20 mL) and extracted with EtOAc (2 × 30 mL). The organic phases were combined, washed with brine (30 mL), dried over anhydrous Na₂SO₄, and concentrated under reduced pressure to give a crude residue. The residue was purified by silica gel column chromatography (Biotage, eluted with 90% ethyl acetate / petroleum ether) to give (S)-5-amino-4-(5-(6-amino-3-cyano-5-methylpyridin-2-yl)-1-oxoisoindololin-2-yl)-5-oxovalerate tert-butyl ester (302 mg, 0.629 mmol, 81%) as a brown solid.
[0859] Example 180
[0860] Benzenesulfonic acid (106 mg, 0.667 mmol) was added to a 30 mL microwave-safe vial containing a well-stirred solution of (S)-5-amino-4-(5-(6-amino-3-cyano-5-methylpyridin-2-yl)-1-oxoisoindolin-2-yl)-5-oxovalerate tert-butyl ester (300 mg, 0.667 mmol) in anhydrous acetonitrile (3.0 mL) under a nitrogen atmosphere at ambient temperature. The contents were heated in a microwave reactor at 120 °C for 2 hours. After the reaction was complete as indicated by LC-MS, excess solvent was removed from the reaction mixture under reduced pressure to give the crude compound. The crude material was purified by preparative HPLC to give 6-amino-2-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)-5-methylnicotinonitrile TFA (121 mg, 0.244 mmol, 36.5%) as a grayish-white solid.
[0861] Preparative HPLC method details: Column: XSelect C18 (150×19) mm, 5 μm, mobile phase A: 0.1% TFA aqueous solution, mobile phase B: acetonitrile, flow rate: 15 mL / min.
[0862] Analytical data: LCMS: XBridge C8 column (50 × 4.6 mm) 3.5 μm, mobile phase A: 0.1% TFA aqueous solution, mobile phase B: 0.1% TFA / ACN. RT = 1.38 min. MS (ES): m / z = 376.1 (M+H) + LCMS purity 93.53%. HPLC: Kinetex Biphenyl (100 × 4.6) mm, 2.6 μm. Mobile phase A: 0.05% TFA aqueous solution; Mobile phase B: 0.05% TFA / ACN; Flow rate: 1.0 mL / min. RT: 4.88 min, purity: 98.65%. 1 H-NMR (400MHz, DMSO-d6) δ11.03(bs,1H),7.96(s,1H),7.89-7.84(m,2H),7.74(d,J=0.80Hz,1H),7.03(s,2H),5.16(dd,J=5.20,13.20Hz,1H ),4.55(d,J=17.60Hz,1H),4.41(d,J=17.60Hz,1H),2.98-2.89(m,1H) ,2.68-2.67(m,1H),2.51-2.34(m,1H),2.12(s,3H),2.08-2.03(m,1H).
[0863] Example 181
[0864] 2-Amino-6-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindoline-5-yl)-5-methoxynicotinonitrile
[0865]
[0866] Preparation 181A. 2-Amino-6-chloro-5-methoxynicotinonitrile
[0867] Ammonium hydroxide (5 mL, 128 mmol) was added to a stirred solution of 2,6-dichloro-5-methoxynicotinonitrile (500 mg, 2.463 mmol) in ethanol (10 mL). The reaction mixture was heated in a pressure vessel at 50 °C. After 48 hours, the mixture was cooled in an ice bath and concentrated under reduced pressure to give 620 mg of crude substance. The residue was purified by silica gel column chromatography (Isolera) using 5–10% EtOAc / hexane as eluent to produce 2-amino-6-chloro-5-methoxynicotinonitrile (100 mg, 0.426 mmol, 17.3%) and 6-amino-2-chloro-5-methoxynicotinonitrile (80 mg, 0.42 mmol, 17.2%) as white solids.
[0868] Preparation 181B.(S)-5-amino-4-(5-(6-amino-5-cyano-3-methoxypyridin-2-yl)-1-oxoisoindolin-2-yl)-5-oxovalerate tert-butyl ester
[0869] At room temperature, tert-butyl (250 mg, 0.563 mmol) of (S)-5-amino-5-oxo-4-(1-oxo-5-(4,4,5,5-tetramethyl-1,3,2-dioxapentylborane-2-yl)isoindolin-2-yl)valerate (250 mg, 0.563 mmol) in 1,4-dioxane (2 mL) with stirring was added to a solution of 2-amino-6-chloro-5-methoxynicotinonitrile (93 mg, 0.506 mmol), followed by a solution of potassium carbonate (194 mg, 1.407 mmol) in water (0.5 mL). The reaction mixture was degassed under nitrogen for 15 min. Under a nitrogen atmosphere, the PdCl2(dppf)-CH2Cl2 adduct (22.97 mg, 0.028 mmol) was added to this reaction mixture. The tube was sealed, heated to 100 °C, and stirred for 2 h. The reaction mixture was cooled to room temperature and filtered through a diatomaceous earth mat. The filtrate was concentrated under reduced pressure to obtain a crude substance, which was purified by silica gel column chromatography (Isolera) using 60% to 70% EtOAc-hexane as eluent to obtain (S)-5-amino-4-(5-(6-amino-5-cyano-3-methoxypyridin-2-yl)-1-oxoisoindoline-2-yl)-5-oxovalerate tert-butyl ester (80 mg, 0.079 mmol, 14.0%) as a brown solid.
[0870] Example 181.
[0871] Benzenesulfonic acid (27.2 mg, 0.172 mmol) was added to a stirred solution of (S)-5-amino-4-(5-(6-amino-5-cyano-3-methoxypyridin-2-yl)-1-oxoisoindolin-2-yl)-5-oxovalerate tert-butyl ester (80 mg, 0.172 mmol) in anhydrous acetonitrile (3 mL). The reaction vial was sealed and irradiated in a microwave reactor at 120 °C for 1 hour. After the reaction was complete, the mixture was concentrated under reduced pressure to give 150 mg of crude substance. The residue was purified by preparative HPLC to give 2-amino-6-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)-5-methoxynicotinonitrile TFA (14 mg, 0.027 mmol, 15.9%) as a white solid.
[0872] Preparative HPLC method details: Column: Sunfire C18 (150×19) mm, 5 μm, mobile phase A: 0.1% TFA aqueous solution, mobile phase B: acetonitrile, flow rate: 15 mL / min.
[0873] Analytical data: HPLC: Column: Kinetex Biphenyl (100×4.6) mm, 2.6 μm; Mobile phase A: 0.05% TFA aqueous solution; Mobile phase B: ACN; Flow rate: 1.0 mL / min; RT = 4.98 min; Purity = 98.58%. LCMS: Column: Kinetex XB-C18 (75×30) mm, 2.6 μm; Mobile phase A: 5 mM ammonium formate; Mobile phase B: ACN; Flow rate: 1.0 mL / min; RT = 2.597 min; MS (ES): m / z = 392.0 [M+1] + Purity = 98.98%. 1 H NMR(400MHz,DMSO-d6)δ11.04(s,1H),8.46(s,1H),8.06(s,1H),7.99(d,J =8.00Hz,1H),7.85(d,J=7.60Hz,1H),7.51(bs,2H),5.16(dd,J=5.20,13.4 0Hz,1H),4.55(d,J=17.60Hz,1H),4.42(d,J=17.60Hz,1H),3.41(s,3H),2 .90-2.94(m,1H),2.60-2.68(m,1H),2.41-2.45(m,1H),2.03-2.06(m,1H).
[0874] Example 182
[0875] 6-Amino-5-cyclopropyl-2-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindoline-5-yl)nicotinonitrile
[0876]
[0877] Preparations 182A and 182B: 2-amino-6-chloro-5-cyclopropylnicotinonitrile and 6-amino-2-chloro-5-cyclopropylnicotinonitrile
[0878] An aqueous solution of NH3 (8 mL) was added to a 100 mL Tinyclave flask containing a well-stirred solution of 2,6-dichloro-5-cyclopropylnicotinonitrile (500 mg, 2.347 mmol) in ethanol (12 mL). The reaction mixture was heated at 50 °C for 48 hours. After the starting material was obtained, the solvent was concentrated under reduced pressure to give a crude product as a regiomeric mixture. The crude material was purified by silica gel (230 to 400 mesh) column chromatography with 5% to 30% EtOAc / petroleum ether to give 2-amino-6-chloro-5-cyclopropylnicotinonitrile-182A (35 mg, 0.175 mmol, 7.47%) and 6-amino-2-chloro-5-cyclopropylnicotinonitrile-182B (195 mg, 1.003 mmol, 42.7%) as a grayish-white solid.
[0879] Preparation 182C.(S)-5-amino-4-(5-(6-amino-3-cyano-5-cyclopropylpyridin-2-yl)-1-oxoisoindoline-2-yl)-5-oxovalerate tert-butyl ester
[0880] A solution of sodium bicarbonate (130 mg, 1.549 mmol) in water (2 mL) was added to a 30 mL microwave-safe vial containing a well-stirred solution of (S)-5-amino-5-oxo-4-(1-oxo-5-(4,4,5,5-tetramethyl-1,3,2-dioxapentylborane-2-yl)isoindolin-2-yl) in 1,4-dioxane (8 mL). The resulting reaction mixture was degassed by bubbling nitrogen into the reaction mixture for 10 minutes. Tetra(triphenylphosphine)palladium (0) (59.7 mg, 0.052 mmol) was then added to the reaction mixture, and the resulting reaction mixture was heated to 120 °C for 90 minutes in a MW reactor under microwave irradiation. The reaction mixture was diluted with EtOAc (25 mL) and filtered through a diatomaceous earth bed. The filtrate was concentrated under vacuum to give the crude compound. The crude material was purified by rapid silica gel (230 to 400 mesh) column purification with 80–90% EtOAc / petroleum ether to give (S)-5-amino-4-(5-(6-amino-3-cyano-5-cyclopropylpyridin-2-yl)-1-oxoisoindoline-2-yl)-5-oxovalerate tert-butyl ester (195 mg, 0.373 mmol, 72.3% yield) as a light brown solid.
[0881] Example 182
[0882] Benzenesulfonic acid (63.2 mg, 0.400 mmol) was added to a stirred solution of (S)-5-amino-4-(5-(6-amino-3-cyano-5-cyclopropylpyridin-2-yl)-1-oxoisoindolin-2-yl)-5-oxovalerate tert-butyl ester (190 mg, 0.400 mmol) in anhydrous acetonitrile (7.0 mL) in a microwave-safe vial. The vial was sealed and microwaved at 130 °C for 90 minutes. After the reaction was complete, the reaction mixture was concentrated to obtain a crude product as a grayish-white solid. Purification by preparative HPLC yielded a white solid of 6-amino-5-cyclopropyl-2-(2-(2,6-dioxopiridin-3-yl)-1-oxoisoindolin-5-yl)nicotinonitrile TFA (107 mg, 0.207 mmol, 51.7%).
[0883] Analytical data: LCMS: Column: Kinetex XB-C18 (75×3.0) mm, 2.6 μm; Mobile phase A: 5 mM ammonium formate aqueous solution; Mobile phase B: ACN; Flow rate: 1.0 mL / min; RT = 1.595; MS (ES): m / z = 402.0 [M+H] +HPLC: Column: Kinetex EVO C18 (100×4.6) mm, 2.6 μm; Mobile phase A: 0.05% TFA aqueous solution; Mobile phase B: ACN; Flow rate: 1.0 mL / min; RT = 5.598 min; Purity: 99.51%. 1 HNMR: 400MHZ(DMSO)δ11.02(s,1H),7.95(s,1H),7.90-7.83(m,2H),7.54(s,1H),7.15(br s,2H),5.16(dd,J=4.80,13.40Hz,1H),4.55(d,J=17.60Hz,1H),4.41(d,J=17.60Hz,1H),2 .90(m,1H),2.63(m,1H),2.45(m,1H),2.05(m,1H),1.70(m,1H),0.92(m,2H),0.67(m,2H). 19 FNMR: 400MHz (DMSO): δ -74.49.
[0884] Example 183
[0885] 2-Amino-5-cyclopropyl-6-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindoline-5-yl)nicotinonitrile
[0886]
[0887] Preparation 183A.(S)-5-amino-4-(5-(6-amino-5-cyano-3-cyclopropylpyridin-2-yl)-1-oxoisoindoline-2-yl)-5-oxovalerate tert-butyl ester
[0888] A solution of sodium bicarbonate (65.1 mg, 0.775 mmol) in water (1 mL) was added to a 10 mL microwave-safe vial containing a well-stirred solution of (S)-5-amino-5-oxo-4-(1-oxo-5-(4,4,5,5-tetramethyl-1,3,2-dioxapentylborane-2-yl)isoindolin-2-yl)valerate (126 mg, 0.284 mmol) and 2-amino-6-chloro-5-cyclopropylnicotinonitrile-182A (50 mg, 0.258 mmol) in 1,4-dioxane (4 mL). The resulting reaction mixture was degassed by bubbling nitrogen into the reaction mixture for 10 minutes. Tetra(triphenylphosphine)palladium (0) (29.8 mg, 0.026 mmol) was then added to the reaction mixture, and the resulting reaction mixture was heated in a MW reactor at 120 °C under microwave irradiation for 90 minutes. The reaction mixture was then diluted with EtOAc (20 mL) and filtered through a diatomaceous earth bed. The filtrate was concentrated under vacuum to give the crude compound. The crude material was purified by rapid silica gel (230 to 400 mesh) column purification with 80–90% EtOAc / petroleum ether to give (S)-5-amino-4-(5-(6-amino-5-cyano-3-cyclopropylpyridin-2-yl)-1-oxoisoindoline-2-yl)-5-oxovalerate tert-butyl ester (65 mg, 0.112 mmol, 43.2%) as a light brown solid.
[0889] Example 183
[0890] Benzenesulfonic acid (19.96 mg, 0.126 mmol) was added to a stirred solution of (S)-5-amino-4-(5-(6-amino-5-cyano-3-cyclopropylpyridin-2-yl)-1-oxoisoindolin-2-yl)-5-oxovalerate tert-butyl ester (60 mg, 0.126 mmol) in anhydrous acetonitrile (3.0 mL) in a microwave-safe vial. The vial was sealed and microwaved at 130 °C for 90 minutes. After the reaction was complete, the reaction mixture was concentrated to obtain a crude product as a grayish-white solid. Purification by preparative HPLC yielded 2-amino-5-cyclopropyl-6-(2-(2,6-dioxopiridin-3-yl)-1-oxoisoindolin-5-yl)nicotinonitrile TFA (31 mg, 0.060 mmol, 47.5%) as a grayish-white solid.
[0891] Details of the preparative HPLC method: Column: XSelect C18 (150×19) mm, 5 μm; Mobile phase A: 0.1% TFA aqueous solution; Mobile phase B: acetonitrile; Flow rate: 15 mL / min.
[0892] Analytical data: (LCMS: Column: Kinetex XB-C18 (75×3.0) mm, 2.6 μm; Mobile phase A: 5 mM ammonium formate aqueous solution; Mobile phase B: ACN; Flow rate: 1.0 mL / min; RT = 1.420, MS (ES): m / z = 404.2 [M+H]) + HPLC purity: Column: Kinetex EVO C18 (100×4.6) mm, 2.6 μm; Mobile phase A: 0.05% TFA aqueous solution; Mobile phase B: ACN; Flow rate: 1.0 mL / min; RT = 6.09 min; Purity: 99.63%. 1 HNMR: 400MHZ (DMSO): δ11.02 (s, 1H), 7.83-7.80 (m, 2H), 7.74 (d, J = 9.20Hz, 1H), 7.63 (s, 1H), 6.82 (br s,2H),5.16(dd,J=4.80,13.40Hz,1H),4.53(d,J=17.60Hz,1H),4.41(d,J=17.60Hz,1H),2 .91(m,1H),2.63(m,1H),2.45(m,1H),2.05(m,1H),1.73(m,1H),0.78(m,2H),0.62(m,2H). 19 FNMR: 400MHz (DMSO): δ -74.48.
[0893] Example 184
[0894] 3-(5-(6-amino-4-(4-benzylpiperazin-1-yl)pyridin-2-yl)-1-oxoisoindololin-2-yl)piperidin-2,6-dione
[0895]
[0896] Preparation 184A. 6-Chloro-4-iodo-N-(4-methoxybenzyl)pyridine-2-amine
[0897] DIPEA (9.57 mL, 54.8 mmol) and 4-methoxybenzylamine (2.62 mL, 20.08 mmol) were successively added to a solution of 2,6-dichloro-4-iodopyridine (5.0 g, 18.26 mmol) in 10 mL of NMP in Biotage microwave vials. The resulting mixture was heated at 120 °C for 2 hours under microwave irradiation. The reaction mixture was diluted with ice-cold water (50 mL) and extracted with ethyl acetate (50 mL × 3). The combined organic layers were washed with water (50 mL) and saturated brine (50 mL), dried over anhydrous Na₂SO₄, filtered, and concentrated under reduced pressure to give a crude product. The crude product was purified by silica gel (230 to 400 mesh) column chromatography (Grace, 100 g snap, anhydrous packaging) by elution with 5–30% ethyl acetate / petroleum ether. The eluents were combined and concentrated under reduced pressure to give 6-chloro-4-iodo-N-(4-methoxybenzyl)pyridine-2-amine (3.0 g, 7.86 mmol, 43.1%) as a grayish-white solid.
[0898] Preparation 184B. 4-(4-phenylmethylpiperazin-1-yl)-6-chloro-N-(4-methoxyphenylmethyl)pyridine-2-amine
[0899] 6-Chloro-4-iodo-N-(4-methoxybenzyl)pyridine-2-amine (0.5 g, 1.335 mmol), cesium carbonate (1.305 g, 4.00 mmol), and 1-benzylpiperazine (0.235 g, 1.335 mmol) were mixed with degassed 1,4-dioxane (15.0 mL). The reaction mixture was purged with N2 for 10 min. XPhos Pd G4 (0.053 g, 0.067 mmol) was then added. The reaction mixture was stirred at 70 °C for 16 h. The reaction vessel was cooled to ambient temperature, diluted with ethyl acetate (150 mL), filtered through a diatomaceous earth bed, and concentrated under vacuum to give a crude product. The crude product was purified by silica gel (230 to 400 mesh) column chromatography (Grace, 25 g snap, anhydrous packaging) by elution with 50–100% ethyl acetate / petroleum ether. The eluents were combined and concentrated under reduced pressure to give 4-(4-benzylpiperazin-1-yl)-6-chloro-N-(4-methoxybenzyl)pyridine-2-amine (0.4 g, 0.801 mmol, 60.0%) as a light brown solid.
[0900] Preparation 184C. 4-(4-phenylmethylpiperazin-1-yl)-6-chloropyridine-2-amine
[0901] TFA (3.0 mL, 38.9 mmol) was added to a stirred solution of 4-(4-phenylmethylpiperazin-1-yl)-6-chloro-N-(4-methoxyphenylmethyl)pyridine-2-amine (0.4 g, 0.946 mmol) in dichloromethane (10.0 mL) at 0 °C. The reaction mixture was stirred at ambient temperature for 5 hours. The solvent was concentrated under reduced pressure to give the crude product. The crude product was purified by silica gel (230 to 400 mesh) column chromatography (Grace, 25 g snap, anhydrous packaging) by elution with 5-20% methanol / dichloromethane. The eluates were combined and concentrated under reduced pressure to give 4-(4-phenylmethylpiperazin-1-yl)-6-chloropyridine-2-amine TFA (0.350 g, 1.089 mmol, 11%) as a light brown solid.
[0902] Preparation of tert-butyl 184C.(S)-5-amino-4-(5-(6-amino-4-(4-benzylpiperazin-1-yl)pyridin-2-yl)-1-oxoisoindololin-2-yl)-5-oxovalerate
[0903] (S)-5-amino-5-oxo-4-(1-oxo-5-(4,4,5,5-tetramethyl-1,3,2-dioxapentylborane-2-yl)isoindolin-2-yl)tert-butyl valerate (0.323 g, 0.727 mmol), 4-(4-benzylpiperazin-1-yl)-6-chloropyridin-2-amine (0.2 g, 0.660 mmol), tripotassium phosphate (1.761 mL, 5.28 mmol), and pre-degassed 1,4-dioxane (10.0 mL) and water (0.5 mL) were mixed. The reaction mixture was purged with N2 for 10 min. XPhos Pd G4 (0.026 g, 0.033 mmol) was then added. The reaction mixture was stirred at 70 °C for 16 h. The reaction vessel was cooled to ambient temperature, diluted with ethyl acetate (150 mL), filtered through a diatomaceous earth bed, and concentrated under vacuum to obtain a crude product. The crude product was purified by silica gel (230 to 400 mesh) column chromatography (Grace, 25 g snap, anhydrous packaging) by elution with 5-20% methanol / dichloromethane. The eluates were combined and concentrated under reduced pressure to give (S)-5-amino-4-(5-(6-amino-4-(4-benzylpiperazin-1-yl)pyridin-2-yl)-1-oxoisoindoline-2-yl)-5-oxovalerate tert-butyl ester (0.13 g, 0.155 mmol, 23.5%) as a light brown solid.
[0904] Example 184
[0905] TFA (1.0 mL) was added to a stirred solution of (S)-5-amino-4-(5-(6-amino-4-(4-benzylpiperazin-1-yl)pyridin-2-yl)-1-oxoisoindoline-2-yl)-5-oxovalerate tert-butyl ester (0.12 g, 0.205 mmol) in acetonitrile (2.0 mL). The reaction mixture was heated at 130 °C for 30 min in a microwave reactor. After the reaction was complete, the reaction mixture was concentrated to give a crude product as a grayish-white solid. The crude product was purified by preparative HPLC, followed by lyophilization of the eluent to give 3-(5-(6-amino-4-(4-benzylpiperazin-1-yl)pyridin-2-yl)-1-oxoisoindoline-2-yl)piperidine-2,6-dione TFA (35 mg, 0.062 mmol, 24.9%) as a white solid.
[0906] Preparative HPLC conditions: Column-X bridge C-18 (150×19) mm, 5 μm, mobile phase A: 0.1% TFA aqueous solution, mobile phase B: acetonitrile, flow rate: 15 mL / min.
[0907] Analytical data: LCMS: Column - XBridge C8 (50 × 4.6 mm) 5 μm, wavelength = 220 nm; mobile phase - 0.1% TFA aqueous solution + acetonitrile. RT = 1.30 min. MS (ES): m / z = 511.2 [M+1] + HPLC: Kinetex EVO C18 (100×4.6) m...
Claims
1. A compound of formula (I), or a salt thereof, wherein: Ring A is: Each R1 is independently F, Cl, Br, -CN, -OH, -NO2, or any of zero to six R 1a Substituted C 1-6 Alkyl, with zero to six R 1a Substituted C 1-3 Alkoxy, -CR x R x OCR x R x (phenyl), -NR y R y 、-NR x C(O)H、-NR x C(O)(C 1-2 Alkyl), -NR x C(O)NR x R x , -C(O)H, -C(O)OH, -C(O)O(C 1-3 Alkyl), -C(O)NR x R x 、-C(O)NR x (C 3-6 Cycloalkyl), -OC(O)(C 1-3 Alkyl), -SO2(C 1-3 Alkyl), -NHN(C 1-2 alkyl)2, -CH2CH2Si(CH3)3 or selected from C 3-6 Cycloalkyl, phenyl, pyridyl, piperidyl, piperazinyl, pyrrolidinyl, morpholinyl and dioxothiomorpholinyl ring groups, wherein the ring groups are substituted with zero to four R 1b replace; Each R 1a are independently F, Cl, -CN, -OH, C 1-2 Alkoxy, C 1-2 Fluoroalkoxy, -SO2(C 1-3 Alkyl) or phenyl; Each R 1b are independently F, Cl, C 1-2 Alkyl, C 1-2 Fluoroalkyl, C 1-2 Alkoxy, C 1-2 Fluoroalkoxy, -C(O)(C 1-3 Alkyl), -SO2(C 1-3 -CH2(phenyl); Each R x are independently H or -CH3; Each R y are independently H or C 1-6 Alkyl; and n is zero, 1, 2, 3, or 4; The prerequisite is that the compound is not 3-(5-(4-(Chloromethyl)pyridin-2-yl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione hydrochloride.
2. The compound according to claim 1 or a salt thereof, wherein: Each R1 is independently F, Cl, Br, -CN, -OH, -NO2, or any of zero to six R 1a Substituted C 1-5 Alkyl, with zero to five R 1a Substituted C 1-2 Alkoxy, -CR x R x OCH2(phenyl), -NR y R y 、-NR x C(O)CH3、-NR x C(O)NR x R x , -C(O)H, -C(O)OH, -C(O)O(C 1-2 Alkyl), -C(O)NR x R x 、-C(O)NR x (cyclopropyl), -OC(O)(C 1-2 Alkyl), -SO2(C 1-2 alkyl), -NHN(CH3)2, -CH2CH2Si(CH3)3 or selected from C 3-6 Cycloalkyl, phenyl, pyridyl, piperidyl, piperazinyl, pyrrolidinyl, morpholinyl and dioxothiomorpholinyl ring groups, wherein the ring groups are substituted with zero to three R 1b replace; Each R 1b are independently F, Cl, C 1-2 Alkyl, -CH2F, -CHF2, -CF3, C 1-2 Alkoxy, -OCF3, -C(O)(C 1-2 Alkyl) or -SO2(C 1-2 alkyl); and n is zero, 1, 2, or 3.
3. The compound according to claim 1 or a salt thereof, wherein: Each R1 is independently F, Cl, Br, -CN, -OH, -NO2, -CH3, -CH2CH3, -CHCH2CH3, -CH(CH3)2, -CH2C(CH3)3, -CF3, -CH2Cl, -CH2CN, -CH2(phenyl), -CH2OH, -CH2OCH2(phenyl), -OCH3, -OCH2CH3, -OCH2(phenyl), -NH2, -NH(CH3), -NH(CH2CH3), -NH(CH(CH3) )CH2CH3), -N(CH3)2, -N(CH2CH3)2, -NHC(O)CH3, -N(CH3)C(O)CH3, -C(O)H, -C(O)OCH3, -C(O)NH(cyclopropyl), -C(O)NH2, -C(O)N(CH3)2, -CH2CH2Si(CH3)3, -OC(O)CH3, -NHN(CH3)2, cyclopropyl, phenyl, pyridyl, (benzyl)morpholinyl, (methylsulfonyl)piperazinyl or acetylpiperazinyl; and n is zero, 1, 2, or 3.
4. The compound or salt thereof according to claim 1, wherein ring A is:
5. The compound or salt thereof according to any one of claims 1 to 3, wherein ring A is:
6. The compound or salt thereof according to any one of claims 1 to 3, wherein ring A is:
7. The compound or salt thereof according to any one of claims 1 to 3, wherein: each R1 is independently F, Cl, Br, -CN, -OH, -NO2, -CH3, -OCH3, -NH2, -NH(CH3), -NH(CH2CH3), -NHC(O)CH3, -NHN(CH3)2, cyclopropyl, phenyl, (benzyl)morpholinyl, (methylsulfonyl)piperazinyl or acetylpiperazinyl; and n is zero, 1, 2, or 3.
8. The compound or salt thereof according to any one of claims 1 to 3, wherein: A is each R1 is independently F, Cl, -CN, -OH, -CH3, -OCH3, -OCH2(phenyl), -NH2, -N(CH3)2, -CH2CH3, -CH(CH3)2, -CH2C(CH3)3, -CF3, -CH2Cl, -CH2CN, -CH2(phenyl), -CH2OH, -CH2OCH2(phenyl), -OCH2CH3, -NH(CH3), -NH(CH2CH3) or -NHC(O)CH3; and n is zero, 1, or 2.
9. The compound or salt thereof according to any one of claims 1 to 3, wherein: Ring A is each R1 is independently F, Cl, -OH, -CH3, -OCH3, -NH2, -C(O)OCH3, -C(O)NH(cyclopropyl) or phenyl; and n is zero, 1, or 2.
10. The compound or salt thereof according to any one of claims 1 to 3, wherein: Ring A is: each R1 is independently -CN, -NH2, -C(O)NH2, phenyl or pyridyl; and n is zero, 1, or 2.
11. The compound or salt thereof according to claim 1, wherein the compound is: 3-[1-Oxo-5-(quinolin-2-yl)-2,3-dihydro-1H-isoindol-2-yl]piperidine-2,6-dione (1); 3-[5-(4-aminoisoquinolin-3-yl)-1-oxo-2,3-dihydro-1H-isoindol-2-yl]piperidine-2,6-dione (2); 3-(5-{8-oxa-3,5-diazatricyclo[7.4.0.0 2 ,7] tridecan-1(9),2,4,6,10,12-hexaen-6-yl}-1-oxo-2,3-dihydro-1H-isoindol-2-yl)piperidin-2,6-dione (3); 3-[5-(1-aminoisoquinolin-3-yl)-1-oxo-2,3-dihydro-1H-isoindol-2-yl]piperidine-2,6-dione (4); 3-[5-(3-aminoquinoxalin-2-yl)-1-oxo-2,3-dihydro-1H-isoindol-2-yl]piperidine-2,6-dione (5); 3-(1-oxo-5-{7H-pyrrolo[2,3-c]pyridazin-3-yl}-2,3-dihydro-1H-isoindol-2-yl)piperidine-2,6-dione (6); 3-[1-Oxo-5-(quinoxalin-2-yl)-2,3-dihydro-1H-isoindol-2-yl]piperidine-2,6-dione (7); 3-[5-(4-aminoquinolin-2-yl)-1-oxo-2,3-dihydro-1H-isoindol-2-yl]piperidine-2,6-dione (8); 3-[1-Oxo-5-(quinazolin-2-yl)-2,3-dihydro-1H-isoindol-2-yl]piperidine-2,6-dione (9); 3-(5-{2-[(But-2-yl)amino]-[1,3]thiazolo[5,4-b]pyridin-5-yl}-1-oxo-2,3-dihydro-1H-isoindol-2-yl)piperidine-2,6-dione (10); 3-(5-{7-fluoro-1H-pyrrolo[3,2-c]pyridin-4-yl}-1-oxo-2,3-dihydro-1H-isoindol-2-yl)piperidine-2,6-dione (11); 3-[5-(4-methoxyquinolin-2-yl)-1-oxo-2,3-dihydro-1H-isoindol-2-yl]piperidine-2,6-dione (12); 3-[1-Oxo-5-(4-phenylquinolin-2-yl)-2,3-dihydro-1H-isoindol-2-yl]piperidine-2,6-dione (13); N-cyclopropyl-2-[2-(2,6-dioxopiperidin-3-yl)-1-oxo-2,3-dihydro-1H-isoindol-5-yl]quinoline-4-carboxamide (14); 3-{5-[6-chloro-4-(diethylamino)quinazolin-2-yl]-1-oxo-2,3-dihydro-1H-isoindol-2-yl}piperidine-2,6-dione (15); 3-[5-(4-amino-6,7-dimethoxyquinazolin-2-yl)-1-oxo-2,3-dihydro-1H-isoindol-2-yl]piperidine-2,6-dione (16); 3-[5-(6-methoxyisoquinolin-1-yl)-1-oxo-2,3-dihydro-1H-isoindol-2-yl]piperidine-2,6-dione (17); 3-[5-(6-Chloroquinoxalin-2-yl)-1-oxo-2,3-dihydro-1H-isoindol-2-yl]piperidine-2,6-dione (18); 3-[5-(7-Fluoroisoquinolin-1-yl)-1-oxo-2,3-dihydro-1H-isoindol-2-yl]piperidine-2,6-dione (19); 3-[5-(5-Fluoroisoquinolin-1-yl)-1-oxo-2,3-dihydro-1H-isoindol-2-yl]piperidine-2,6-dione (20); 3-[5-(1,5-naphthyridin-2-yl)-1-oxo-2,3-dihydro-1H-isoindol-2-yl]piperidine-2,6-dione (21); 3-[5-(4-aminoquinazolin-2-yl)-1-oxo-2,3-dihydro-1H-isoindol-2-yl]piperidine-2,6-dione (22); 3-[5-(6-methylisoquinolin-1-yl)-1-oxo-2,3-dihydro-1H-isoindol-2-yl]piperidine-2,6-dione (23); 3-[5-(4-methylquinolin-2-yl)-1-oxo-2,3-dihydro-1H-isoindol-2-yl]piperidine-2,6-dione (24); 3-[5-(3-aminoisoquinolin-1-yl)-1-oxo-2,3-dihydro-1H-isoindol-2-yl]piperidine-2,6-dione (25); 3-[5-(6-Fluoroquinoxalin-2-yl)-1-oxo-2,3-dihydro-1H-isoindol-2-yl]piperidine-2,6-dione (26); 3-[5-(6-Chloroquinolin-2-yl)-1-oxo-2,3-dihydro-1H-isoindol-2-yl]piperidine-2,6-dione (27); 3-[5-(7-chloroquinolin-2-yl)-1-oxo-2,3-dihydro-1H-isoindol-2-yl]piperidine-2,6-dione (28); 3-[5-(6-methoxyquinolin-2-yl)-1-oxo-2,3-dihydro-1H-isoindol-2-yl]piperidine-2,6-dione (29); 3-[2-(2,6-dioxopiperidin-3-yl)-1-oxo-2,3-dihydro-1H-isoindol-5-yl]quinoxaline-2-carboxylic acid ethyl ester (30); 2-[2-(2,6-dioxopiperidin-3-yl)-1-oxo-2,3-dihydro-1H-isoindol-5-yl]quinoline-6-carboxylic acid methyl ester (31); 3-[5-(3-methylquinolin-2-yl)-1-oxo-2,3-dihydro-1H-isoindol-2-yl]piperidine-2,6-dione (32); 3-[5-(8-methoxyquinolin-2-yl)-1-oxo-2,3-dihydro-1H-isoindol-2-yl]piperidine-2,6-dione (33); 3-[5-(8-Chloroquinolin-2-yl)-1-oxo-2,3-dihydro-1H-isoindol-2-yl]piperidine-2,6-dione (34); 3-[5-(6-Fluoroquinazolin-2-yl)-1-oxo-2,3-dihydro-1H-isoindol-2-yl]piperidine-2,6-dione (35); 3-[5-(3-chloroquinolin-2-yl)-1-oxo-2,3-dihydro-1H-isoindol-2-yl]piperidine-2,6-dione (36); 3-[5-(4-Hydroxyquinolin-2-yl)-1-oxo-2,3-dihydro-1H-isoindol-2-yl]piperidine-2,6-dione (37); 3-[5-(6-Fluoroquinolin-2-yl)-1-oxo-2,3-dihydro-1H-isoindol-2-yl]piperidine-2,6-dione (38); 3-[5-(6-Methylquinolin-2-yl)-1-oxo-2,3-dihydro-1H-isoindol-2-yl]piperidine-2,6-dione (39); 3-[5-(6-Hydroxyquinolin-2-yl)-1-oxo-2,3-dihydro-1H-isoindol-2-yl]piperidine-2,6-dione (40); 2-[2-(2,6-dioxopiperidin-3-yl)-1-oxo-2,3-dihydro-1H-isoindol-5-yl]quinazoline-7-carboxylic acid methyl ester (41); 3-(5-{5-amino-3-[2-(trimethylsilyl)ethyl]-3H-[1,2,3]triazolo[4,5-d]pyrimidin-7-yl}-1-oxo-2,3-dihydro-1H-isoindol-2-yl)piperidine-2,6-dione (42); 3-[5-(2-amino-9H-purin-6-yl)-1-oxo-2,3-dihydro-1H-isoindol-2-yl]piperidine-2,6-dione (43); 3-[5-(6-amino-7H-purin-2-yl)-1-oxo-2,3-dihydro-1H-isoindol-2-yl]piperidine-2,6-dione (44); 3-(5-{6-amino-1-ethyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl}-1-oxo-2,3-dihydro-1H-isoindol-2-yl)piperidine-2,6-dione (45); 3-{5-[5-amino-1-(2,2-dimethylpropyl)-4-oxo-1,4-dihydro-1,6-naphthyridin-7-yl]-1-oxo-2,3-dihydro-1H-isoindol-2-yl}piperidine-2,6-dione (46); 3-[5-(5-amino-4-oxo-1,4-dihydro-1,6-naphthyridin-7-yl)-1-oxo-2,3-dihydro-1H-isoindol-2-yl]piperidine-2,6-dione (47); N-{3-[2-(2,6-dioxopiperidin-3-yl)-1-oxo-2,3-dihydro-1H-isoindol-5-yl]isoquinolin-1-yl}acetamide (48); 3-{5-[1-(Dimethylamino)isoquinolin-3-yl]-1-oxo-2,3-dihydro-1H-isoindol-2-yl}piperidine-2,6-dione (49); 3-{5-[1-(Methylamino)isoquinolin-3-yl]-1-oxo-2,3-dihydro-1H-isoindol-2-yl}piperidine-2,6-dione (50); 3-{5-[5-(methylamino)-1,6-naphthyridin-7-yl]-1-oxo-2,3-dihydro-1H-isoindol-2-yl}piperidine-2,6-dione (51); N-{3-[2-(2,6-dioxopiperidin-3-yl)-1-oxo-2,3-dihydro-1H-isoindol-5-yl]isoquinolin-1-yl}-N-methylacetamide (52); 3-[5-(6-amino-1,7-naphthyridin-8-yl)-1-oxo-2,3-dihydro-1H-isoindol-2-yl]piperidine-2,6-dione (53); 3-[5-(3-Amino-5-methoxyisoquinolin-1-yl)-1-oxo-2,3-dihydro-1H-isoindol-2-yl]piperidine-2,6-dione (54); 3-(5-(4-(4-acetylpiperazin-1-yl)pyrido[2,3-d]pyrimidin-2-yl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione (55); 3-(5-{4-bromo-1H-pyrrolo[2,3-c]pyridin-7-yl}-1-oxo-2,3-dihydro-1H-isoindol-2-yl)piperidine-2,6-dione (56); 3-[5-(5-amino-1,6-naphthyridin-7-yl)-1-oxo-2,3-dihydro-1H-isoindol-2-yl]piperidine-2,6-dione (57); 3-[5-(3,6-dimethoxyisoquinolin-1-yl)-1-oxo-2,3-dihydro-1H-isoindol-2-yl]piperidine-2,6-dione (58); 1-[2-(2,6-dioxopiperidin-3-yl)-1-oxo-2,3-dihydro-1H-isoindol-5-yl]isoquinoline-3-carbonitrile (59); 4-[2-(2,6-dioxopiperidin-3-yl)-1-oxo-2,3-dihydro-1H-isoindol-5-yl]thieno[3,2-c]pyridine-2-carbaldehyde (60); 3-{5-[1-methyl-4-(methylamino)-1H-imidazo[4,5-c]pyridin-6-yl]-1-oxo-2,3-dihydro-1H-isoindol-2-yl}piperidine-2,6-dione (61); 3-(5-{2-methyl-4-oxo-4H-pyrano[2,3-b]pyridin-7-yl}-1-oxo-2,3-dihydro-1H-isoindol-2-yl)piperidine-2,6-dione (62); 3-{5-[5,7-dichloro-3-(dimethylamino)isoquinolin-1-yl]-1-oxo-2,3-dihydro-1H-isoindol-2-yl}piperidine-2,6-dione (63); 3-[5-(1,7-naphthyridin-8-yl)-1-oxo-2,3-dihydro-1H-isoindol-2-yl]piperidine-2,6-dione (64); 3-(5-{2-aminoimidazo[1,2-b]pyridazin-6-yl}-1-oxo-2,3-dihydro-1H-isoindol-2-yl)piperidine-2,6-dione (65); 3-[5-(Isoquinolin-1-yl)-1-oxo-2,3-dihydro-1H-isoindol-2-yl]piperidine-2,6-dione (66); 3-[5-(Isoquinolin-3-yl)-1-oxo-2,3-dihydro-1H-isoindol-2-yl]piperidine-2,6-dione (67); 3-(5-(2-amino-6-methoxypyrimidin-4-yl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione (68); 3-(5-(6-aminopyridin-2-yl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione (69); 3-(5-(2-aminopyrimidin-4-yl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione (70); 3-(1-oxo-5-(4-phenylpyrimidin-2-yl)isoindolin-2-yl)piperidine-2,6-dione (71); 3-(1-oxo-5-(4-(pyridin-3-yl)pyrimidin-2-yl)isoindolin-2-yl)piperidine-2,6-dione (72); 3-(5-(4-amino-6-phenyl-1,3,5-triazine-2-yl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione (73); 3-(1-Oxo-5-(4-phenylpyridin-2-yl)isoindolin-2-yl)piperidine-2,6-dione (74); 3-(1-oxo-5-(4-(pyridin-2-yl)pyrimidin-2-yl)isoindolin-2-yl)piperidine-2,6-dione (75); 3-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)pyridazine-4-carbonitrile (76); 6-[2-(2,6-dioxopiperidin-3-yl)-1-oxo-2,3-dihydro-1H-isoindol-5-yl]pyridazine-3-carbonitrile (77); 6-[2-(2,6-dioxopiperidin-3-yl)-1-oxo-2,3-dihydro-1H-isoindol-5-yl]pyridazine-3-carboxamide (78); 3-[5-(6-amino-3-nitropyridin-2-yl)-1-oxo-2,3-dihydro-1H-isoindol-2-yl]piperidine-2,6-dione (79); 4-Amino-2-[2-(2,6-dioxopiperidin-3-yl)-1-oxo-2,3-dihydro-1H-isoindol-5-yl]pyrimidine-5-carbonitrile (80); 4-amino-2-[2-(2,6-dioxopiperidin-3-yl)-1-oxo-2,3-dihydro-1H-isoindol-5-yl]pyrimidine-5-carboxamide (81); (3S)-3-[5-(1-aminoisoquinolin-3-yl)-1-oxo-2,3-dihydro-1H-isoindol-2-yl]piperidine-2,6-dione (82); (3R)-3-[5-(1-aminoisoquinolin-3-yl)-1-oxo-2,3-dihydro-1H-isoindol-2-yl]piperidine-2,6-dione (83); (3S)-3-[5-(1-amino-4-ethoxyisoquinolin-3-yl)-1-oxo-2,3-dihydro-1H-isoindol-2-yl]piperidine-2,6-dione (84); 3-(5-(4-ethoxyisoquinolin-3-yl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione (85); 3-(5-(1-chloro-4-ethoxyisoquinolin-3-yl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione (86); 3-(5-(2,3-dihydro-1H-pyrido[3,4-b][1,4]oxazin-7-yl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione (87); 3-(5-(1-methylisoquinolin-3-yl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione (88); 3-(5-(1-cyclopropylisoquinolin-3-yl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione (89); 1-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)isoquinoline-4-carbonitrile (90); 3-(1-Oxo-5-(quinazolin-4-yl)isoindolin-2-yl)piperidine-2,6-dione (91); 3-(5-(6-methyl-5-oxo-5,6,7,8-tetrahydro-1,6-naphthyridin-2-yl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione (92); 3-(5-(3-chloroquinoxalin-2-yl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione (93); 3-(5-(3-methoxyquinoxalin-2-yl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione (94); 3-(5-(3-(Ethylamino)quinoxalin-2-yl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione (95); 3-(5-(3-Hydroxyquinoxalin-2-yl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione (96); 3-(5-(3-cyclopropylquinoxalin-2-yl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione (97); 3-(5-(3-isopropylquinoxalin-2-yl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione (98); 3-(1-Oxo-5-(3-phenylquinoxalin-2-yl)isoindolin-2-yl)piperidine-2,6-dione (99); 3-(5-(1,6-naphthyridin-5-yl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione (100); 3-(5-(6-amino-3-bromopyridin-2-yl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione (101); 3-(5-(6-aminoisoquinolin-3-yl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione (102); 3-(5-(4-methoxyisoquinolin-1-yl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione (103); 3-(5-(3-methoxypyridin-2-yl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione (104); 3-(5-(4-(Benzyloxy)isoquinolin-1-yl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione (105); 3-(5-(6-amino-3-methoxypyridin-2-yl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione (106); 3-(5-(3-(Hydroxymethyl)pyridin-2-yl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione (107); 3-(5-(4-(Hydroxymethyl)pyridin-2-yl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione (108); 3-(1-oxo-5-(pyridin-2-yl)isoindolin-2-yl)piperidine-2,6-dione (109); 2-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)isonicotinonitrile (110); 2-(2-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)pyridin-4-yl)acetonitrile (111); 3-(5-(6-amino-4-(hydroxymethyl)pyridin-2-yl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione (112); 3-(5-(2,3-dihydro-1H-pyrrolo[2,3-c]pyridin-5-yl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione (113); 3-(1-oxo-5-(2-oxo-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-6-yl)isoindolin-2-yl)piperidine-2,6-dione (114); 3-(1-oxo-5-(5,6,7,8-tetrahydroisoquinolin-3-yl)isoindolin-2-yl)piperidine-2,6-dione (115); 3-(5-(6-amino-5-methylpyridin-2-yl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione (116); 3-(5-(5,6-diaminopyridin-2-yl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione (117); 3-(1-Oxo-5-(1,2,3,4-tetrahydropyrido[2,3-b]pyrazin-6-yl)isoindolin-2-yl)piperidine-2,6-dione (118); 3-(5-(5-amino-4,6-dimethylpyridin-2-yl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione (119); 3-(5-(6-amino-4-(trifluoromethyl)pyridin-2-yl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione (120); 3-(5-(4,5-dimethylpyridin-2-yl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione (121); (3S)-3-[5-(1,8-naphthyridin-2-yl)-1-oxo-2,3-dihydro-1H-isoindol-2-yl]piperidine-2,6-dione (122); (S)-3-(5-(3-aminoisoquinolin-1-yl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione (123); (S)-N-(1-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)isoquinolin-3-yl)acetamide (124); 3-{2-[(3S)-2,6-dioxopiperidin-3-yl]-1-oxo-2,3-dihydro-1H-isoindol-5-yl}isoquinoline-1-carbonitrile (125); 3-{2-[(3S)-2,6-dioxopiperidin-3-yl]-1-oxo-2,3-dihydro-1H-isoindol-5-yl}isoquinoline-1-carboxamide (126); (4S)-7-{2-[(3S)-2,6-dioxopiperidin-3-yl]-1-oxo-2,3-dihydro-1H-isoindol-5-yl}-2H,3H,4H-pyrano[2,3-b]pyridine-4-yl acetate (127); (4R)-7-{2-[(3S)-2,6-dioxopiperidin-3-yl]-1-oxo-2,3-dihydro-1H-isoindol-5-yl}-2H,3H,4H-pyrano[2,3-b]pyridine-4-yl acetate (128); 3-{5-[7-chloro-4-(dimethylamino)isoquinolin-1-yl]-1-oxo-2,3-dihydro-1H-isoindol-2-yl}piperidine-2,6-dione (129); 1-Amino-3-[2-(2,6-dioxopiperidin-3-yl)-1-oxo-2,3-dihydro-1H-isoindol-5-yl]-N,N-dimethylisoquinoline-4-carboxamide (130); 3-[5-(1-amino-4-methylisoquinolin-3-yl)-1-oxo-2,3-dihydro-1H-isoindol-2-yl]piperidine-2,6-dione (131); 3-[5-(6-amino-3-cyclopropylpyridin-2-yl)-1-oxo-2,3-dihydro-1H-isoindol-2-yl]piperidine-2,6-dione (132); 3-[5-(6-aminoisoquinolin-1-yl)-1-oxo-2,3-dihydro-1H-isoindol-2-yl]piperidine-2,6-dione (133); N-{1-[2-(2,6-dioxopiperidin-3-yl)-1-oxo-2,3-dihydro-1H-isoindol-5-yl]isoquinolin-6-yl}acetamide (134); 3-{5-[6-amino-4-(chloromethyl)pyridin-2-yl]-1-oxo-2,3-dihydro-1H-isoindol-2-yl}piperidine-2,6-dione (135); 3-(1-Oxo-5-{5H,6H,7H,8H,9H-pyrido[2,3-b]azepin-2-yl}-2,3-dihydro-1H-isoindol-2-yl)piperidine-2,6-dione (136); 3-[1-Oxo-5-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)-2,3-dihydro-1H-isoindol-2-yl]piperidine-2,6-dione (137); 3-{5-[6-(2,2-dimethylhydrazine-1-yl)pyridin-2-yl]-1-oxo-2,3-dihydro-1H-isoindol-2-yl}piperidine-2,6-dione (138); 3-(5-(1H-imidazo[4,5-b]pyridin-5-yl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione (139); 3-(5-(6-amino-4-methylpyridin-2-yl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione (140); 3-(5-(3,4-dihydro-2H-pyrido[3,2-b][1,4]oxazin-6-yl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione (141); 3-(5-(6-aminopyrazin-2-yl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione (142); 3-(5-(2-amino-6-methylpyrimidin-4-yl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione (143); 3-(5-(4,6-dimethylpyridin-2-yl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione (144); 3-(5-(5-chloro-3-hydroxyisoquinolin-1-yl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione (145); 3-(5-(6-methoxy-4-methylpyridin-2-yl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione (146); 3-(5-(6-Hydroxy-4-methylpyridin-2-yl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione (147); 2-amino-6-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)-4-methylnicotinonitrile (148); 2-Amino-6-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)isonicotinonitrile (149); 3-(5-(1-amino-5,6,7,8-tetrahydroisoquinolin-3-yl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione (150); 3-(5-(6-amino-4,5-dimethylpyridin-2-yl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione (151); 6-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)-4-methylnicotinonitrile (152); 3-(5-(6-amino-5-methoxy-4-methylpyridin-2-yl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione (153); 3-(5-(6-amino-5-methoxy-4-methylpyridin-2-yl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione (154); 3-[5-(6-Methoxypyridin-2-yl)-1-oxo-2,3-dihydro-1H-isoindol-2-yl]piperidine-2,6-dione (155); 3-[5-(1-methoxyisoquinolin-3-yl)-1-oxo-2,3-dihydro-1H-isoindol-2-yl]piperidine-2,6-dione (156); 3-[1-Oxo-5-(1-oxo-1,2-dihydroisoquinolin-3-yl)-2,3-dihydro-1H-isoindol-2-yl]piperidine-2,6-dione (157); 3-(5-{1-Benzyl-1H-pyrrolo[3,2-c]pyridin-6-yl}-1-oxo-2,3-dihydro-1H-isoindol-2-yl)piperidine-2,6-dione (158); 3-(1-Oxo-5-(1H-pyrrolo[3,2-c]pyridin-6-yl)isoindolin-2-yl)piperidine-2,6-dione (159); 3-(1-Oxo-5-(1H-pyrrolo[3,2-c]pyridin-4-yl)isoindolin-2-yl)piperidine-2,6-dione (160); 3-(5-(1-Benzyl-1H-pyrrolo[3,2-c]pyridin-4-yl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione (161); 6-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)2-cyanopyridine (162); 3-(5-(6-amino-4-(trifluoromethyl)pyridin-2-yl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione (163); 3-(5-(6-amino-4-methoxypyridin-2-yl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione (164); 3-(5-(6-amino-4-chloropyridin-2-yl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione (165); 2-Amino-6-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)nicotinonitrile (166); 2-Amino-6-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)pyridine-3,5-dicarbonitrile (168); 2-Amino-6-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)-5-fluoronicotinonitrile (169); 3-(5-(6-amino-4-phenylpyridin-2-yl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione (170); 6-amino-2-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)-4-(trifluoromethyl)nicotine-carbonitrile (171); 2-Amino-6-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)-4-propylnicotinonitrile (172); 6-amino-2-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)-4-propylnicotinonitrile (173); 6-amino-4-(difluoromethyl)-2-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)nicotinonitrile (174); 2-Amino-6-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)-5-(trifluoromethyl)nicotinonitrile (175); 2-amino-4-(difluoromethyl)-6-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)nicotinonitrile (176); 2-Amino-6-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)-4-(trifluoromethyl)nicotine-carbonitrile (177); 2-amino-6-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)-4-isopropylnicotinonitrile (178); 6-amino-2-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)-4-isopropylnicotinonitrile (179); 6-amino-2-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)-5-methylnicotinonitrile (180); 2-Amino-6-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)-5-methoxynicotinonitrile (181); 6-amino-5-cyclopropyl-2-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)nicotinonitrile (182); 2-Amino-5-cyclopropyl-6-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)nicotinonitrile (183); 3-(5-(6-amino-4-(4-benzylpiperazin-1-yl)pyridin-2-yl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione (184); 3-(5-(6-amino-4-(4-(methylsulfonyl)piperazin-1-yl)pyridin-2-yl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione (185); 3-(5-(4-(4-acetylpiperazin-1-yl)-6-aminopyridin-2-yl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione (186); 3-(5-(4-methyl-6-(methylamino)pyridin-2-yl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione (187); 3-(5-(6-(ethylamino)-4-methylpyridin-2-yl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione (188); or 3-(5-(4,5-Dimethyl-6-(methylamino)pyridin-2-yl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione (189).
12. A pharmaceutical composition comprising a compound according to any one of claims 1 to 11 or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable carrier.
13. Use of a compound according to any one of claims 1 to 11 or a pharmaceutically acceptable salt thereof in the preparation of a medicament for treating cancer.
14. Use according to claim 13, wherein the cancer is selected from the group consisting of colon cancer, stomach cancer, pancreatic cancer, breast cancer, prostate cancer, lung cancer, ovarian cancer, cervical cancer, kidney cancer, head and neck cancer, lymphoma, leukemia and melanoma.
15. Use of a compound according to any one of claims 1 to 11 or a pharmaceutically acceptable salt thereof in the preparation of a medicament for reducing the Helios protein content, Helios activity level or Helios expression level in a cell.
16. The use according to claim 15, wherein the Helios protein is an amino acid sequence encoded by SEQ ID NO: 1, 2, 3, 4 or 5.
